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ABSTRACT 
Tuberculosis (TB), declared a global health emergency more than a 
decade ago, is the second leading cause of death worldwide from a single 
infectious agent. TB resurgence is assuming threatening proportions, and 
among the most important reasons for this causative killer parasite spiralling 
out of control at an alarming rate is attributed to the emergence of multidrug-
resistant strains and the AIDS epidemic. 
Mycobacterium tuberculosis, the causative agent of tuberculosis, is 
responsible for 1.5 million deaths per year, although only 10% of 
immunocompetent people infected with M. tuberculosis develop active 
tuberculosis. The resurgence of tuberculosis as a major disease with an 
estimated 10.2 million new cases in 2005 is fuelling an urgent need for 
developing novel therapeutic strategies against the causative organism, M. 
tuberculosis. To overcome the increase of drug resistance in M. tuberculosis, 
one of the most pressing needs is the discovery of new antimycobacterial 
agents focus has now shifted to development of compounds from natural 
sources. By boosting host immunologic responsiveness, these compounds 
may be particularly useful in the treatment of drug-resistant tuberculosis. We 
studied the incorporation of such compounds, like EGCG from green tea, as 
the herbal component for tuberculosis management. 
The interaction of microbes with monocytes is likely to have an 
enormous impact on the initiation of the immune response against a pathogen. 
The initial interaction of mononuclear phagocytes with M tuberculosis gives 
rise to a cytokine profile dominated by TNF-a. It is well established that both 
phagocytic and non-phagocytic interaction of M. tuberculosis bacilli with 
mononuclear phagocytes as well as mycobacterial protein and non-protein 
components can induce this pro-inflammatory cytokine. In the early stages of 
infection, TNF-a secreted by macrophages is one of the pivotal pro-
inflammatory cytokines responsible for disease localization and granuloma 
formation. Paradoxically, in the more advanced and chronic stage of 
mycobacterial diseases, TNF-a has been shown to be responsible for disease 
severity and pathogenesis. Antigen 850 is one of the many M. tuberculosis 
products that induce production of TNF-a. Along with the other two proteins in 
the M. tuberculosis 85 complex (85A and 85C), 85B is abundantly secreted by 
M. tuberculosis. 
In the present study, Initial part involves characterization of sera and 
monocytes of patients with active tuberculosis in order to evaluate the 
expression of TNF-a and M. tuberculosis 85B. Direct binding ELISA on 
microtitre plates coated with protein antigens of H37Rv bacilli sonicate showed 
remarkable reactivity against antibodies found in sera of tuberculosis patients, 
as evidenced by an antibody titre >1:12800. Similarly, an appreciable reactivity 
was observed with tuberculosis sera against secreted culture filtrate protein 
antigens with an antibody titre >1:6400, whereas no reactivity was observed 
with normal human sera in either case. 
Infection of host with M. tuberculosis gives rise to a cytokine profile that 
is dominated by TNF-a. In our study also, estimation by ELISA showed an 
appreciable magnitude of soluble TNF-a in sera of tuberculosis patients. 
Furthermore, M. tuberculosis 85B is a predominant protein produced during 
human M. tuberculosis infection; however its role in tuberculosis pathogenesis 
is not clear and warrants further investigation. The presence of circulating M. 
tuberculosis 858 antigen in sera of tuberculosis patients, either in the free fomri 
or complexed with fibronectin has been well established. We also found an 
appreciably elevated level of antigen 85B in sera of tuberculosis patients. 
After characterizing sera, an attempt was made to characterize 
monocytes from tuberculosis patients with respect to TNF-a and 85B. 
Monocytes from tuberculosis patients were subjected to TNF-a and 858 
mRNA evaluation by real-time RT-PCR and revealed appreciably high basal 
levels of both mRNA expression. TNF-a and 858 proteins were also found to 
be significantly elevated in supernatants of monocyte cultures of tuberculosis 
patients. 
Being an opportunistic intracellular pathogen and despite of 
encountering a robust immune response, M. tuberculosis successfully survives 
and persists in its human host. Of the various M. tuberculosis genes shown to 
be up regulated after M. tuberculosis infection of human mononuclear cells. 
the 85B gene was expressed most frequently. Antigen 85B is a mycolyl 
transferase involved in cell wall biosynthesis shown to catalyse the formation 
of trehalose dimycolate which enhances the host inflammatory response. 
Thus, in the present study, we investigated the early regulation of M. 
tuberculosis 85B gene by EGCG in M. tuberculosis cultures. 
The data obtained by real-time RT-PCR showed that EGCG down 
regulated the expression of 858 mRNA in M. tuberculosis (H37Rv) cultures in 
a dose-dependent manner, without any significant effect on the expression of 
the housekeeping gene of M. tuberculosis, i.e., 16S rRNA. An appreciable 
suppression of 858 mRNA by 2.6 and 3.1 (P<0.001 for both)) logs was 
recorded with 5 and 25 pg/ml of EGCG, respectively. From our data it is 
evident that the concentrations of EGCG that have been employed in this 
study do not affect M. tuberculosis growth, but on the contrary, it appreciably 
downregulates the M. tuberculosis 858 gene expression. 
The effect of EGCG on expression of M. tuberculosis antigen 85 
complex (30/31 kDa) in M. tuberculosis sonic extract as revealed by gradient 
SDS-PAGE was also found to be dose-dependent. EGCG concentrations of 5 
ug/ml and above proved to be a potent inhibitor of antigen 85 complex protein 
expression. In supernatants obtained from 14 days M. tuberculosis cultures 
receiving various doses of EGCG, the secretion of antigen 85 complex was 
found to be dose-dependent. EGCG decreased the specificity of TB-antibodies 
for M. tuberculosis protein antigens as revealed by immunoassays for sonic 
extract and culture filtrate protein antigens of M. tuberculosis co-cultured with 
EGCG against TB-antibodies. 
Interestingly, antigen 858 is immunodominant and potently induces 
TNF-a when complexed to fibronectin in mononuclear phagocytes. Therefore, 
the role of M. tuberculosis 858 in intracellular infection may be the 
maintenance of an inflammatory response. Through sustaining TNF-a activity, 
the abundant release of M. tuberculosis 858 in situ may contribute to the 
pathogenesis of M. tuberculosis infection. The expression of 85B in M. 
Ill 
tuberculosis-'mfected monocytes correlates positively with both the amount of 
secreted TNF-a and subsequent intracellular mycobacterial growth. 
From our study it was observed that in M. tuberculosis infection had no 
effect on host housekeeping genes such as the R18 gene (18S rRNA) as 
revealed by quantitative real-time RT-PCR data. Also, the kinetics (0-120 
hours) of expression of TNF-a and M. tuberculosis 85B mRNA in M. 
tuberculosis-'miecXed monocytes by real-time RT-PCR and ELISA was 
investigated. The data revealed that the expression of TNF-o mRNA in 
infected monocytes as well as secreted TNF-a in culture supematants was 
time-dependent, maximal at 24 hours of infection, followed by a substantial 
decrease at the remaining time intervals of infection. 
Furthermore, 16S rRNA expression in M. fubercu/os/s-infected 
monocytes was observed to linearly increase with time. The expression of M. 
tuberculosis 85B mRNA was found to continue to increase up to 120 hours of 
infection. The ratio of 85B:16S was also increased with increasing time 
periods of infection and correlated with 858 mRNA levels at various time 
periods. Also, in the supematants of infected monocyte cultures the 
expression of secreted antigen 85 complex increased with time. Furthemnore, 
the M. tuberculosis-'mfected monocytes exhibited a linear time-dependent 
decrease in GPx activity in comparison to control monocytes. 
The above data suggested a role for endogenous TNF-a in auto-
induction and in the induction of M. tuberculosis 858 gene expression. To 
further assess the role of TNF-a, in other experiments, exogenous rhTNF-a 
and soluble TNF-a receptors were added to M. tuberculosis-'mfected 
monocytes, and then TNF-a and 858 mRNA were assessed. The cell 
activation by exogenous rhTNF-a induces both TNF-a and M. tuberculosis 
858 genes in M. tuberculosis-Infected monocytes, whereas inhibition of 
endogenous TNF-a by TNFR-I and TNFR-II was associated with down-
modulation of both TNF-a and M. tuberculosis 858 gene expression. The 
results indicate sTNFR-l to be a stronger inhibitor of TNF-a and M. 
IV 
tuberculosis 85B gene expression in M. tuberculosis-mfected monocytes tiian 
sTNFR-ll. 
Cellular activation, and thereby induction of TNF-a, is mediated via NF-
KB. It has been well documented that TNF-a induced nuclear translocation of 
NF-KB was inhibited in SN50 peptide-treated human monocytic cell lines as 
demonstrated in EMSA. Thus, we employed SN50, an inhibitor of NF-KB, to 
assess the role of NF-KB in activation of gene expression in M. tuberculosis-
infected monocytes. Our results clearly show that the increased expression of 
TNF-a and 85B mRNA in M. tuberculosis-\nfec\ed monocytes is mediated 
mainly via NF-KB. Interestingly, inhibition of reactive oxygen intermediates 
(ROIs) and reactive nitrogen intermediates (RNIs), reduced expression of 
TNF-a and M. tuberculosis 85B genes in M. tuberculosis-Infected monocytes. 
EGCG a Green tea polyphenol is a potent anti-oxidant it is effective 
scavenger of physiologically relevant reactive oxygen species in-vitro and may 
olso inhibit the formation of reactive oxygen species by inhibiting the pro-
oxidant enzymes such as Inducible nitric oxide synthase, 
lipoxygenases, cyclooxygenases and xanthine oxidase and 
moreover it induces of phase II and antioxidant enzymes, such as 
glutathione S-transferases and superoxide dismutases. It may also 
function indirectly as anti-oxidants through inhibition of redox-
sensitive transcription factors, nuclear factor- KB and activator protein-
1. EGCG has radical scavenging properties in activated granulocytes and may 
also inhibit inducible nitric oxide synthase expression in activated 
macrophages. 
It is proven to be effective in many diseases. Most promising are the 
consistent findings in animal models of skin, lung, colon, liver and pancreatic 
cancer, by inhibiting the carcinogen-induced increases in the oxidized 
DNA base, 8-hydroxy-2-deoxyguanosine. Green tea administration 
in atherosclerosis animal model has resulted in modest 
improvement in the resistance of lipoproteins to ex-vivo oxidation, 
although limited data suggest it inhibit atherosclerosis. In mice 
infected with Mycobacterium tuberculosis, oral administration of 
green tea extract to mice infected with M. tuberculosis attenuated 
infection-associated decreases in erythrocyte superoxide 
dismutase (SOD) activity, while oral administration of either black 
or green tea extract resulted in increased serum SOD activity 
erythrocyte GSH concentrations and erythrocyte superoxide 
dismutase (SOD) activity 
Here we investigated the effect of EGCG on expression of TNF-a and 
M. tuberculosis 85B in M. tuberculosis-infected monocytes after 24 liours of 
Infection. In the present study, we employed EGCG concentrations in between 
0-25 ug/ml, which failed to show any toxic effect on monocytes as revealed by 
MTT assay. Also, no effect was observed on housekeeping genes: R18 (18S 
rRNA) by quantitative real-time RT-PCR, thereby indicating that EGCG did not 
non-specifically affect human TNF-a transcription in M. tuberculosis-'mfected 
monocytes. Also, the effect of various doses of EGCG employed in the 
present study failed to show any toxic or inhibitory effect on the mycobacterial 
housekeeping gene M. tuberculosis 16S rRNA by quantitative real-time RT-
PCR in monocytes infected with M. tuberculosis. 
The present study revealed EGCG to down regulate the expression of 
TNF-a gene in M. tuberculosis-mfecled monocytes as well as the secretion of 
soluble TNF-a in culture supernatants in a dose-dependent manner. The 
results indicate an appreciable suppression in endogenous TNF-a mRNA 
expression by 5 and 25 ug/ml of EGCG, respectively in M. tuberculosis-
infected monocytes. Furthermore, EGCG was also found to suppress the 
expression of 85B gene and secreted antigen 85 complex in a dose-
dependent manner. 
Interestingly, in comparison to the inhibitory effects of EGCG with those 
of NAC, SN50 and anti-TNF-a antibody, EGCG was found to be the most 
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potent inhibitor of TNF-a and M. tuberculosis 85B expression in M. 
tuberculosis-mfected monocytes. 
Our results indicate that the increased expression of TNF-a and 85B 
mRNA in M. tuberculosis-'in^ecled monocytes is mediated via activation of NF-
KB, as evidenced by the suppression of TNF-a mRNA in the presence of 
SN50, an inhibitor of NF-KB. SN50/M, an inactive analogue of SN50 failed to 
show any such effect. In view of it, our data demonstrated that this effect 
Involved inhibition of the NF-KB pathway induced by EGCG probably by 
inhibiting the degradation of kBa. Since a number of genes involved in 
inflammatory responses are regulated by NF-KB pathway, thus a high 
magnitude downregulation of the NF-KB pathway by EGCG would predictably 
reduce the elaboration of NF-KB-mediated TNF-a mRNA expression and, in 
turn, 85B gene expression. 
We observed in this study that addition of anti-oxidants like EGCG and NAC in 
MTB-infected monocytes exhibited a decrease in level of soluble IFN-y. Thus, 
it appears that down-regulation of sIFN-y levels in culture supernatants of 
MTB-infected monocytes is augmented or reversed by EGCG. Further in-
depth investigation revealed EGCG to be a better suppresser of anti-TNF-
alpha and MTB 85B gene expressions in comparison to antibiotics like 
streptomycin, rifampicin or isoniazid. 
Glutathione directly reacts with ROS, and glutathione peroxidase (GPx) 
catalyzes the removal of hydrogen peroxide. Decrease in GPx activity 
indicates impairment of hydrogen peroxide-neutralizing mechanisms. Here, we 
observed a decline in GPx activity in M. tuberculosis-iniected monocytes. 
Enhancement of GPx activity in M. tuberculosis-iniected monocyte cultures 
after addition of NAC, a precursor of the in vivo antioxidant glutathione, 
indicates reversal of impaired neutralizing mechanisms. Surprisingly, here a 
slightly greater augmentation in GPx activity was observed when EGCG was 
co-cultured instead of NAC, indicating EGCG to be an effective natural 
VII 
antioxidant combating ROS, generated as a consequence of cellular activation 
in M. tuberculosis-infected monocytes. 
In conclusion, the presence of elevated levels of TNF-a and M. 
tuberculosis 85B in tuberculosis patients is the indication of severity of the 
disease. The expression of M. tuberculosis 85B was downregulated by EGCG 
in a dose-dependent manner in H37Rv cultures. Furthermore, M. tuberculosis 
infection of monocytes leads to a concomitant activation of TNF-a and 
expression of M. tuberculosis 85B gene. M. tuberculosis infection of human 
monocytes initiates a cascade of events whereby cellular activation by TNF-a, 
RNl, and ROl enhances the expression of M. tuberculosis 858 in monocytes. 
The augmented expression of TNF-a and M. tuberculosis 858 gene in M. 
fubercu/os/s-infected monocytes by cellular activation and ROS was 
suppressed by EGCG in a dose-dependent manner. The effect of EGCG was 
mediated by suppression of NF-K8. Also, EGCG enhanced the GPx activity, 
which correlated inversely with the downregulation of TNF-a and M. 
tuberculosis 858 in M. tuberculosis-mlected monocytes. EGCG may prove to 
be valuable in the containment of M tuberculosis and, therefore, be useful as 
an adjunct in treatment of tuberculosis. These observations strengthen the 
idea that EGCG should be tested in in vivo models to evaluate its therapeutic 
potential in the pathogenesis of tuberculosis. 
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ABSTRACT 
Tuberculosis (TB), declared a global health emergency more than a 
decade ago, is the second leading cause of death worldwide from a single 
infectious agent. TB resurgence is assuming threatening proportions, and 
among the most important reasons for this causative killer parasite spiralling 
out of control at an alamning rate is attributed to the emergence of multidrug-
resistant strains and the AIDS epidemic. 
Mycobacterium tuberculosis, the causative agent of tuberculosis, is 
responsible for 1.5 million deaths per year, although only 10% of 
immunocompetent people infected with M. tuberculosis develop active 
tuberculosis. The resurgence of tuberculosis as a major disease with an 
estimated 10.2 million new cases in 2005 is fuelling an urgent need for 
developing novel therapeutic strategies against the causative organism, M. 
tuberculosis. To overcome the increase of drug resistance in M. tuberculosis, 
one of the most pressing needs is the discovery of new antimycobacterial 
agents focus has now shifted to development of compounds from natural 
sources. By boosting host immunologic responsiveness, these compounds 
may be particularly useful in the treatment of drug-resistant tuberculosis. We 
studied the incorporation of such compounds, like EGCG from green tea, as 
the herbal component for tuberculosis management. 
The interaction of microbes with monocytes is likely to have an 
enormous impact on the initiation of the immune response against a pathogen. 
The initial interaction of mononuclear phagocytes with M. tuberculosis gives 
rise to a cytokine profile dominated by TNF-a. It is well established that both 
phagocytic and non-phagocytic interaction of M. tuberculosis bacilli with 
mononuclear phagocytes as well as mycobacterial protein and non-protein 
components can induce this pro-inflammatory cytokine. In the early stages of 
infection, TNF-a secreted by macrophages is one of the pivotal pro-
inflammatory cytokines responsible for disease localization and granuloma 
formation. Paradoxically, in the more advanced and chronic stage of 
mycobacterial diseases, TNF-a has been shown to be responsible for disease 
severity and pathogenesis. Antigen 85B is one of the many M. tuberculosis 
products that induce production of TNF-a. Along with the other two proteins in 
the M. tuberculosis 85 complex (85A and 85C), 85B is abundantly secreted by 
M. tuberculosis. 
In the present study, initial part involves characterization of sera and 
monocytes of patients with active tuberculosis in order to evaluate the 
expression of TNF-a and M. tuberculosis 85B. Direct binding ELISA on 
microtitre plates coated with protein antigens of H37Rv bacilli sonicate showed 
remarkable reactivity against antibodies found in sera of tuberculosis patients, 
as evidenced by an antibody titre >1:12800. Similarly, an appreciable reactivity 
was observed with tuberculosis sera against secreted culture filtrate protein 
antigens with an antibody titre >1:6400, whereas no reactivity was observed 
with normal human sera in either case. 
Infection of host with M. tuberculosis gives rise to a cytokine profile that 
is dominated by TNF-a. In our study also, estimation by ELISA showed an 
appreciable magnitude of soluble TNF-a in sera of tuberculosis patients. 
Furthermore, M. tuberculosis 85B is a predominant protein produced during 
human M. tuberculosis infection; however its role in tuberculosis pathogenesis 
is not clear and warrants further investigation. The presence of circulating M. 
tuberculosis 858 antigen in sera of tuberculosis patients, either in the free form 
or complexed with fibronectin has been well established. We also found an 
appreciably elevated level of antigen 858 in sera of tuberculosis patients. 
After characterizing sera, an attempt was made to characterize 
monocytes from tuberculosis patients with respect to TNF-a and 858. 
Monocytes from tuberculosis patients were subjected to TNF-a and 858 
mRNA evaluation by real-time RT-PCR and revealed appreciably high basal 
levels of both mRNA expression. TNF-a and 858 proteins were also found to 
be significantly elevated in supernatants of monocyte cultures of tuberculosis 
patients. 
Being an opportunistic intracellular pathogen and despite of 
encountering a robust immune response, M. tuberculosis successfully survives 
and persists in its human host. Of the various M. tuberculosis genes shown to 
be up regulated after M. tuberculosis infection of human mononuclear cells, 
the 85B gene was expressed most frequently. Antigen 85B is a mycolyl 
transferase involved in cell wall biosynthesis shown to catalyse the formation 
of trehalose dimycolate which enhances the host inflammatory response. 
Thus, in the present study, we investigated the early regulation of M. 
tuberculosis 85B gene by EGCG in M. tuberculosis cultures. 
The data obtained by real-time RT-PCR showed that EGCG down 
regulated the expression of 858 mRNA in M. tuberculosis (H37Rv) cultures in 
a dose-dependent manner, without any significant effect on the expression of 
the housekeeping gene of M. tuberculosis, i.e., 16S rRNA. An appreciable 
suppression of 858 mRNA by 2.6 and 3.1 (P<0.001 for both)) logs was 
recorded with 5 and 25 pg/ml of EGCG, respectively. From our data it is 
evident that the concentrations of EGCG that have been employed in this 
study do not affect M. tuberculosis growth, but on the contrary, it appreciably 
downregulates the M. tuberculosis 858 gene expression. 
The effect of EGCG on expression of M. tuberculosis antigen 85 
complex (30/31 kDa) in M. tuberculosis sonic extract as revealed by gradient 
SDS-PAGE was also found to be dose-dependent. EGCG concentrations of 5 
ug/ml and above proved to be a potent inhibitor of antigen 85 complex protein 
expression. In supernatants obtained from 14 days M. tuberculosis cultures 
receiving various doses of EGCG, the secretion of antigen 85 complex was 
found to be dose-dependent. EGCG decreased the specificity of T8-antibodies 
for M. tuberculosis protein antigens as revealed by immunoassays for sonic 
extract and culture filtrate protein antigens of M. tuberculosis co-cultured with 
EGCG against T8-antibodies. 
Interestingly, antigen 858 is immunodominant and potently induces 
TNF-a when complexed to fibronectin in mononuclear phagocytes. Therefore, 
the role of M. tuberculosis 858 in intracellular infection may be the 
maintenance of an inflammatory response. Through sustaining TNF-a activity, 
the abundant release of M. tuberculosis 858 in situ may contribute to the 
pathogenesis of M. tuberculosis infection. The expression of 858 in M. 
Ill 
tuberculosis-'mfected monocytes correlates positively with both the amount of 
secreted TNF-a and subsequent intracellular mycobacterial growth. 
From our study it was observed that in M. tuberculosis infection had no 
effect on host housekeeping genes such as the R18 gene (18S rRNA) as 
revealed by quantitative real-time RT-PCR data. Also, the kinetics (0-120 
hours) of expression of TNF-a and M. tuberculosis 85B mRNA in M. 
tuberculosis-'mfected monocytes by real-time RT-PCR and ELISA was 
investigated. The data revealed that the expression of TNF-a mRNA in 
infected monocytes as well as secreted TNF-a in culture supernatants was 
time-dependent, maximal at 24 hours of infection, followed by a substantial 
decrease at the remaining time intervals of infection. 
Furthermore, 16S rRNA expression in M. tuberculosis-mtected 
monocytes was observed to linearly increase with time. The expression of M. 
tuberculosis 85B mRNA was found to continue to increase up to 120 hours of 
infection. The ratio of 85B:16S was also increased with increasing time 
periods of infection and correlated with 858 mRNA levels at various time 
periods. Also, in the supernatants of infected monocyte cultures the 
expression of secreted antigen 85 complex increased with time. Furthermore, 
the M. tuberculosis-'mfected monocytes exhibited a linear time-dependent 
decrease In GPx activity in comparison to control monocytes. 
The above data suggested a role for endogenous TNF-a in auto-
induction and in the induction of M. tuberculosis 858 gene expression. To 
further assess the role of TNF-a, in other experiments, exogenous rhTNF-a 
and soluble TNF-a receptors were added to M. tuberculosis-mfected 
monocytes, and then TNF-a and 858 mRNA were assessed. The cell 
activation by exogenous rhTNF-a induces both TNF-a and M. tuberculosis 
858 genes in M. tuberculosis-mfected monocytes, whereas inhibition of 
endogenous TNF-a by TNFR-I and TNFR-II was associated with down-
modulation of both TNF-a and M. tuberculosis 858 gene expression. The 
results indicate sTNFR-l to be a stronger inhibitor of TNF-a and M. 
IV 
tuberculosis 85B gene expression in M. tuberculosis-mfected monocytes than 
sTNFR-ll. 
Cellular activation, and thereby induction of TNF-a, is mediated via NF-
KB. It has been well documented that TNF-a induced nuclear translocation of 
NF-KB was Inhibited in SN50 peptide-treated human monocytic cell lines as 
demonstrated in EMSA. Thus, we employed SN50, an inhibitor of NF-KB, to 
assess the role of NF-KB in activation of gene expression in M. tuberculosis-
Infected monocytes. Our results clearly show that the increased expression of 
TNF-a and 85B mRNA in M. tuberculosis-mfected monocytes Is mediated 
mainly via NF-KB. Interestingly, inhibition of reactive oxygen intermediates 
(ROIs) and reactive nitrogen intermediates (RNIs), reduced expression of 
TNF-a and M. tuberculosis 85B genes in Af. fu/jercw/os/s-infected monocytes. 
EGCG a Green tea polyphenol is a potent anti-oxidant it is effective 
scavenger of physiologically relevant reactive oxygen species in-vitro and may 
olso inhibit the formation of reactive oxygen species by inhibiting the pro-
oxidant enzymes such as inducible nitric oxide synthase, 
lipoxygenases, cyclooxygenases and xanthine oxidase and 
moreover it induces of phase II and antioxidant enzymes, such as 
glutathione S-transferases and superoxide dismutases. It may also 
function indirectly as anti-oxidants through inhibition of redox-
sensitive transcription factors, nuclear factor- KB and activator protein-
1. EGCG has radical scavenging properties in activated granulocytes and may 
also inhibit inducible nitric oxide synthase expression in activated 
macrophages. 
It is proven to be effective in many diseases. Most promising are the 
consistent findings in animal models of skin, lung, colon, liver and pancreatic 
cancer, by inhibiting the carcinogen-induced increases in the oxidized 
DNA base, 8-hydroxy-2-deoxyguanosine. Green tea administration 
in atherosclerosis animal model has resulted in modest 
improvement in the resistance of lipoproteins to ex-vivo oxidation, 
although limited data suggest it inhibit atherosclerosis. In mice 
infected with Mycobacterium tuberculosis, oral administration of 
green tea extract to mice infected with M. tuberculosis attenuated 
infection-associated decreases in erythrocyte superoxide 
dismutase (SOD) activity, while oral administration of either black 
or green tea extract resulted in increased serum SOD activity 
erythrocyte GSH concentrations and erythrocyte superoxide 
dismutase (SOD) activity 
Here we investigated the effect of EGCG on expression of TNF-a and 
M. tuberculosis 85B in M. tuberculosis-miecied monocytes after 24 hours of 
infection. In the present study, we employed EGCG concentrations in between 
0-25 ug/ml, which failed to show any toxic effect on monocytes as revealed by 
MTT assay. Also, no effect was observed on housekeeping genes: R18 (18S 
rRNA) by quantitative real-time RT-PCR, thereby indicating that EGCG did not 
non-specifically affect human TNF-a transcription in M. tuberculosis-'mlected 
monocytes. Also, the effect of various doses of EGCG employed in the 
present study failed to show any toxic or inhibitory effect on the mycobacterial 
housekeeping gene M. tuberculosis 16S rRNA by quantitative real-time RT-
PCR in monocytes infected with M. tuberculosis. 
The present study revealed EGCG to down regulate the expression of 
TNF-a gene in M. tuberculosis-Infected monocytes as well as the secretion of 
soluble TNF-a in culture supernatants in a dose-dependent manner. The 
results indicate an appreciable suppression in endogenous TNF-a mRNA 
expression by 5 and 25 ug/ml of EGCG, respectively in M. tuberculosis-
infected monocytes. Furthermore, EGCG was also found to suppress the 
expression of 85B gene and secreted antigen 85 complex in a dose-
dependent manner. 
Interestingly, in comparison to the inhibitory effects of EGCG with those 
of NAC, SN50 and anti-TNF-a antibody, EGCG was found to be the most 
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potent inhibitor of TNF-a and M. tuberculosis 85B expression in M. 
tuberculosis-Infected monocytes. 
Our results indicate that the increased expression of TNF-a and 85B 
mRNA in M. tuberculosis-Infected monocytes is mediated via activation of NF-
KB, as evidenced by the suppression of TNF-a mRNA in the presence of 
SN50, an inhibitor of NF-KB. SNSO/IVI, an inactive analogue of SN50 failed to 
show any such effect. In view of it, our data demonstrated that this effect 
involved inhibition of the NF-KB pathway induced by EGCG probably by 
inhibiting the degradation of IKBO. Since a number of genes involved in 
inflammatory responses are regulated by NF-KB pathway, thus a high 
magnitude down regulation of the NF-KB pathway by EGCG would predictably 
reduce the elaboration of NF-KB-mediated TNF-a mRNA expression and, in 
turn, 85B gene expression. 
We observed in this study that addition of anti-oxidants like EGCG and NAC in 
MTB-infected monocytes exhibited a decrease in level of soluble IFN-y. Thus, 
it appears that down-regulation of sIFN-y levels in culture supernatants of 
MTB-infected monocytes is augmented or reversed by EGCG. Further in-
depth investigation revealed EGCG to be a better suppresser of anti-TNF-
alpha and MTB 85B gene expressions in comparison to antibiotics like 
streptomycin, rifampicin or isoniazid. 
Glutathione directly reacts with ROS, and glutathione peroxidase (GPx) 
catalyzes the removal of hydrogen peroxide. Decrease in GPx activity 
indicates impairment of hydrogen peroxide-neutralizing mechanisms. Here, we 
observed a decline in GPx activity in M. tuberculosis-infected monocytes. 
Enhancement of GPx activity in M. tuberculosis-'mfected monocyte cultures 
after addition of NAC, a precursor of the in vivo antioxidant glutathione, 
indicates reversal of impaired neutralizing mechanisms. Surprisingly, here a 
slightly greater augmentation in GPx activity was observed when EGCG was 
co-cultured instead of NAC, indicating EGCG to be an effective natural 
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antioxidant combating ROS, generated as a consequence of cellular activation 
in M. tuberculosis-'miected monocytes. 
In conclusion, the presence of elevated levels of TNF-a and M. 
tuberculosis 85B in tuberculosis patients is the indication of severity of the 
disease. The expression of M. tuberculosis 85B was downregulated by EGCG 
in a dose-dependent manner in H37Rv cultures. Furthermore, M. tuberculosis 
infection of monocytes leads to a concomitant activation of TNF-a and 
expression of M. tuberculosis 85B gene. M. tuberculosis infection of human 
monocytes initiates a cascade of events whereby cellular activation by TNF-a, 
RNI, and ROI enhances the expression of M. tuberculosis 858 in monocytes. 
The augmented expression of TNF-a and M. tuberculosis 858 gene in M. 
tuberculosis-infected monocytes by cellular activation and ROS was 
suppressed by EGCG in a dose-dependent manner. The effect of EGCG was 
mediated by suppression of NF-K8. Also, EGCG enhanced the GPx activity, 
which correlated inversely with the downregulation of TNF-a and M. 
tuberculosis 858 in M. tuberculosis-'mfected monocytes. EGCG may prove to 
be valuable in the containment of M tuberculosis and, therefore, be useful as 
an adjunct in treatment of tuberculosis. These observations strengthen the 
idea that EGCG should be tested in in vivo models to evaluate its therapeutic 
potential in the pathogenesis of tuberculosis. 
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INTRODUCTION 
INTRODUCTION 
Tuberculosis - a disease of great antiquity lias been in association 
with man for many centuries. Tuberculosis is most common among 
the elderly, poor, malnourished, or immuno-compromised, especially 
persons infected with human immunodeficiency virus (HIV). Persistent 
infection may reactivate after decades owing to deterioration of 
immune status; exogenous re-infection also occurs. Only around 5-
10% of infected normal individuals develop active disease. 
Tuberculosis primarily affects the lower respiratory system. Chronic 
productive cough, low-grade fever, night sweats, and weight loss are 
the main characteristics of this infectious disease. 
Mycobacterium tuberculosis are slender, curved rods that are acid fast 
and resistant to acids, alkalis, and dehydration. The cell wall contains 
complex waxes and glycolipids. Multiplication on enriched media is 
very slow, with doubling times of 18 to 24 hours; clinical isolates may 
require 4 to 6 weeks to grow. On the basis of growth rate, catalase 
and niacin production as well as pigmentation in light or dark, 
mycobacteria are classified into members of the Mycobacterium 
tuberculosis and nontuberculous species, which in turn can be 
distinguished by gene probe technology. The route of entry of 
tuberculous mycobacteria is through the alveoli by airborne 
transmission. They resist destruction by alveolar macrophages and 
multiply, forming the primary lesion or tubercle; they then spread to 
regional lymph nodes, enter the circulation, and reseed the lungs (1). 
Clinical signs and symptoms develop in only a small proportion (5-10 
percent) of infected healthy people. These patients usually present 
with pulmonary disease; prominent symptoms are chronic, productive 
cough, low-grade fever, night sweats, easy fatigability, and weight 
loss. Tuberculosis may present with or also exhibit extrapulmonary 
manifestations including lymphadenitis; kidney, bone, or joint 
involvement; meningitis; or disseminated (miliary) disease. 
Lymphadenitis and meningitis are more common among normal 
infants with tuberculosis, and all extrapulmonary manifestations are 
increased in frequency among immunocompromised individuals such 
as patients on chronic renal dialysis and elderly, malnourished, or 
HIV-infected individuals. 
Tuberculosis (often called TB) is an infectious disease that usually 
attacks the lungs, but can attack almost any part of the body. 
Tuberculosis is spread from person to person through the air. The 
microorganism Mycobacterium tuberculosis causes it. It can affect 
several organs of the human body, including the brain, the kidneys 
and the bones; but most commonly it affects the lungs (Pulmonary 
Tuberculosis). The first stage of the infection usually lasts for several 
months. During this period, the body's natural defenses (immune 
system) resist the disease, and a fibrous capsule that develops 
around the area walls most or all of the bacteria in. Before the initial 
attack is over, a few bacteria may escape into the bloodstream and be 
carried elsewhere in the body, where they are again walled in. In 
many cases, the disease never develops beyond this stage - and is 
referred to as TB infection. If the immune system fails to stop the 
infection and it is left untreated, the disease progresses to the second 
stage, active disease. There, the germ multiplies rapidly and destroys 
the tissues of the lungs (or the other affected organ). In some cases, 
the disease, although halted at first, flares up after a latent period. 
Sometimes, the latent period is many years, and the bacteria become 
active when the opportunity presents itself, especially when immunity 
is low. The second stage of the disease is manifested by destruction 
or "consumption" of the tissues of the affected organ. When the lung 
is affected, it results in diminished respiratory capacity, associated 
with other symptoms; when other organs are affected, even if treated 
adequately, it may leave permanent, disabling scar tissue. 
There are two possible ways a person can become sick with TB 
disease: 
1. The first applies to a person who may have been infected with TB for 
years and has been perfectly healthy. The time may come when this 
person suffers a change in health. The cause of this change in health 
may be another disease like AIDS or diabetes. Or it may be drug or 
alcohol abuse or a lack of health care because of homelessness. 
Whatever the cause, when the body's ability to protect itself is 
damaged, the TB infection can become TB disease. In this way, a 
person may become sick with TB disease months or even years after 
they first breathed in the TB germs. 
2. The other way TB disease develops happens much more quickly. 
Sometimes when a person first breathes in the TB germs the body is 
unable to protect itself against the disease. The germs then develop 
into active TB disease within weeks. 
The TB skin test is a way to find out if a person has TB infection. 
Although there is more than one TB skin test, the preferred method of 
testing is to use the Mantoux test. For this test, a small amount of 
testing material is placed just below the top layers of skin, usually on 
the arm. Two to three days later a health care worker checks the arm 
to see if a bump has developed and measures the size of the bump. If 
the bump is of a certain size (varying with group) the test is significant 
and the person is presumed to have TB infection. 
Epidemiology: 
Tuberculosis is a devastating communicable disease and a global 
killer as the second leading cause of death worldwide from a single 
infectious agent (2). Tuberculosis has confounded attempts at control 
ever since the discovery of M. tuberculosis by Robert Koch, 120 years 
ago for which he was honoured with the Noble Prize. The staggering 
extent of infection by this exclusively human pathogen, M. 
tuberculosis, encompasses a total of two billion persons, 
approximately eight million people develop active disease and nearly 
two million are killed each year (3,4). Moreover, it was declared a 
global health emergency by WHO in 1993 (5). Targets were 
established to measure progress in the implementation of the DOTS 
strategy to combat tuberculosis by 2005. The targets include 100% 
population coverage with DOTS, 70% case detection and 85% 
treatment success rate. In spite of this, the number of new cases of 
tuberculosis is projected to reach 11.9 million by the end of 2006, if 
current control efforts are not strengthened (6). Although a cure was 
available for the second half of the 20*^  century, various demographic 
and socioeconomic factors make both prevention and treatment 
difficult (7). Most cases are in populous and less developed countries 
of Asia, with India, China, Indonesia, Bangladesh and Pakistan 
together accounting for more than half the global burden. The global 
tuberculosis caseload appears to be growing slowly with increased 
incidence in the former Soviet Union and Africa (8). The recent 
resurgence in tuberculosis is attributed partly to the AIDS epidemic 
with the emergence of multidrug resistance strains especially in areas 
where the WHO recommended DOTS strategy is not yet implemented 
(9). Coinfection with the human immunodeficiency virus (HIV), 
tuberculosis forms a lethal combination, each speeding the others 
progress. Sub-Saharan Africa bears the brunt of the HIV-fuelled 
tuberculosis epidemic (10). 
Clinical manifestations 
The most common clinical manifestation of tuberculosis is pulmonary 
disease. Extra pulmonary tuberculosis accounts for about 20% of 
disease in HIV-seronegative people but is more common in HIV-
seropositive individuals (10). Among people not infected with HIV, 
extrapulmonary disease, particularly lymphatic tuberculosis, is 
particularly common in women and young children (11). 
Pleural tuberculosis occurs as a result of either primary progressive 
infection or reactivation of latent infection. Unlike other clinical 
manifestations of tuberculosis, pleural disease probably represents an 
Increased, rather than diminished, immune response (2). 
The most serious clinical manifestation of tuberculosis is involvement 
of the central nervous system. Such involvement can include 
inflammation of the meninges, as well as space-occupying lesions 
(tuberculomas) of the brain. The clinical manifestations are due to the 
presence of bacilli as well as the inflammatory host immune response. 
Children under 5 years of age and HIV-infected individuals are at 
increased risk of tuberculous meningitis (12), which can present 
clinically as chronic meningitis, with headache, fever, and changed 
mental status. Neurological manifestations can include cranial nerve 
palsies and motor, sensory, and cerebellar defects, according to the 
location of the tuberculomas; seizures can also occur. Meningitis is 
fatal in almost all cases without chemotherapy, and prompt 
identification and treatment are essential to prevent serious 
neurological sequelae (2). 
Tuberculosis can affect any bone or joint, but the spine (i.e., Pott's 
disease) is the most common bony structure involved. In the spine, 
the most common location is the thoracic section. Vertebral-body 
involvement can be followed by disease of an adjacent intervertebral 
disc (13). 
Genitourinary tuberculosis (including involvement of the renal and 
male and female genital tracts) is uncommon and is difficult to 
distinguish from other infections of the genitourinary tract (2). In men, 
manifestations include those of prostatitis or prostate enlargement, 
epididymitis, and orchitis, but disease can also present as a painless 
scrotal mass..Urine analysis may show red or white blood cells, or 
both, with a negative urine culture for bacteria (sterile pyuria). In 
women, genitourinary tuberculosis is an important cause of infertility in 
areas with high tuberculosis incidence (14). 
Disseminated tuberculosis is defined as involvement of many organs 
simultaneously and can occur as a result of primary progressive 
disease or reactivation of latent infection. The clinical manifestation of 
pulmonary involvement is a miliary (millet seed) pattern rather than an 
infiltrate in most cases, but not all patients with disseminated disease 
have pulmonary involvement (2). Mortality is high despite 
chemotherapy and may be related to delays in diagnosis and other 
commonly present underlying medical conditions (11). 
Pathophysiology 
The pathogenesis of tuberculosis is complex and its manifestations 
diverse, reflecting a lifetime of dynamic interactions between 
mycobacterial virulence factors and the human immune system (15). 
M. tuberculosis is an extra ordinarily effective human pathogen. 
Surveys with purified protein derivative (PPD) or positive tuberculin 
skin tests suggest that one third of the world's population is infected 
with the bacillus (16). Primary infection leads to active disease in only 
about 10% of infected individuals, mostly within two years (17). In the 
remaining 90% majority of cases the immune system contains the 
infection and the individual is non-infectious and symptom-free. This 
clinical latency can persist throughout the person's lifetime. 
Deactivation of latent infection can result when host immune 
responses are perturbed through advanced immunosuppression (e.g. 
AIDS/HIV infection, use of steroids, malnutrition, etc.) or advanced 
age (7). The risk of developing reactivation disease is between 2 to 
23%, but for HIV infected individuals it is estimated to be as high as 
10% annually (18). Reactivation of latent infection contributes 
substantially to the incidence of adult TB, especially in more 
developed countries where disease prevalence is fairly low (19). 
Tuberculosis is spread by airborne aerosolized droplet nuclei, which 
are particles of 1-5 pm in diameter that contain M. tuberculosis. 
Because of their small size, the particles can remain airborne for 
minutes to hours after expectoration by diseased patients (20). The 
infectious droplet nuclei are inhaled and lodge in the alveoli in the 
distal airways (2). M. tuberculosis exhibits specific cellular tropism for 
mononuclear phagocytes, i.e. alveolar macrophages, monocytes and 
dendritic cells (3). M. tuberculosis has the remarkable capacity to 
circumvent destruction within one of the most hostile cell types of a 
vertebrate host: the macrophage, where they establish a niche to 
survive and even replicate (21). M. tuberculosis infection initiates a 
cascade of events resulting in either successful containment of the 
infection or progression to active disease (2). 
In brief, after being ingested by alveolar macrophages, M. tuberculosis 
replicates and spreads via the lymphatic system to the hilar lymph 
nodes. The bacterium thus utilizes the host cell as a mechanism of 
transport into the blood stream and deeper tissues. Cell mediated 
immunity usually develops 2-8 weeks after infection. Activated 
lymphocytes and macrophages form granulomas that limit further 
replication and spread of the organism (22). Although the host 
response is essential to control of infection, the tubercle bacillus 
participates in the establishment of latency by using various strategies 
to evade elimination by the host. The evasion and interaction of 
pathogenic mycobacteria with the host immune system is discussed in 
greater detail as follows: 
An orchestrated series of innate immune pathways, and T-helper 1 
(Thl)-dominant adaptive immune pathways are activated following 
phagocytosis of the bacteria, to culminate in a granuloma at the initial 
focus of infection (23). The innate host response is necessary for 
induction of adaptive immunity to M. tuberculosis (24). 
Non-Specific Innate Host Defense and Immune-Evasion 
Strategies of M. tuberculosis 
The first step in the innate host defense is cellular uptake of M. 
tuberculosis, which involves different cellular receptors and humoral 
factors. Toll-like receptors seem to play a crucial role in immune 
recognition of M. tuberculosis, which is the next step. The subsequent 
inflammatory response is regulated by production of pro- and anti-
inflammatory cytokines and chemokines. Effector mechanisms also 
contribute to innate immunity. Most of the mediators at this point are 
derived from macrophages and dendritic cells. The initial response 
determines the local outgrowth, sometimes dissemination of M. 
tuberculosis or containment of infection (24). 
Phagocytosis of M. tuberculosis 
M. tuberculosis primarily infects macrophages and later dendritic cells 
and monocyte-derived macrophages by using multiple phagocytic cell 
surface receptors to gain entry (25). These receptors include the 
mannose receptors, complement receptors and Fc receptors. 
Endocytosis involves receptor binding to nonopsonized M. 
tuberculosis or by recognition of opsonins on the surface of M. 
tuberculosis (24). 
The best characterized receptor for non opsonin-mediated 
phagocytosis of M. tuberculosis is the macrophage mannose receptor, 
which recognizes terminal mannose residues on mycobacteria (26). 
Phagocytosis through mannose receptors does not trigger O2' 
production (27) and M. tuberculosis exerts an anti-inflammatory signal 
through this receptor (28). M. tuberculosis opsonized with complement 
factor C3 bind and are taken up through complement receptor 1 
(CR1), CR3andCR4. 
Fc receptors, which facilitate phagocytosis of particles coated with IgG 
antibodies, seem to play little role in tuberculosis (29). However, Fc 
receptor mediated phagocytosis is directly linked to an inflammatory 
response (binding to CR is not) (25). Distinct routes of entry of M. 
tuberculosis may lead to differences in signal transduction, immune 
activation and intracellular survival of M. tuberculosis (24). 
Recognition of M. tuberculosis: Role of Toll-Lilte 
Receptors (TLRs) 
The initial interaction of M. tuberculosis with phagocytes through toll-
like receptors (TLRs) can affect induction of the adaptive response by 
inflammatory cytokine production as well as begin the process of 
bacterial containment by induction of antimycobacterial functions (30). 
It is partly through this interaction with TLRs that macrophages 
produce inflammatory cytokines and chemokines that serve as signals 
of infection (7). TLRs mediate the activation of cells of the innate 
immune system, resulting in destruction of invading microbes through 
the activation of several signaling cascades. 
Besides phagocytosis, recognition of M. tuberculosis or mycobacterial 
products is a crucial step in an effective host response. TLRs are 
phylogenetically conserved mediators of innate immunity, which are 
essential for microbial recognition on macrophages and dendritic cells 
(31). Activation of TLRs is an important link between innate cellular 
responses and the subsequent activation of adaptive immune 
defenses against microbial pathogens (23). 
TLRs signaling ieads to the nuciear transiocation of 
nuclear factor-KB. 
NF-KB is a transcription factor involved in the expression of many 
immune response genes such as those encoding the cytokines TNF-a 
and interleukins (21). TLRs signaling also trigger differentiation of 
monocytes into macrophages and dendritic cells, thereby generating 
the cellular populations necessary for a potent innate and adaptive 
immune response (32). 
Members of the TLR family are transmembrane proteins containing 
repeated leucine-rich motifs in their extracellular domains, similar to 
other pattern-recognizing proteins of the innate immune system (24). 
The cytoplasmic domain of TLR is homologous to the signaling 
domain of IL-1 receptor (IL-1R) and links to IRAK (IL-1R associated 
kinase), a serine kinase that activates transcription factors like NF-KB 
to signal the production of cytokines (33). 
Through TLRs M. tuberculosis lysate or soluble mycobacterial cell wall 
associated lipoproteins induce production of IL-12, a strong pro-
inflammatory cytokine (34). Myeloid differentiation protein 88 (MyD88), 
a common signaling component that links all TLRs to IRAK (33), was 
found to be essential for M. tuberculosis induced macrophage 
activation (35). From several lines of evidence it has become clear 
that phagocytosis does not lead to immune activation in the absence 
of functional TLRs (24). 
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TLR2 binds with lipid derivatives of M. tuberculosis lipoarabinomannon 
(l-AIVI) in the context of CD14 (23) and to a 19 l<Da M. tuberculosis 
lipoprotein (34). This interaction with TLR2 induces a predominantly 
pro-inflammatory cellular response (23). In addition, the 19 kDa 
lipoprotein inhibits macrophage MHC class II antigen presentation and 
responsiveness to IFN-y in a TLR2 dependent mechanism. 
TLR4 binds to an undefined heat-labile cell associated factor (36). 
Other TLRs may be involved in immune recognition of M. tuberculosis 
heterodimerization of TLR2 with TLR6 or TLR1 is necessary for signal 
transduction, and TLR9 binds CpG dinucleotides in bacterial DNA. 
Also, mycobacterial infection and pro-inflammatory cytokines increase 
surface expression of TLR2. TLRs are expressed not only at the cell 
surface, but also in phagosomes. 
Besides generating cytokine activity, TLR stimulation in macrophages 
upregulates phagocytosis of bacteria (37) and apoptotic cells (38). 
TLRs also appear to regulate fusion events between phagosomes and 
lysosomes (37). Whether or not pathogenic mycobacteria interfere 
with TLR signaling to block their delivery to phagosomes e.g. through 
modulation of MAPK signaling pathways remains to be established in 
vivo (21). 
Effecter Mechanisms for Killing of M. tuberculosis 
(1) Avoidance of Macrophage-mediated Killing 
Although macrophages provide an effective initial barrier against 
infection by bacterial pathogens, M. tuberculosis has evolved 
numerous strategies that allow it to survive and set up initial residence 
within these cells (39) after gaining entry via multiple cell surface 
receptors (e.g. mannose receptors, complement receptors and Fc 
receptors). 
Pathogenic mycobacteria coat themselves with a serum protein that is 
recognized by complement, thereby avoiding host inflammatory 
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response (40). M. tuberculosis crosses the first line of defense, i.e. the 
alveolar barrier by invading the alveolar epithelial cell and secondarily, 
the endothelial layer, or it does so within infected macrophages (41). 
M. tuberculosis evades the innate antimicrobial defenses of 
macrophages by inhibiting the maturation of its phagosome to a 
bactericidal phagolysosome (3). Mycobacterial induced inhibition of 
phagosome-lysosome fusion has been considered the central feature 
of tuberculous pathogenesis, providing the organism with a means to 
avoid both the direct antimicrobial activity of the innate immune 
system as well as effective antigen presentation by inhibiting MHC 
class II dependent antigen presentation pathway and elicitation of 
adaptive immunity (42). 
Once inside the host macrophages, M. tuberculosis delays or inhibits 
fusion of the phagosome, within which it resides to lysosomes. Thus, 
the survival mechanisms or pathogenic strategies involved include 
inhibition of phagosome maturation and acidification, modification of 
normal phagosomal trafficking pathway, and alteration of recruitment 
or association of various proteins to the phagosomal membrane. 
These are discussed below: 
Inhibition of phagosome maturation and the consequent intracellular 
survival of M. tuberculosis occur via inhibition of macrophage Ca^*-
mediated signal transduction. M. tuberculosis blocks macrophage 
Ca^* signaling via inhibition of macrophage sphingosine kinase (3). 
Many lipid components of the mycobacterial cell wall have essential 
roles in the innate ability of mycobacteria to block the fusion of the 
bacterial phagosome to lysosomes (21). 
Altered phagosomal maturation is associated with alteration in the 
protein content of the vacuole including altered Rab GTPase 
composition (43), exclusion of the vacuolar protein ATPase with 
consequent lack of acidification (44), and retention of a protein 
designated TACO (76). Uptake of mycobacteria by macrophages and 
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subsequent retention of TACO on the phagosome appears to be 
dependent upon the accumulation of host cell-derived cholesterol in 
the plasma membrane at the point of bacterial entry. 
Whereas some mycobacterial cell wall lipids, such as trehalose 
mycolates, influence the inflammatory response (46), other 
components modulate trafficking inside the macrophage. For e.g. the 
M. tuberculosis Ptd lns-3P analog, glycosylated phosphatidyl inisitol 
lipoarabinomanen (Man LAM), blocks phagosome maturation (47) and 
inhibits the rise in Ca "^" concentration in the macrophage cytosol upon 
phagocytosis of mycobacteria. 
(2) Role of Nitric oxide (NO) 
Putative and effective host defense mechanisms by innate immune 
cells to M. tuberculosis within the phagolysosomes of activated 
macrophages include the production of reactive oxygen (ROI) and 
reactive nitrogen intermediates (RNI). Catalytic action of the 
respiratory burst by the NADPH-oxidase complex produces ROI such 
as hydrogen peroxide (H2O2), superoxide anion (O2") and hydroxyl 
radical (OH ) (48). NO is a non-specific, chemically reactive molecule 
that is important in host defense against a wide variety of microbial 
pathogens. Although controversial, there is a growing body of 
evidence that NO produced by M. tuberculosis infected human 
macrophages and epithelial cells is also antimycobacterial against M. 
tuberculosis (4, 50). Human macrophages produce NO from increased 
iNOS activity (82) as in human lung epithelial cells (51). TNF-a and IL-
1p, along with IFN-y produced by T-lymphocytes, can induce NO in 
macrophages via inducible form of the enzyme nitric oxide synthase 
(iNOS) (52). Mycobacterial cell wall components such as LAM and 19 
kDa lipoprotein, along with T-cell-derived IFN-y may also induce NO 
expression (34). 
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Specific Acquired/Adaptive Immune Response: 
T-ceil mediated immunity 
In most infected individuals, cell-mediated immunity develops 2-8 
weeks after infection. The development of cell-mediated immunity is 
associated with the development of a positive result in the tuberculin 
skin test (2). 
Macrophages and dendritic cells, the primary cell types involved in the 
innate immune response to M. tuberculosis, play a crucial role in the 
initiation of adaptive immunity (24). The initial interaction of M. 
tuberculosis with phagocytes through toll-like receptors can affect 
induction of the adaptive response by inflammatory cytokine 
production, as well as begin the process of bacterial containment by 
induction of antimycobacterial functions. The initiation of the adaptive 
immune response to the organism is likely to be a major determinant 
of long-term control of the infection (53). Thus, TLRs are an important 
link between innate and adaptive immunity (54). The significance of 
TLRs in activating adaptive immunity is well established (55); TLR-
mediated activation of dendritic cells is a crucial step in this process. 
Other mechanisms involved include induction of expression of 
cytokines and co-stimulatory proteins (54). Signaling through TLRs 
favours the development of a Th1-type response, in which IL-12 has 
an important role (34). 
CD4 T-cells have a crucial role in protection against tuberculosis (7). 
In human beings, CDS T-cells have been reported to be involved in 
control of both acute and chronic infection (55). CDS T-cells specific 
for M. tuberculosis can directly kill intracellular bacilli via a granule-
associated protein, granulysin (57). 
In brief, at the focal site of infection in the lungs, the dendritic cells that 
engulf bacteria mature (5S) and migrate to the required lymph node. 
Once there, CD4 and CDS T-cells are primed against mycobacterial 
antigens. Primed T-cells expand and migrate back to the lungs and 
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through the lung tissue to the focus of infection, presumably in 
response to signals such as chemokines produced by or in response 
to infected cells (7). M. tuberculosis-'mlected macrophages release IL-
12 and IL-18 which stimulate the CD4 and CD8 T-cells to release IFN-
y (59). IFN-y is crucial for the control of M. tuberculosis infection (60). 
It stimulates phagocytosis of M. tuberculosis and also the release of 
TNF-a from macrophages, which is important in granuloma formation 
and control of the extent of infection (61). 
Three processes contribute to the infection of adaptive immunity: 
antigen presentation, costimulation, and cytokine production. These 
are discussed below: 
(1) Antigen Presentation 
The T-lymphocyte response is antigen specific and is influenced by 
the major histocompatibility complex (62). MHC class II molecules are 
expressed on professional antigen-presenting cells (APCs). They 
present mycobacterial proteins to antigen-specific CD4 T-cells. These 
antigens are processed in the phagolysosomes of APCs (52). MHC 
class I molecules are expressed on all nucleated cells. They present 
mycobacterial proteins to antigen-specific CDS T-cells. This is 
important for the presentation of cytosolic antigens, which may be 
important as certain mycobacteral antigens may somehow escape the 
phagosome (63). 
Pro-inflammatory cytokines, primarily IFN-y stimulate MHC 
expression, whereas anti-inflammatory cytokines inhibit its expression. 
Polymorphism of MHC may contribute to differences in disease 
susceptibility or outcome (64). The expression of particular class I and 
class II MHC alleles in an individual determines (mycobacterial) 
antigens and epitopes (24). Certain allelic human leukocyte antigen 
variants (HLA polymorphism) have been associated with tuberculosis 
and susceptibility to it (64, 65). 
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(2) Costimulation 
Maturation of dendritic cells induced by TLR stimulation results in 
accumulation of antigen-MHC II complexes on the cell surface, thus 
facilitating antigen presentation (66). Antigen presentation only leads 
to T-cells stimulation in the presence of particular costimulatory 
signals. The co-stimulatory proteins CD80 (116), CD86 (69) and CD70 
are upregulated on antigen-presenting cells after TLR activation (96). 
These molecules (CD80 and CD86) bind to CD28 and CTLA-4 on T-
cells (24). In the absence of proper co-stimulatory signals, antigen 
presentation may lead to increased apoptosis of T-cells (69). 
(3) Cytokine Production 
Cytokine production by activated macrophages and dendritic cells is 
important for T-cell stimulation. These cytokines include IL-12, IL-18, 
and IL-23 as well as IL-1 and TNF-a (70). IL-12 is the inducer cytokine 
that mediates protection (71). During the ensuing immune response, 
IL-12 plays a key part in driving the activation, differentiation from 
CD4* T-cells, and expansion of antigen-specific T-helper type 1 (Thi) 
cells. These cells are a major source of IFN-y during the adaptive 
immune response and are necessary for the control of the chronic 
phase of infection (72). The activation of infected macrophages by 
IFN-y in synergy with TNF-a is a major effector mechanism of cell-
mediated immunity. M. tuberculosis induces TNF-a synthesis by a 
TLR2-dependent pathway (73). IFN-y, together with TNF-a. which is 
released by T-cells and phagocytes, activates microbicidal 
mechanisms in mononuclear phagocytes (74). 
Granuloma formation 
The granuloma is a hallmark protective immunopatholgical response 
of the host following infection with M. tuberculosis. It is considered to 
be a protective structure since it curtails the spread of the pathogen 
and at the same time localizes inflammation and damage to the lungs 
(23). Primed T cells in the lymph nodes expand and migrate back to 
the lungs and then through the lung tissue to the focus of infection in 
response to chemokine signals especially TNF-a. This culminates in 
the formation of a granuloma, a characteristic feature of tuberculosis 
(7). Besides T cells and infected macrophages, additional immune 
host cells are recruited, including B cells, dendritic cells, endothelial 
cells, fibroblasts, and probably stromal cells (75). The granuloma 
encompasses the bacilli, which reside within macrophages, and 
serves to wall off the bacteria from the rest of the lung, limiting spread. 
In addition, the granuloma functions as an immune microenvironment 
to facilitate interactions between T cells and macrophages and 
cytokines. However, the garnuloma can also provide a home for M. 
tuberculosis for an extended period, because some bacteria can avoid 
elimination within the granuloma (7). The granuloma subsequently 
develops central areas of necrosis (called caseum, from the word 
'cheese'), resulting in the death of the majority of the bacteria and 
destruction of the surrounding host tissue. The surviving bacilli exist in 
a latent state and can become reactivated to develop active disease 
(76). Proteosome mediated inactivation of NO stress is important for 
the survival of mycobacteria within granuloma structures (77). 
Although excessive replication of bacteria seems to result in loss of 
granuloma structure, extensive necrosis, and cavity formation, in most 
cases the granuloma contains the infection, but a limited number of 
bacilli survive, which is termed latent tuberculosis. A person who has a 
delayed type hypersensitivity response to mycobacterial antigens 
(PPD) without signs of active TB is deemed to have latent infection 
and not to be contagious. 
The Bacterium 
The cause of tuberculosis, Mycobacterium tuberculosis is a Gram-
positive aerobic bacterium that divides every 16-20 hours. It is a small 
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rod-like bacillus, which can withstand weak disinfectants and can 
survive in a dry state for weeks but can only grow within a host 
organism. 
M. tuberculosis Cell Envelope: Architecture and Composition. 
M. tuberculosis is surrounded by a complex envelope of unusually low 
permeability, which contributes to the resistance of this bacterium to 
host defense mechanisms (78). In general, the bacterial cell envelope 
is composed of a plasma membrane, a complex wall comprising a 
variety of covalently and non-covalently linked carbohydrates and 
lipids, and finally an outer layer (capsule) of polysaccharides, proteins 
and small amounts of lipids. The plasma membrane is a typical bilayer 
of proteins and phospholipids. Similar to classical bacterial cell walls, 
the cell envelope of M. tuberculosis contains a cell membrane and a 
peptidoglycan layer (79). The thick peptidoglycan layer is covalently 
linked to a heteropolysaccharide, namely arabinogalactan. However, 
in other aspects, the M. tuberculosis cell envelope differs substantially 
from the canonical cell wall structures of both gram-negative and 
gram-positive bacteria (Figure 1). The cell envelope is typified by the 
presence of a large hydrophobic layer of unusual long-chain fatty 
acids: mycolic acids esterified to the cell wall, named the mycolyl 
arabinogalactan (MAG) (79). Mycolic acids are long chain (60-90 
carbon atoms), branched, a-P hydroxyl fatty acids that exist either 
covalently attached to the cell wall or non-covalently attached in the 
form of trehalose dimycolate (TDM). The arabinan segments of 
arabinogalactan in the peptidoglycal layer are terminated by a hexa-
arabinosyl unit esterified by the various types of mycolic acid residues 
elaborated by the species (80). These long-chain fatty acids are 
probably arranged into an asymmetric bilayer with other non-
covalently linked lipids, which forms a virtually impermeable outer 
barrier obstructing access of hydrophilic substances. l\/lycolic acids are 
behind to play an important role in the structure of the cell wall and to 
contribute to the resistance of mycobacteria to many therapeutic 
agents (81). Among the non-covalently linked lipids that can be found 
in the outer bilayer are trehalose dimycolates (TDM), trehalose 
monomycolates (TMM), glycerol monomycolates and phospholipids. A 
wide array of unique lipids and glycolipids are non-covalently 
associated with the cell envelope and confer extreme hydrophobicity 
to the outer surface of the organism (80). 
Many of these molecules are potent immune modulators, suggesting a 
role in virulence. For example, lipoarabinomannan, a major cell wall 
associated glycolipid, has been extensively examined in vitro and can 
inhibit gamma interferon activation of macrophages (82), induce TNF-
a release from macrophages (83), and scavenge oxygen free radicals 
(84). 
TDM, a mycolic acid-containing glycolipid, can produce 
granulomatous inflammation and thymic atrophy when injected into 
mice (85) in addition to affecting membrane fusion in model systems 
(86) and toxicity for mitochondria. 
Despite such an elaborate array of bioactive chemical entities in the 
cell envelope of pathogenic mycobacteria, detailed understanding of 
each of their roles in M. tuberculosis pathogenesis has been limited 
due to limitations in genetic analysis. However, recently a cluster of M. 
tuberculosis genes necessary for replication has been identified in 
mice. It was demonstrated that inactivation of two genes in this region 
abolished synthesis of phthiocerol dimycocerosate (PDIM), a complex 
lipid non-covalently attached to the mycobacterial cell envelope. 
Synthesis and proper transport of PDIM was found to be necessary for 
organ-specific replication of M. tuberculosis (i.e. in the lungs). 
A specific sub-class of mycolic acids was also shown to have a role in 
mycobacterial replication in vivo. The evidence for the role of an 
individual lipid molecule was arrived at with the disruption of the 
mmaA4 gene, which impaired the replication of the mutant obtained 
thus MmaA4 is one member of a large family of SAM-dependent 
methyl transferases that modify the mycolic acids of the M. 
tuberculosis cell wall by introducing cyclopropane rings and methyl 
branches. 
In addition, erp was identified as a repetitive protein that is essential 
for normal replication of M. tuberculosis in macrophages of mice. katG 
codes for a catalase-peroxidase produced by -M. tuberculosis and 
confer virulence, making it important for in vivo survival in the 
chemically hostile environment in a macrophage, including ROS and 
RNI. Like gram-positive bacteria, the mycobacterial cell envelope 
contains proteins, including some with pore-forming ability (80). The 
increasing number of enzymes recently identified as being involved in 
cell envelope biogenesis includes the three predominant secreted 
proteins of M. tuberculosis, antigens 85A, 85B and 85C (87). 
M. tuberculosis antigen 85 complex 
The antigen 85 complex consists of three internally cross-reacting 
antigens encoded by three independent genes, fbpA, fbpB, fbpC, 
found in the genomes of M. tuberculosis, M. leprae and M. avium (88, 
80). In antigen 85 complex, the gene for antigen 85A encodes a 294-
amino-acid mature protein (89), which shows 79% homology with the 
deduced 285-aminoacid sequence of antigen 85B (90). The antigen 
85 complex is often referred to as the 30/31- kDa doublet and the 
molecular masses of the individual components of the antigen 85 
complex are as follows: antigen 858, 30 kDa; antigen 85A, 31 kDa; 
antigen 85C, 31.5 kDa. Antigen 85C appears to be slightly heavier 
than antigen 85A, and in most SDS-PAGE runs these two 
components are not properly resolved (91). Thus, the pattern in 
Western immunoblotting usually reveals a doublet in the 30-kDa 
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region, as exemplified by using tlie monoclonal antibody HYT27 (92) 
which reacts with all three components of the complex (87). The 
components are clearly resolved in isoelectric focusing, providing 
three distinct bands (93). In M. tuberculosis H37RV culture fluid 
obtained from a batch with minimal cell lysis, the quantitatively 
dominating components of the antigen 85 complex, antigens 85A and 
85B, constituted about 60% of total protein and that there was slightly 
more antigen 85B than antigen 85A (87). Although antigen 85 
complex is a major constituent of the mycobacterial culture fluid, it is 
also found in association with the bacterial surface. Soluble extracts of 
washed disrupted cells, prepared by sonication under careful 
temperature control, contain only small amounts of the antigen 85 
complex (87). The monoclonal antibody HYT27 gave a positive signal 
in ELISA with whole M. tuberculosis cells (92). The localization index 
for antigen 85A has consistently been found to be higher than for 
antigen 85B, indicating that antigen 85B may be less efficiently 
secreted and more closely associated with the bacterial surface (87, 
95). Worsaae et al. (96) performed skin testing with the antigen 85 
complex affinity purified with monoclonal antibody HYT27. The 
available results indicate that antigen 85B is a relatively good skin test 
reagent whereas antigen 85A is not. The information on antigen 85C 
remains to be established (87). Antigen 85B is a mycolyl transferase 
involved in cell wall biosynthesis. In an in vitro enzymatic assay, 
antigen 85B have been shown to catalyse the transfer of a mycolyl 
residue from one molecule of TMM to another, leading to the 
formation of TDM (or cord factor) (97). It stimulates lymphocyte 
blastogenesis and interferon-y production in healthy individuals, but 
not in patients with pulmonary tuberculosis (98). In contrast, antibody 
to the 85B antigen is increased in patients with tuberculosis (99). 
Interestingly, antigen 85B is immunodominant (100) and potently 
induces TNF-a when complexed to fibronectin (fn) in mononuclear 
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phagocytes (101). Fibronectins are a family of high molecular weight 
glycoproteins found in plasma and tissues that are involved in cell 
motility and adhesion, regulation of cell morphology, phagocytic 
function, and wound healing (102). The expression of 85B in M. 
tuberculosis-m^ecied monocytes correlates positively with both the 
amount of secreted TNF-a and subsequent intracellular mycobacterial 
growth (103). Antigen 85B mRNA in both broth cultures and sputum 
specimens correlates well with the yield of viable M. tuberculosis 
(104). 
Drug Susceptibility Testing 
Where resources for diagnosis and treatment of drug-resistant 
tuberculosis allow, drug-susceptibility testing (DST) should ideally be 
done on all initial M. tubeculosis isolates (105). However, DST is only 
of value when it is quality controlled for accuracy. DST should also be 
considered when cultures remain positive after 3 months of treatment, 
or become positive after being previously negative. Nucleic acid 
amplification assays are employed in DST and can be used directly on 
clinical specimens, but are limited by high cost. Amplification tests do 
not replace the sputum-smear (which provides a gauge of 
infectiousness) or solid/liquid culture (which is necessary for DST) 
(7,106). Susceptibility to isoniazid and rifampicin as an absolute 
minimum should be established within 30 days (106). Rapid detection 
of rifampicin resistance is particularly important, and new methods to 
detect this and other types of resistance are coming into clinical 
practice. 
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Treatment and Control 
The goals of treatment are to ensure cure without relapse, to prevent 
death, to stop transmission, and to prevent the emergence of drug 
resistance (2). To control tuberculosis, WHO and lUATLD recommend 
the DOTS strategy (107), directly observed treatment, which has fine 
elements: political commitment, diagnosis primarily by sputum-smear 
microscopy among patients attending health facilities, short-course 
treatment with effective case management (i.e. direct observation), 
regular drug supply, and systematic monitoring to assess outcomes of 
every patients started on treatment. 
TNF-a blockade: antl-TNF-a agents 
Attenuation of the biological activity of TNF has lately become an 
important therapeutic intervention in the management of a wide variety 
of chronic Inflammatory diseases (108). Currently two major protocols 
are being used for the treatment of various chronic inflammatory 
diseases: Infliximab, an anti-TNF neutralizing antibody, and 
Etanercept, a recombinant molecule made up of two identical chains 
of the human 75 kDa TNF receptor II fused to the Fc portion of human 
lgG1 (109). 
Infliximab is a human-murine (25% murine) chimeric monoclonal 
antibody with high binding affinity (110) and specificity for TNF-a 
(111). It forms stable complexes with the monomeric and trimeric 
forms of soluble TNF-a and with the transmembrane forms of TNF-a 
(112). It also has the ability to cross-link TNF-a molecules. Binding to 
transmembrane TNF-a results in macrophage and monocyte lysis by 
cytotoxicity that depends on antibodies and complement (113). 
Infliximab does not bind to related cytokines, such as TNF-P 
(lymphotoxin-a), which is involved in the Thi response (114). 
23 
Etanercept is a dimeric fusion protein and consists of the extracellular 
ligand portion of the human TNFRp75 linked with the Fc portion of 
human IgGI (115). In comparison with infliximab, etanercept forms 
less stable complexes with membrane-bound TNF-a and monomeric 
TNF-a (112), but it does bind significantly with the trimeric form of 
soluble TNF-a. Owing to its relatively fast dissociation rate (compared 
with infliximab), etanercept sheds about 50% of soluble TNF-a and 
90% of transmembrane TNF-a only 10 minutes after binding. 
There are subtle differences in the mechanisms of action of these two 
agents in particular; drug-mediated apoptosis and monocytopenia 
appear to be unique to infliximab (109). Infliximab binds more avidly 
than etanercept does to transmembrane TNF-a and form a more 
stable complex. More infliximab than etanercept binds to 
transmembrane TNF-a. Infliximab is more effective at inhibiting 
transmembrane TNF-a-mediated activation of endothelial cells. 
Infliximab binds both the monomeric and trimeric form of soluble TNF-
a, whereas etanercept effectively binds only to the trimeric form. 
Etanercept-TNF-a complexes are unstable, resulting in the release of 
soluble TNF-a. On the basis of these differences, infliximab might be 
predicted to have a more significant effect on the host's ability to 
suppress M. tuberculosis infection (109). 
There is a growing body of clinical evidence that neutralization of TNF-
a is associated with an increased risk of opportunistic infections, 
including mycobacterial diseases (116). A major side effect of anti-
TNF therapy is the increased risk of developing tuberculosis (109). 
TNF-blockade-associated tuberculosis shows granuloma 
disorganization, which may be deficient in restricting inflammation to a 
localized environment. This could lead to extension of the 
inflammatory response into otherwise unaffected lung tissues, 
resulting in the aberrant pathology observed in tuberculous patients 
24 
treated with TNF blockade (117). Treatment with anti-TNF-a 
antibodies readily leads to tuberculosis reactivation in patients with 
rheumatoid arthritis (118). 
Drawback of Current Treatment and Control Regimens 
The side effects of TNF-a blockade have been discussed previously. 
In addition, drug-induced hepatotoxicity, leading cause of liver injury, 
is an important and commonly encountered adverse effect with anti-
tuberculosis treatment with three potential hepatotoxic drugs: 
isoniazid, rifampicin and pyrazinamide (119). Pyrazinamide was found 
to significantly contribute to the development of hepatotoxicity when 
given along with isoniazid and rifampicin (120). The use or misuse of 
these drugs over the years has led to an increasing prevalence of 
multiple-drug resistance (MDR) strains, establishing an urgent need to 
develop new effective agents (121). MDR-tuberculosis is defined as 
the disease due to tuberculosis bacilli resistant to atleast isoniazid and 
rifampicin, the two most powerful anti-tuberculosis drugs (122). 
The current vaccine BCG is an attenuated strain of 
Mycobacterium bovis, which primarily causes bovine disease and is a 
close relative of M. tuberculosis. Most studies have demonstrated that 
BCG vaccines afford a higher degree of protection against severe 
forms of tuberculosis, such as meningitis and disseminated 
tuberculosis, than against moderate forms of the disease (122). Even 
with high coverage, BCG has not had any substantial effect on 
transmission or incidence, because its main action is to prevent 
serious (but infectious) disease in children (123). Adverse events from 
BCG vaccination can occur, including local subcutaneous abscess 
and ulcers, supportive lymphadenitis, and, more rarely, disseminated 
disease (124). In addition, BCG vaccination may only provide 
protection against primary infection and be of little help in already 
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infected individuals or in cases of reactivation tuberculosis (125). 
Despite continuing efforts to develop more effective tuberculosis 
vaccines, none have been identified to date. Even if one were to be 
developed, It might not prevent progression to active disease among 
the more than two billion people already infected with M. tuberculosis. 
Therefore, even if a new vaccine were to be implemented worldwide, 
more effective treatment systems would be required for decades (2). 
Natural antioxidant in tuberculosis prevention - EGCG 
from Green Tea 
Tea {Camellia sinensis) has been used as a daily beverage for several 
thousand years since it was introduced as a beverage in China and is 
now the second most common beverage consumed by humans (126). 
Even though it has been known traditionally that tea may have some 
beneficial health effects, such effects were not demonstrated by well-
controlled laboratory studies until the 1970s (126). However, recent 
studies have revealed the biological effects of tea, such as antitumor 
as well as antimicrobial effects, even at the molecular level. The active 
components of tea responsible for such biological effects are now 
known to be catechins (also known as polyphenols), which are known 
to be constituted of seven forms, including epigallocatechin gallate 
(EGCG). EGCG is a major catechin compound in tea extracts and is 
also the most active form among the tea catechins in a variety of 
biological activities. For instance, EGCG has anticarciogenic (127, 
128), antioxidant (129), as well as antimicrobial activities (130, 131). 
Although the mechanism of antimicrobial activity of EGCG has been 
studied, it is still unclear. However, the immunomodulatory effect of 
EGCG has been increasingly recognized, since the bioavailability of 
EGCG in plasma after drinking tea is known to be high (132). In fact, it 
is known that EGCG potently stimulates the production of interleukin-1 
alpha (IL-1a), IL-1b, and tumor necrosis factor alpha (TNF-a) by 
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cultured human peripheral blood mononuclear cells (133). 
Furthermore, EGCG protects against UV radiation-induced 
immunosuppression and tolerance induction by reducing IL-10 
production and increasing IL-12 production in epidermal and dermal 
cells (134). However, the detailed immunomodulatory effects of EGCG 
on immune cells have not been investigated. 
Brief about present study: 
As a matter of fact, till date, human immune response to M. 
tuberculosis is not well characterized. Thus, in order to investigate the 
cellular immune response to tuberculosis in a better way, in the 
present study, a human monocyte culture system infected with M. 
tuberculosis at an infective ratio of 1:1 (bacteriaxell) was employed. 
Here we have examined the interaction of virulent M. tuberculosis 
(H37RV) with human monocytes, focussing on the role of TNF-a and 
M. tuberculosis 85B. In this investigation, real-time RT-PCR, direct 
binding ELISA and competition ELISA carried out a systematic study 
to characterize the sera and monocytes of tuberculosis patients with 
respect to TNF-a and M. tuberculosis 85B. Real-time RT-PCR, SDS-
PAGE, gel retardation assay, direct binding ELISA and competition 
ELISA evaluated the modulatory effects of the natural antioxidant 
EGCG on M. tuberculosis 85B expression in H37RV cultures. The 
interaction of M. tuberculosis 85B and TNF-a after 24 hours of 
infection of human monocytes with M. tuberculosis was investigated 
by RT-PCR and real-time RT-PCR. To fully delineate the contribution 
of the innate immune response to the pathogenesis of M. tuberculosis 
infection, the roles played by ROIs and RNIs, induction of TNF-a, 
activation of NF-KB and monocyte activation, in the expression of M. 
tuberculosis 85B were examined. 
Assessment of EGCG on the viability of human monocytes was 
assessed by cell viability assays like MTT and trypan blue exclusion 
assay as well as by assessing human housekeeping genes like 188 
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rRNA by real-time RT-PCR, respectively. Real-time RT-PCR and 
ELISA probed the effects of EGCG in cornparison to known TB 
antibiotics like streptomycin, rifampicin and isoniazid on the 
expression of TNF-a and M. tuberculosis 85B in M. tuberculosis-
infected monocytes after 24 hours of infection. Commercially available 
ELISA kits assessed the repertoire of TNF-a, TNFR-I and TNFR-II in 
supernatants of M. tuberculosis-'m^ected monocyte cultures that were 
treated and untreated with EGCG. Glutathione peroxidase activity, 
glutathione and IFN-y levels were also evaluated in M. tuberculosis-
infected monocytes after 24 hours of infection in the presence or 
absence of EGCG. 
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Fig 2: Monocytes floating in a sea of platelets. © American 
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EXPERIMENTALS 
Materials: 
N-acetyl-cysteine, EGCG, SN50 (an inhibitor of NF-KB) and its 
analogue SN50/M, recombinant human (rh) TNF-a, monoclonal anti-
TNF-a antibody, soluble TNFR-I, soluble TNFR-II, H2O2, oxidized 
ATP, N°-monomethyl-L-arginine-monoacetate, nonoate-9, sodium 
nitroprusside, agarose, bovine serum albumin, Coomassie Brilliant 
Blue G-250 and R-250, Tween-20, p-nitrophenyl phosphate, anti-
human IgG alkaline phosphate conjugate, dithiothreiotol, 
phenylmethylsulphonyl fluoride, standard protein markers, protein A 
sepharose CL-4B, sodium azide, ethidium bromide, chloroform, 
isoamyl alcohol, reduced glutathione, glutathione reductase, cumene 
hydroperoxide and reduced p-nicotinamide adenine dinucleotide 
phosphate were from Sigma Chemical Company, U.S.A. SN50 is a 
hybrid peptide containing nuclear localization sequence of p50 subunit 
of NF-KB heterodimer and has been shown to completely inhibit the 
translocation of NF-KB in human cell lines at 100 pg/ml (135). 
Middlebrook 7H9 broth, Middlebrook ADC enrichment fluid, 
RPMI-1640 medium were from HiMedia, India. Ficoll-Paque was from 
Pharmacia, Piscataway, NJ, U.S.A. Immunoassay kits for TNF-a and 
its receptors and MTT cell viability assay kit were of R & D Systems, 
U.S.A. 12-wells tissue culture plates were obtained from Techno 
Piastic Products (TPP), Switzerland. Polystyrene mlcrotltre fiat bottom 
ELISA plates having 96 wells (7 mm diameter) were from NUNC, 
Denmark. All other chemicals were of the highest analytical grade 
available. 
Study subjects: 
Healthy adult volunteers who were nonsmoking and had no 
history of tuberculosis or positive tuberculin skin test served as donors 
for venous blood. Apart from the above, blood from patients with 
active pulmonary tuberculosis was also obtained from the patients 
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admitted to the J.N. Medical College Hospital of A.M.U. Diagnosis of 
tuberculosis was based on demonstration of acid-fast bacilli on 
sputum smear and later confirmed by positive culture of M. 
tuberculosis. Serum was separated and stored at -20°C until required. 
Determination of protein concentration: 
The methods described by Lowry et ai. (136) and Bradford 
(137) were employed for the determination of protein concentrations 
as described below. 
(A) Lowry (Folin-Ciocalteau) method: 
Protein estimation by this method involves complexing of the 
protein's peptide bonds with Cu^* under alkaline conditions (136). The 
resultant Cu"" appears to catalyze the oxidation of tyrosine and 
tryptophan residues by reducing phosphomolybdotungstate anions in 
the Folin reagent (a mixture of sodium tungstate, molybdate and 
phosphate), added subsequently. This reaction develops a blue colour 
due to the formation of heteropolymolybdenum blue, which can be 
quantified by its absorbance at 660 nm. 
Reagents: 
(i) Folin-Ciocalteau reagent 
The reagent was diluted 1:4 with distilled water before use. 
(II) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as 
follows: 
(a) 2% sodium carbonate in 100 mM NaOH 
(b) 0.5% copper sulphate in 1% sodium potassium tartarate 
The working reagent was prepared fresh before use by mixing the two 
components in the ratio 50:1, respectively. 
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Procedure: 
To 1.0 ml of protein sample was added 5.0 ml of freshly 
prepared alkaline copper reagent. After thorough mixing, the reaction 
mixture was allowed to stand at room temperature for 10 minutes, 
followed by the addition of 1.0 ml of 1:4 times diluted Folin-Ciocalteau 
reagent. The contents were mixed immediately. The reaction was 
allowed to proceed for 30 minutes at room temperature and each tube 
was subsequently monitored at 660 nm. The protein content of the 
unknown sample was detemiined by using bovine serum albumin to 
construct a standard calibration curve. 
(B) Bradford method: 
This method is based on strong binding of the dye Coomassie 
Brilliant Blue G-250, in acidic medium, to protein hydrophoblcally and 
at positively charged groups (137). In the environment of these 
positively charged groups, protonation is suppressed and a blue color 
develops (Amax-595 nm). 
Preparation of dye: 
100 mg of Coomassie Brilliant Blue G-250 was dissolved in 50 
ml of 95% ethanol and 100 ml of 85% (v/v) orthophosphoric acid was 
added. The resulting solution was diluted to a final volume of 1.0 litre 
and filtered through Whatman No. 1 filter paper to remove undissolved 
particles. 
Procedure: 
To 1.0 ml of solution containing 10-100 pg protein was added 
5.0 ml of dye solution. The contents were mixed thoroughly by 
vortexing. The absorbance was read at 595 nm after 5 minutes 
against a reagent blank. 
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Agarose gel electrophoresis: 
Agarose gel was prepared by bringing 2% agarose to molten 
state in electrophoresis buffer (0.04 M Tris acetate, pH 8.0 containing 
0.002 M EDTA). Molten agarose was poured on the gel tray and 
allowed to solidify for 1 hour at room temperature. The nucleic acid 
samples in one-tenth volume of stop-mix (30% ficoll, 0.025% xylene 
cyanole FF and 500 mM EDTA in 10X TAE buffer) were 
electropheresed for 2-4 hours at 30 mA in the same buffer. The gel 
was stained with ethidium bromide (0.5 pg/ml). 
Polyacrylamlde gel electrophoresis of proteins: 
The method described by Laemmli (138) was employed for 
carrying out polyacrylamlde gel electrophoresis under denaturing 
conditions. 
Reagents: 
(i) Aeryiamide-bisacrylamide (30:0.8) 
A stock solution of 30% acrylamide containing 0.8% 
bisacrylamide was prepared by dissolving 30 gm of acrylamide and 
0.8 gm of bisacrylamide in a total volume of 100 ml. The solution was 
stored at 4°C in an amber coloured bottle. 
(ii) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base 
in 48 ml of 1 N HCI. The contents were mixed, pH adjusted to 8.8 and 
the final volume brought to 100 ml with distilled water. 
(ill) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH 
adjusted to 6.8 with 1 N HCI and the final volume adjusted to 100 
ml with distilled water. 
(iv) Electrode buffer 
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3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved 
in distilled water, pH adjusted to 8.3 and the final volume made up to 
1.0 litre with distilled water. 
(v) Sample buffer 
(a) 6.0 gm of Tris was dissolved in 80 ml distilled water and pH 
adjusted to 6.8 with phosphoric acid. The final volume was brought to 
100 ml with distilled water. 
(b) 1.0 mg of bromophenol blue and 12.5 ml of glycerol were added 
to 12.5 ml of the above solution, p-mercaptoethanol was added just 
before use. 
Procedure: 
The glass plates (18 cm x 16 cm) were soaked in chromic acid 
and thoroughly washed with tap water followed by a final rinse with 
distilled water and ethanol. The plates were dried and sealed with 1% 
agarose and 1.5 mm thick spacers. The reagents were mixed and 
poured between the glass plates. The resolving gel was allowed to 
polymerize at room temperature, following which, the stacking gel was 
layered on top. A well-forming comb was inserted immediately and the 
gel was left to polymerize at room temperature. In case of gradient 
gels, a gradient of resolving gel was formed with the help of a gradient 
former (Bio-Rad, model 385). After ensuring complete polymerization, 
the protein samples (25-100 pg) in one-fourth volume of sample 
buffer were electrcphoresed at 80 volts at room temperature. The gels 
were stained using 0.25% Coomassie Brilliant Blue R-250 or with 
silver stain reagent. 
Silver staining: 
Silver staining was done by the method of Merri! et al. (139). 
Briefly, the gel was incubated in 40% methanol and 12% acetic acid 
for 45 minutes followed by incubation in 50% ethanol for 30 minutes. 
Next the gel was treated with 0.02% hypo (sodium thiosulphate) for 1 
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minute. After washing with distilled water, the gel was placed in 0.2% 
silver nitrate (with 0.05% v/v formaldehyde), washed again with 
distilled water, and transferred to a 6% solution of sodium carbonate 
(with 0.05% v/v formaldehyde). After colour development, the gel was 
washed with distilled water and treating the gel with 3% v/v acetic acid 
and 5% v/v methanol arrested the reaction. All the reagents used in 
this procedure were freshly prepared. 
Recipe for 10-20% Gradient Gel 
Resolving Gel (total volume: 30 ml) 
Reagents 
Acrylamide-bisacrylamide 
(30:0.8) 
Resolving gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
10% 
5.0 ml 
3.8 ml 
150 Ml 
50 pi 
10 Ml 
20% 
10 ml 
3.8 ml 
150 Ml 
50 Ml 
10 Ml 
The final volume was raised to 15 ml each with distilled water. 
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2.5% Stacking Gel (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Stacking gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
0.8 ml 
2.5 ml 
100 pi 
75 pi 
25 pi 
The final volume was raised to 10 ml with distilled water. 
Recipe for 7.5% SDS-PAGE (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
2.5 ml 
2.5 ml 
100 pi 
50 pi 
10 pi 
The final volume was raised to 10 ml with distilled water. 
Gel retardation assay: 
The binding of antibodies in TB patient's sera with M. 
tuberculosis sonic extract proteins as well as with MTCF proteins was 
analyzed by altered electrophoretic mobility on SDS-PAGE under non-
reducing conditions. M. tuberculosis proteins were allowed to interact 
with antibodies for 2 hours at 37°C and overnight at 4°C. This resulted 
in the formation of immune complex (IC). Thereafter, the complex was 
electrophoresed on 7% SDS-PAGE under non-reducing conditions for 2 
hours at 80 V. The electrophoresed gels were visualized by staining 
with 0.25% Coomassie Brilliant Blue R-250. 
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Enzyme-linked immunosorbent assay (ELiSA): 
Antibodies were detected and quantified by ELISA using 
polystyrene flat-bottom microtitre plates as solid phase. The method 
described by us earlier (140, 141) was followed for the assay. 
Buffers and reagents: 
(i) Tris-buffered saline (TBS) 
10 mM Tris, 150 mM NaCI, pH 7.4 
(ii) Tris-buffered saline Tween-20 (TBS-T) 
20 mM Tris, 144 mM NaCI, 2.68 mM KCI and 1.0 ml/litre 
Tween-20, pH 7.4 
(iii) Bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6 
(iv) Substrate buffer (for anti-human IgG alkaline phosphatase 
conjugate) 
15 mM sodium carbonate, 35 mM sodium bicarbonate and 
2 mM magnesium chloride, pH 9.6 
Substrate: 0.5 mg/ml of p-nitrophenyl phosphate 
(A) Direct binding ELISA: 
Polystyrene microtitre plates were incubated with 100 pi of 
protein antigen (30pg/ml in carbonate/bicarbonate buffer, pH 9.6) for 
two hours at room temperature followed by overnight incubation at 
4°C. The plates were washed thrice with TBS-T and unoccupied sites 
blocked by 150 pi of BSA (1.5% in TBS, pH 7.4) for 4-6 hours at room 
temperature. Serially diluted sera in TBS were added to antigen-
coated as well as control (antigen uncoated) wells. The antigen-
antibody interaction was allowed to proceed for two hours at room 
temperature followed by overnight incubation at 4°C and subsequently 
the plates were washed four times with TBS-T in order to remove the 
unbound antibodies. Bound antibodies were assayed by means of 
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appropriate anti-immunoglobulin alkaline phosphatase conjugate 
using p-NPP as substrate. The reaction was stopped with 3 N 
NaOH and the absorbance of each well was monitored at 405 nm 
on an ELISA microplate reader. Each sample was coated in 
duplicate and the results were expressed as a mean of Atest -
Acontrol-
(B) inhibition ELISA: 
The antigen binding specificity of antibody was determined by 
inhibition experiments (142). Varying concentration of inhibitors (0-20 
pg/ml) were mixed with a constant amount of antiserum or IgG. The 
mixture was incubated for two hours at 37°C followed by overnight 
incubation at 4°C. The resulting immune complex was employed in the 
immunoassay instead of serum. The rest of the steps were as in direct 
binding ELISA. The results were expressed as percent Inhibition. 
Anhibited 
Percent inhibition = (1 ) x 100 
Auninhibited 
Preparation of mycobacteria: 
Laboratory-adapted virulent M. tuberculosis (H37RV) strain was 
grown in Middlebrook 7H9 broth supplemented with Middlebrook ADC 
enrichment fluid at 37°C in 5% CO2. Mycobacterial cultures were 
harvested at midlogarithmic (14 days) phase. Aliquots of the stock 
were kept at -70°C until use. The viability of the stock remained 
>99% at 1 year. Before use, aliquots were defrosted, then vortexed 
with glass beads for 15 minutes, followed by equilibration at 37°C for 
45 minutes. This treatment results in single cell suspension of 
mycobacteria (143) 
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Isolation of mycobacterial antigens: 
Mycobacterial cultures from mldlogarithmlc phase (14 days) 
were heat-killed at 100°C for one hour in a boiling water bath. 
Thereafter, this was followed by centrifugation at 10,000 rpm for 30 
minutes at 4°C. The culture filtrate containing secreted proteins was 
separated and stored at -20°C until further use. 
(A) Desalting of M. tuberculosis culture filtrate (MTCF) 
proteins: 
The supernatant was sterilized by filtration through a 0.22-
micron pore size membrane (Millipore Corp., USA). MTCF was 
concentrated 50 fold by ammonium sulphate and dialyzed against 10 
mM PBS, pH 7.4 for desalting. The protein content was determined by 
the method of Lowry et al. against a BSA standard. The culture filtrate 
preparations were stored in small allquots at -20°C. 
(B) M. tuberculosis sonic extract (MTSE) proteins: 
Heat-killed bacilli were washed with sterile TBS, pH 7.4 and 
suspended in sonicating buffer containing 1 mM DTT, 1 mM PMSF, 
1.0 pl/ml p-mercaptoethanol and proteinase inhibitors cocktail in TBS, 
pH 7.4. The cell suspension was disrupted by sonicating at 4°C for 15 
minutes in a sonicator and the cell debris was removed by ultra 
centrifugation at 20,000 rpm for 15 minutes. The protein content was 
determined by the method of Lowry et al. The sonic extract 
preparations were stored at -20°C in small aliquots until required. 
Preparation of RPMI-1640 medium: 
RPMI-1640 medium (dehydrated) from one unit vial (16.3 gm) 
was suspended in 950 ml of tissue culture-grade water at room 
temperature with constant, gentle stirring until the medium was 
completely dissolved. The container was rinsed with tissue culture 
grade water to remove all traces of powder and added to the above 
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solution. 3.7 gm sodium bicarbonate was added to the medium and 
stirred until dissolved. The final volume was brought to 1000 ml with 
tissue culture grade water. The medium was sterilized immediately by 
filtering through a sterile membrane filter with a porosity of 0.22 micron 
using positive pressure rather than vacuum to minimize the loss of 
carbon dioxide, and stored at 4°C till use. 
Preparation of PBMC: 
For the isolation of peripheral blood mononuclear cells (PBMCs), 60 
ml of blood was drawn from a healthy volunteer into 60 cm^ syringes 
containing 3.8 units heparin/ml. 
The heparinized blood was collected in 15 ml aliquots. Thereafter, they 
were transferred to sterile 50 ml of polypropylene centrifuge tubes and 
diluted 1:1 with sterile 10 mM, PBS, pH 7.4 at room temperature, 
followed by gentle mixing by inverting the tube a few times. 
Next, diluted blood was underlayered with 15 ml of Ficoll-Paque at room 
temperature using an 18 gauge spinal needle. Care was taken to 
prevent mixing of the layers. The gradient was centrifuged at 1800 rpm 
for 30 minutes at room temperature with the centrifuge brake turned off. 
Thereafter, by using a sterile pipette, the upper clear layer containing 
plasma was removed. The PBMCs appeared as a dense white band 
(buffy layer) above the red blood cells and granulocytes layer. This 
was removed with another sterile pipette. The banded cells were 
combined in 10 ml aliquots. 
Then, ten milliliters of banded PBMCs were diluted with 25 ml of PBS 
in sterile 50 ml polypropylene centrifuge tubes and centrifuged at 1100 
rpm for 12 minutes at room temperature to remove platelets, which 
remain in the supernatant. The PBMC pellets were combined to four 
tubes, diluted in 30 ml PBS and centrifuged at 1100 rpm for 10 
minutes at room temperature. This wash was repeated. 
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Finally, the pellets were then combined and resuspended in 30 ml 
complete medium (CM) (RPMI-1640 medium containing 2 M L-
glutamine, 25 mM HEPES, and no antibiotics). An aliquot was diluted 
20-fold and counted using a hemocytometer under a light microscope 
using 10x ocular and 40x objective. 
Preparation of autologous serum for monocyte 
culture: 
From the same donor, 30 ml of blood was drawn without 
anticoagulant and transferred to serum separator tubes. The blood 
was allowed to clot for at least 30 minutes, and then centrifuged at 
3000 rpm for 15 minutes at room temperature and the serum filtered 
through a sterile 0.22-pm filter unit. Autologous serum can be stored 
for a year or longer at -20°C. 
Cell culture: 
PBMCs (5x10^ cells/well) were added in 12-wells tissue culture 
plates in complete RPMI-1640 medium, and were subsequently 
incubated at 37°C, 5% COafor 1-2 hours for adherence. Thereafter, 
non-adherent cells were removed by washing the plates extensively 4 
times with RPMI-1640 medium. The adherent monocytes were 
cultured in RPMI-1640 supplemented with 2% autologous serum, 
followed by overnight resting at 37°C, 5% CO2. This population of 
adherent cells is up to 95% monocytes, as observed by cytostaining 
and is 99% viable (143). Prior to infection, the plates were washed 
twice with RPMI-1640 medium. 
infection and co-culture of monocytes with 
supplements: 
Monocytes were infected with M. tuberculosis (H37RV) at 1:1 
(bacteria/cell) in 30% autologous unheated serum for 90 minutes at 
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37°C, 5% CO2. Subsequent to this, the infected monocytes were 
washed four tinnes with complete medium. Cells harvested at this time 
point were considered as time zero after infection (to). Other cultures 
received RPMI-1640 medium with 2% autologous serum. As per 
experimental design, some cultures, immediately after infection 
received 10 ng/ml rhTNF-a, 10 ng/ml anti-TNF-a antibodies, varying 
doses of EGCG (0-500 ng/ml) and a mixture of 10 ng/ml rhTNF-a and 
500 ng/ml EGCG, respectively. Also, some cultures received 10 mM 
NAC, 100 pg/ml SN50, 100 MQ/m' SN50/M, 100 jjg/ml streptomycin, 
100 |jg/ml rifampicin and 100 pg/ml isoniazid. Cultures were then 
harvested after 24 hours or any other time intervals as per 
experimental design and cells were lysed in 0.5 ml of TRIZOL Reagent 
(Invitrogen Inc. Carlsbad, CA, USA). The cell-free culture supernatants 
were kept at -70°C. 
Treatment with EGCG and monocytes viability assay; 
The effect of EGCG (0-50 pg/ml) on the viability of monocytes 
was assessed by using MTT Cell Viability Assay Kit (R&D Systems) 
according to the manufacture's instructions provided 
Reagents supplied in the kit: 
Component 
MTT 
reagent 
Detergent 
reagent 
Quantity 
25 ml 
250 ml 
Storage 
conditions 
2 -8X 
18-24X 
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Assay procedure: 
Adherent monocytes infected with M. tuberculosis (H37RV) at 1:1 
(bacteria/cell) were gently scraped with RPMI-1640 medium. After 
this, monocytes (3 x lO'' ceils/well in 100 1^) were added in 96-well 
tissue culture plates. Cells were incubated in RPMI-1640 with 2% 
autologous serum containing EGCG (0-50 pg/ml) for 24 hours at 37°C, 
5% CO2. After 24 hours, 10 pi of MTT reagent (3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide) was added to each well and 
incubation was continued for an additional two hours. When a purple 
precipitate was clearly visible under the microscope, 100 ^1 of 
detergent reagent was added to all wells, including control wells and 
incubated for two hours in the dark at 20°C. After incubation, the 
precipitate was solubilized and the absorbance of the resulting solution 
was measured at 570 nm using a microplate reader. Control cells were 
treated exactly the same except that no EGCG was added to the wells. 
The percentage of viable cells was calculated by the fomnula as 
described by Islam et al. (144) and the results are expressed as 
"Viable cells (% of control cells)". 
Absorbance value of control cells 
Viable monocytes (% of control cells) = x^ 100 
Absorbance value of treated cells 
Trypan blue exclusion assay for monocytes viability: 
Adherent monocytes were gently scraped with RPMI-1640 
medium. Trypan blue suspension (1.6 mg/ml in saline solution) was 
added to the monocytes at a final concentration of 0.8 mg/ml. The 
cells were kept at 37°C for 7 minutes in a CO2 chamber (5%), 
mounted on a hemocytometer and then observed under light 
microscope. The cells taking up Trypan blue (dead cells), and cells 
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excluding the dye (viable cells) were counted. Percentage of viable 
cells was calculated by the following formula: 
Total viable cells (unstained) 
% Cell viability = x100 
Total cells (stained plus unstained) 
TNF-a Immunoassay: 
The levels of TNF-a in various culture supernatants as well as 
in serum of tuberculosis patients was determined by use of a 
commercial ELISA Kit ( R & D Systems). This assay employed the 
quantitative sandwich enzyme immunoassay technique. A monoclonal 
antibody specific for TNF-a was available pre-coated onto a 
microplate. Standards and samples were pipetted into the wells and 
any soluble TNF-a present was bound by the immobilized antibody. 
After washing away any unbound substances, an enzyme-linked 
polyclonal antibody specific for TNF- a was added to the wells. 
Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution was added to the wells and colour developed in 
proportion to the amount of TNF-a bound in the initial step. The colour 
development was stopped and the intensity of the colour was 
measured. 
Reagents supplied in the kit: 
TNF-a microplate - 96 well polystyrene microplate (12 strips of 8 
wells) coated with a mouse monoclonal antibody against TNF-a. 
TNF-a conjugate - 21 ml of polyclonal antibody against TNF-a 
conjugated to horseradish peroxidase, with preservatives. 
TNF-a standard - 10 ng of recombinant human TNF-a in a buffered 
protein base with preservatives, lyophilized. 
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Assay diluent RD1F - 6 ml of a buffered protein base with 
preservatives. It contained a precipitate and was mixed well before 
and during use. 
Calibrator diluent RD6-35 - 21 ml of animal serum with 
preservatives. 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution 
of buffered surfactant with preservatives. 
Colour reagent A -12.5 ml of stabilized hydrogen peroxide. 
Colour reagent B - 12.5 ml of stabilized chromogen 
(tetramethylbenzidine). 
Stop solution - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Working reagents: 
Wash buffer - 20 ml of wash buffer concentrate was diluted into 
deionized or distilled water to prepare 500 ml of wash buffer. 
Diluted calibrator diluent RD6-35 - 20 ml of calibrator diluent RD6-
35 was mixed with 80 ml of deionized or distilled water to yield 100 ml 
of diluted calibrator diluent RD6-35. 
Substrate solution - Colour reagents A and B were mixed together in 
equal volumes within 15 minutes of use to form substrate solution. It 
was protected from light. 
TNF-a standard - TNF-a standard was reconstituted with 1.0 ml of 
distilled water. This reconstitution produced a stock solution of 10,000 
pg/ml. The standard was allowed to sit for a minimum of 15 minutes 
with gentle agitation prior to making dilutions. 
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Assay procedure: 
50 pi of assay diluent RD1F was added to each well of 96 well 
polystyrene microplate coated with a mouse monoclonal antibody 
against TNF-a. Thereafter, 200 pi of standards, samples, or control 
per well was added, covered with the adhesive strip provided and 
incubated for 2 hours at room temperature. The plate was washed 
four times by filling each well with wash buffer using a squirt bottle. 
After washing, 200 pi of TNF-a conjugate was added to each well, 
covered with a new adhesive strip and incubated for 1 hour for cell 
culture supernatants and 2 hours for serum samples at room 
temperature. After four washings with wash buffer, 200 pi of substrate 
solution was added to each well and incubated for 20 minutes at room 
temperature in the dark, a blue colour appeared. Thereafter, 50 pi of 
stop solution was added to each well to stop the reaction. Then the 
absorbance of each well was determined within 30 minutes, using a 
microplate reader set to 450 nm. The cut off or lower limit of sensitivity 
was 4.4 pg/ml. 
Soluble TNFR-I and TNFR-II Immunoassay: 
The concentrations of soluble TNFR-I and TNFR-II in various 
culture supernatants were determined by use of commercial ELISA 
Kits (R&D Systems). 
Reagents supplied with TNFR-I kit: 
sTNFR-l microplate - 96 well polystyrene microplate (12 strips of 8 
wells) coated with a mouse monoclonal antibody against sTNFR-l. 
sTNFR-l conjugate - 21 ml of polyclonal antibody against sTNFR-l 
conjugated to horseradish peroxidase, with preservatives. 
sTNFR-l standard - 2.5 ng of recombinant human sTNFR-l in a 
buffered protein base with preservatives, lyophilized. 
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Assay diluent HD1-7 - 6 ml of a buffered protein base with 
preservatives. 
Calibrator diluent RD5-5 - 2 vials (21 ml/vial) of a buffered protein 
base with preservatives. 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution 
of buffered surfactant with preservatives. 
Colour reagent A -12.5 ml of stabilized hydrogen peroxide. 
Colour reagent B - 12.5 ml of stabilized chromogen 
(tetramethylbenzidine). 
Stop solution - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Reagents supplied with TNFR-li kit: 
sTNFR-ll microplate - 96 well polystyrene microplate (12 strips of 8 
wells) coated with a mouse monoclonal antibody against sTNFR-ll. 
sTNFR-ll conjugate - 21 ml of polyclonal antibody against sTNFR-ll 
conjugated to horseradish peroxidase, with preservatives. 
sTNFR-ll standard - 2.5 ng of recombinant human sTNFR-ll in a 
buffered protein base with preservatives, lyophilized. 
Assay diluent RD1-6 - 11 ml of a buffered protein base with 
preservatives. 
Calibrator diluent RD5-5 - 2 vials (21 ml/vial) of a buffered protein 
base with preservatives. 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution 
of buffered surfactant with preservatives. 
Colour reagent A -12.5 ml of stabilized hydrogen peroxide. 
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Colour reagent B - 12.5 ml of stabilized chromogen 
(tetramethylbenzidine). 
Stop solution - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Working reagents: 
Wash buffer - 20 ml of wash buffer concentrate was diluted to 500 ml 
with distilled water to prepare wash buffer. 
Substrate solution - Colour reagents A and B were mixed together in 
equal volumes within 15 minutes of use. 
sTNFR-l and sTNFR-ll standards - sTNFR-l or sTNFR-ll were 
reconstituted with 5 ml of calibrator diluent RD5-5 to make a stock 
solution of 500 pg/ml. 
Assay procedure: 
50 pi of assay diluents HD1-7 for sTNFR-l and RD1-6 for 
sTNFR-ll were added to each well of microplate coated with mouse 
monoclonal antibody against sTNFR-l and sTNFR-ll, respectively. 
Thereafter, 200 |JI of standards and each sample (culture 
supernatants) were added to the wells and incubated for 2 hours at 
room temperature, followed by washing three times with wash buffer. 
200 pi of sTNFR-l conjugate or sTNFR-ll conjugate were added to 
each well, incubated for 2 hours for TNFR-I or 1 hour for TNFR-II at 
room temperature and washed thrice. Thereafter, 200 pi of substrate 
solutions were added and incubated for 20 minutes at room 
temperature, followed by the addition of 50 pi of stop solution to each 
well to stop the reaction. Absorbance of each well was determined at 
450 nm using a microplate reader. 
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Measurement of M. tuberculosis 85 complex protein 
by ELISA: 
An ELISA for detection of the mycobacterial 85 complex 
(includes M. tuberculosis 85A, B, and C proteins) was used by the 
method of Islam et al. (145). Immunoplates of 96-wells were coated 
with 100 pi of monoclonal antibody to mycobacterial 85 complex (CS-
90; Colorado State University, Fort Collins) and incubated overnight at 
4°C. The wells were then washed twice and then non-specific sites in 
the coated wells were blocked by the addition of 150 pi of 1.5% BSA 
and incubated for 4-6 hours at room temperature. The blocking 
solution was then removed from the wells. 100 pi of the samples was 
added to the wells and incubated at 37°C for 90 minutes. The wells 
were again washed two times. 100 pi of polyclonal rabbit anti-
Mycobacterium bovis antibody (Dako, Carpinteria, CA, USA) as 
detection reagent was added to the wells and incubated for 2 hours at 
room temperature. The wells were again washed four times. 100 pi of 
alkaline phosphatase-conjugated anti-rabbit IgG diluted 1:10,000 in 
TBS was added into the wells and incubated for 2 hours at room 
temperature. After another four washings, lOOpI of p-NPP substrate 
solution was added into the wells and incubated at room temperature 
for about 30 minutes. The absorbance of each well was read at 405 
nm on a microplate reader. Purified antigen 85 complex (Colorado 
State University) was used as a standard. The results from the 
specimens were compared to those of a serially diluted standard at 1 -
lOOOpg/ml. 
Glutathione peroxidase assay: 
Glutathione peroxidase activity (GPx) was determined as 
described elsewhere (146, 147). The oxidized glutathione (GSSG) 
produced during GPx reaction was immediately reduced by NADPH 
and glutathione reductase. Therefore, the rate of NADPH consumption 
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was regarded as the rate of GSSG formation during the GPx reaction. 
M. tuberculosis-infected monocytes were co-cultured for 24 hours with 
or without 10 mM NAC. 100 pg/ml SN50, 100 pg/ml SNSO/IVI and 0-25 
|jg/mi EGCG. Thereafter, cells were gently scraped with lysis buffer 
containing protease inhibitors (50 mM Tris/HCI, pH 7.4; 1 mM EDTA; 
500 mM PMSF). The cell suspension was homogenized with a 
sonicator on ice and centrifuged at 10,000 rpm for 10 minutes. Protein 
concentrations of supernatants were determined by the method of 
Bradford with BSA as the standard, and were subjected to GPx 
activity determination. The reaction mixture (1.0 ml) containing 50 mM 
potassium phosphate (pH 7.0), 1 mM sodium azide, 2 mM GSH, 0.2 
mM NADPH, 1 unit/ml glutathione reductase, 1.5 mM cumene 
hydroperoxide, and 20-100 pi of samples were incubated at 25^0 for 
5 minutes. The reaction was initiated by the addition of cumene 
hydroperoxide. The kinetic change was spectrophotometrically 
recorded at 340 nm (37°C) for 3 minutes. GPx activity was calculated 
after subtraction of the blank value, as pmol of NADPH 
oxidized/minute/mg protein (U/mg protein). 
RNA extraction: 
Uninfected and infected adherent monocytes were lysed in 0.5 
ml TRIZOL Reagent as described earlier (145). For MTB-infected 
monocytes, the cell lysates were agitated with glass beads to 
complete cell wall disruption. After cooling on ice the tubes were again 
subjected to repeated disruption as above. The tubes were cooled and 
200 \i\ of chloroform was added to each sample, followed by vortexing 
for 2 minutes, and centrifugation at 3000 rpm for 5 minutes. Samples 
were then transferred to fresh eppendorf tubes and centrifuged at 
14,000 rpm for 15 minutes at 4°C. The aqueous layer was harvested 
and transferred to a fresh tube. After addition of 100 pi Cleanascite 
(CPG Inc., Lincoln Park, NJ, USA), samples were gently rocked for 10 
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minutes and then centrifuged at 14,000 rpm for one minute. The 
aqueous layer obtained was mixed with 500 pi of chloroform-isoamyl 
alcohol (24:1) and vortexed. RNA was precipitated using 50 pi of 1 M 
sodium acetate, and 475 pi of isopropanol at -20°C for 3 hours in the 
presence of glycogen. This was followed by centrifugation at 14,000 
rpm and the pellet obtained was washed two times with 75% ethanol, 
and resuspended in 87 pi DEPC-water. DNAase 1 digestion (10 pi of 
10X DNAse 1 buffer in 0.5 M Tris pH 7.5, 0.1 M MgCb, 1 mM DTT; 
and 50 pg/ml BSA, 2.0 pi RNAase inhibitor; 10U RNAase free 
DNAase 1) was employed to remove DNA. The reaction was stopped 
by the addition of 700 pi of 0.5 M NH4OAC and the RNA was re-
extracted using 500 pi of acid phenol-chloroform (1:1). The aqueous 
layer was harvested, extracted again with chloroform-isoamyl alcohol 
and precipitated. 
Real-time RT-PCR: 
Real-time quantitative reverse transcriptase PCR (RT-PCR), 
which is an advanced innovation in the field of PCR technology, 
provides a sensitive, reproducible, and accurate method for 
determining mRNA levels in tissues or cells. The method is based on 
the detection of a fluorescent signal produced and monitored during 
the amplification process, without the need for post-PCR processing 
(148). 
Two important findings led to the discovery of real-time PCR. 
First, the Taq polymerase has a 5-3' exonuclease activity (149), apart 
from its polymerase activity. Second, dual-labelled fluorogenic 
oligonucleotide probes have been created which emit a fluorescent 
signal only upon cleavage, based on the principle of fluorescence 
resonance energy transfer (150). In the TaqMan assay (Applied 
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Biosystems, Foster City, CA, USA), these two principles are 
combined. In this system a probe, the so-called TaqMan probe, is 
designed to anneal to the target sequence between the classical 
forward and reverse primers. The probe is dually labelled, with a 
reporter fluorochrome (eg., 5-carbofluorescein, or FAM) at one end 
and a quencher dye (eg., N,N,N',N'-tetramethyl-6-carborhodamine, or 
TAMRA) at the other end. In the intact probe, the fluorescence 
emission of the reporter dye will be absorbed by the quencher dye. 
The probe will be degraded during the extension phase by the 5-3' 
exonuclease activity of the Taq polymerase, separating the reporter 
and quencher, thus resulting in an increase in reporter fluorescence 
emission. The amount of fluorescence released is directly proportional 
to the amount of product generated in each PCR cycle and thus can 
be applied as a quantitative measure of PCR product formation. 
Procedure: 
Internal fluorescent hybridization probes were used in ABI 
Prism 7700 Detection System (ABI/PerkinElmer (PE) Biosystems, 
Foster City, CA, USA), which allows the sensitive and specific 
quantification of individual host (151), as well as M. tuberculosis RNA, 
transcripts (103) by quantitative real-time RT-PCR. TaqMan™ PCR 
primers and probes as well as target-specific RT primer for each 
assay were designed as described elsewhere (103; 145). The primer 
and probe sequences used as depicted in Table 1 have been 
previously reported (145). The primer and probe combination for M. 
tuberculosis 85B is specific for 85B and does not detect the closely 
related 85A or 85C sequences. All probes were dually labeled with 
FAM at the 5' end and TAMRA at the 3' end. The proximity of the dye 
(FAM) and the quencher (TAMRA) on the intact probe prevents 
detection of any fluorescence. However, degradation of the probe 
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during the course of PCR allows the release and detection of FAM 
(149). The PCRs for all amplifications were similar: 5 pi of each cDNA, 
20 |jl of Taqman Universal PCR Master Mix (PE Biosystems), which 
contains optimal amounts of AmpliTaq Gold DNA polymerase (which 
protects against amplicon carryover) and of dNTPs, and optimal 
amounts of probe and primers calibrated to allow measurement of the 
targets. First, cDNA was synthesized in the presence of 0.5 pi of 
murine leukemia virus enzyme (Invitrogen, USA)/reaction and 10 pM 
each RT primer, dNTPs, and other substrate. Conditions for PCR 
were similar for all products (1 cycle of 2 minutes at 50°C and 1 cycle 
of 10 minutes at .95°C and then 40 cycles of 15 seconds at 95°C and 1 
minute at 60°C). The cycle threshold for each sample was compared 
with the cycle threshold values of known amounts of a standard DNA 
constructed for each target and amplified simultaneously. To assure 
lack of DNA contamination in the RNA samples, in some experiments, 
a duplicate tube of sample with no RT enzyme was included as 
control. DNA contamination remained negligible. In each sample, host 
18S ribosomal RNA was used as the internal control. Expression of 
TNF-a mRNA was corrected to internal control (host 18S rRNA) in the 
same sample and was expressed as copies of TNF-a in 10 °^ copies of 
R18 (equivalent to 1 x 10^ monocytes). M tuberculosis 85B mRNA was 
corrected to mycobacterial 16S rRNA in the j^^g^^^ianiple^'aivi 
expressed as 858:16S. 
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Table 1. Sequences of primers and probes for quantification of human 
TNF-a and M. tuberculosis 85B mRNA in infected monocytes. 
Target, strain, 
primer 
Human 
TNF-a 
RT 
Forward 
Reverse 
R18 
RT 
Forward 
Reverse 
M. tuberculosis 
85B 
RT 
Forward 
Reverse 
16S 
RT 
Forward 
Reverse 
PCR primer sequence, Taqman probe sequence, 
5 ' ^ 3 ' 5'-»3' 
CCAGAGGGAAGAGTTCCCCAGGGAC 
GGTTTCTACAACA 
AGGCGGTGCTTGTTCCTCA 
GTTCGAGAAGATGATCTGACTGCC 
ACCGGCGCAAGACGGACCAGA 
GACGGTATCTGATC 
CGCCGCTAGAGGTGAAATTC 
CATTCTTGGCAAATGCTTTC 
TCGAGTGACCCGGCATGGGAGCG 
TGTTGnTGCGA 
TCAGGGGATGGGGCCTAGCC 
GCTTGGGGATCTGCTGCGTA 
AGCACCGGCCAACTACGTGCCAG 
CCCAGTAATTCC 
TTCTCTCGGATTGACGGTAGGT 
CGCTCGCACCCTACGTATTAC 
Measurement of secreted IFN-y by ELISA. 
The amount of soluble secreted IFN-y in various culture supernatants 
was determined by use of commercial ELISA Kits ( R & D systems), 
according to the manufacturer's specifications. 
Statistical analysis: Results were analyzed by paired t-test and 
the data expressed as mean ± SEM of six experiments unless 
otherwise specified. P<0.05 was considered statistically significant. 
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RESULTS 
RESULTS: 
(A) CHARACTERIZATION OF SERA AND MONOCYTES 
FROM PATIENTS WITH ACTIVE TUBERCULOSIS: 
Prior to any in-depth study, an attempt was made to characterize the 
monocytes and sera from patients with active tuberculosis as follows: 
(a) ELISA: 
Prior to any study, the reactivity of sera from tuberculosis patients (n=15) 
used in this study was probed against M. tuberculosis antigens secreted 
in M. tuberculosis (H37RV) culture filtrate (MTCF) as well as against 
intracellular protein antigens in bacilli sonic extract (MTSE). Direct 
binding ELISA on microtitre plates coated with total protein antigens of 
MTCF showed remarkable reactivity against antibodies found in sera of 
tuberculosis patients, as evident from Fig. 6, where most of the sera 
exhibited an antibody titre >1:12800. No binding was observed with 
normal human sera. Similar binding were also observed on plates coated 
with total sonicate proteins (Table 2). Thus, the results show that all the 
patients selected in this study had a high degree of active tuberculosis. 
Thereafter, the specificity of tuberculosis sera used in this study against 
M. tuberculosis antigens was probed by employing inhibition ELISA. The 
data obtained from inhibition ELISA, depicted in Table 3, exhibited high 
magnitude inhibition of tuberculosis sera antibody activity with MTSE and 
MTCF protein antigens. A maximum of 74.4% inhibition in antibody 
activity was achieved at a maximum inhibitor concentration of 20|jg/ml of 
MTSE protein antigens. 50% inhibition was recorded at an inhibitor 
concentration of 0.8pg/ml. Similarly, with MTCF proteins as an inhibitor, 
a maximum of 69.5% inhibition in the antibody activity was observed at a 
maximum inhibitor concentration of 20pg/ml, where 50% inhibition was 
achieved at an inhibitor concentration of 0.9pg/ml. Thus, inhibition data 
depicted in Table 3 showed that the intracellular protein antigens. 
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liberated from bacilli by sonication, as well as secretory MTCF protein 
antigens have high magnitude of specificity for tuberculosis antibody. 
(b) Levels of soluble cytokine TNF-a in sera of tuberculosis 
patients by ELISA: 
TNF-a show both deleterious as well as beneficial effects in 
tuberculosis, and is therefore designated as an autocrine cytokine. In 
view of its autocrine nature, an attempt was made to probe the levels of 
soluble TNF-a in serum of patients with active tuberculosis selected in 
this study, and in turn, was compared to sera from normal healthy 
individuals. ELISA results depicted in Fig. 7 clearly show an appreciable 
magnitude of soluble TNF-a present in sera of tuberculosis patients. As 
is evident from the data, a mean ± SEM concentration of soluble TNF-a 
was 208 ± 22 pg/ml (P<0.001) in sera from tuberculosis patients (n=15), 
whereas no or negligible (9.93 pg/ml) sTNF-a was detected in sera 
from normal healthy individuals (n=15). 
(c) Levels of circulating M. tuberculosis antigen 85 complex in 
sera of tuberculosis patients by ELISA: 
The presence of circulating M. tuberculosis 85B antigen (30 kDa) in sera 
of tuberculosis patients, either in the free form or complexed with 
fibronectin has been well established. Thus, in the present study, the 
selected tuberculosis sera were further characterized by subjecting them 
to evaluation of M. tuberculosis antigen 85 complex. The mean ± SEM 
concentration of M. tuberculosis 85 complex detected in sera of 
tuberculosis patients was 688 ± 67 pg/ml (n=10) (Fig. 8), whereas M. 
tuberculosis 85 complex was not detected in sera from normal healthy 
individuals (n=10). 
(d) Quantification of (a) soluble TNF-a in supernatants of monocyte 
cultures of tuberculosis patients: 
58 
Adherent monocytes from PBMC's of tuberculosis patients were cultured 
for 24 hours. Supernatants were then subjected to evaluation of soluble 
TNF-a as by ELISA. The levels of soluble TNF-a was found to be to the 
order of 232 ± 38 pg/ml (mean ± SEM; P<0.001) (Fig. 9). On the 
contrary, negligible and insignificant amounts of soluble TNF-a were 
observed in supernatants of normal healthy monocyte cultures. 
Interestingly, co-culturing of TB-MN's for 24 hrs with glutathione 
exhibited a much down-regulated soluble TNF-a expression (94 pg/ml, 
p>0.001)(Fig.9). 
(e) Determination of TNF-a mRNA expression in monocytes of 
tuberculosis patients by quantitative RT-PCR: 
Next, an attempt was made for the characterization of monocytes from 
tuberculosis patients, with respect to TNF-a mRNA. PBMCs were 
isolated from the blood of tuberculosis patients to obtain adherent 
monocytes as described in methods. Monocytes from tuberculosis 
patients were subjected to TNF-a mRNA evaluation by real-time RT-
PCR, and that, monocytes from healthy individuals served as 
corresponding control. As evident from Fig. 10, in comparison to control 
monocytes, the monocytes of tuberculosis patients revealed the 
presence of high basal levels of TNF-a mRNA copy number which was 
to the order of 5.47E+05 (P<0.001), i.e., basal levels of -5.5 logs. Thus, 
the data depicted in the above said figure revealed appreciably high 
basal levels of TNF-a in monocytes of patients with active tuberculosis. 
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(B) PRELIMINARY INVESTIGATIONS FOR IDENTIFICATION OF 
NATURAL ANTAGONIST OF M. tuberculosis 85B: 
Prior to any further in-depth studies, and after ensuring that our 
laboratory protocols yielded established results with minor variation, an 
attempt was made to carry out preliminary studies in order to Identify a 
natural antagonist of M. tuberculosis 85B. This was done in order to 
explore an economical and natural antioxidant(s) option towards 
combating tuberculosis. Taking into consideration the proven beneficial 
role of green tea polyphenols in other diseases, we opted to study its 
active component, EGCG. 
(a) Dose-response effect of EGCG on MTB 85B mRNA 
Housekeeping 163 rRNA expressions in H37RV cultures: 
M. tuberculosis (H37RV) co-cultured with various concentrations of 
EGCG (0, 2, 5, 15, 20 and 25 [ig/m\), as well as culture devoid of EGCG 
which served as the corresponding control, were grown In Middlebrook 
7H9 broth for 14 days at 37°C in 5% CO2. After lysis of bacilli, RNA was 
extracted and assessed for 168 rRNA and 85B mRNA. None of the 
concentrations of EGCG had any significant effect on the expression of 
the housekeeping gene of M. tuberculosis, i.e., 163 rRNA (Fig. 11), 
thereby indicating that EGCG did not non-specifically affect M. 
tuberculosis transcription. On the contrary, the results exhibited an 
appreciable effect of EGCG on the expression of M. tuberculosis 85B 
mRNA. As is evident from Fig. 12, cultures of H37RV, receiving 2|jg/ml 
EGCG exhibited low magnitude changes in 85B mRNA level in 
comparison to control cultures devoid of EGCG. Further increase in 
EGCG concentrations to 5, 20 and 25 [ig/ml in H37RV cultures exhibited 
an appreciable suppression in M. tuberculosis 85B mRNA by ~2.1, 2.6 
logs, 2.8 logs, 2.9 logs and 3.1 logs (P<0.001 for both), respectively, in 
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comparison to control cultures (Fig. 12). The decrease in the 85B:16S 
ratio (Fig. 13) to the extent of more than 95% observed for cultures 
challenged with concentrations of above 5 pg/ml of EGCG, when 
compared to control cultures devoid of EGCG, supports the above data. 
The results show that the concentrations of EGCG selected in this study 
failed to show any inhibitory affect on the M. tuberculosis growth, but it 
appreciably exerted down-regulation in the M. tuberculosis 85B gene 
expression. 
(b) EGCG-induced effect on the expression of antigen 85 complex 
in H37RV culture supernatants: 
MTB (H37RV) was cultured in Middlebrook 7H9 broth for 14 days 
with varying concentrations of EGCG (0, 2, 5, 15, 20 and 25 pg/ml) as 
mentioned above. Thereafter, cultures were harvested and the 
supernatants obtained were subjected to ELISA to evaluate secreted M. 
tuberculosis antigen 85 complex. As evident from Fig. 14, the secretion 
of antigen 85 complex was found to be dose-dependent and decreased 
by an appreciable amount with 5, 15, 20 and 25pg/ml EGCG. Similar 
observations were also recorded in gradient (10-20%) SDS-PAGE 
experiments (Figs. 15A and 158). Hence, this decrease in antigen 85 
complex as demonstrated in Figs. 14 and 15 substantiates the above 
gene results. 
(C) IN VITRO STUDIES ON HEALTHY MONOCYTES INFECTED WITH 
M. tuberculosis: 
(a) Time-course kinetics of M. tuberculosis infection on the 
expression of human housekeeping genes and on the 
expression of TNF-a mRNA and secreted TNF-a: 
We probed the effect of M. tuberculosis (H37RV) infection, if any, on 
the human housekeeping R18 gene (18S rRNA). It was observed that M 
tuberculosis infection had no effect at any time intervals (0-120 hours) of 
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culturing of infected monocytes on the host housekeeping genes lil^ e R18 
gene (18S rRNA) as revealed by quantitative real-time RT-PCR (Fig. 16). 
Thereafter, we probed the time course (0-120 hours) expression 
of TNF-a mRNA in M. tuberculosis-lnlected monocytes. TNF-o mRNA 
was corrected to host internal control, I.e., 18S rRNA, in the same 
sample. As evident from Fig. 17, the effect of M. tuberculosis infection on 
TNF-a mRNA was found to be time-dependent. The levels were found to 
increase till 24 hrs, followed by sharp decrease in expression at the 
remaining time points. The levels of TNF-a mRNA copy numbers in 
infected monocytes at various time intervals were recorded as 2.1 logs, 
6.4 logs (P<0.001), 11.3 logs (P<0.001), 5.1 logs (P<0.001) and 2.0 logs 
(P<0.05), after 0, 4, 24, 72 and 120 hours of M. tuberculosis infection, 
respectively. Thus, the expression of TNF-a was maximal at 24 hours, 
which decreased considerably thereafter. Furthermore, we probed the 
effect of M. tuberculosis infection on secreted TNF-a in culture 
supernatants that were harvested at various time intervals (0-120 
hours). As evident from Fig. 18, the effect of M. tuberculosis infection on 
secreted TNF-a was found to be time-dependent. The concentration of 
soluble TNF-a secreted in supernatants of infected monocyte cultures at 
various time intervals was observed as 30.2, 65.0 (P<0.001), 93.2 
(P<0.001), 194.3 (P<0.001), 112.2 (P<0.001), 65.8 (P<0.001) and 13.8 
(P<0.001) pg/ml after 0, 4, 12, 24, 48, 72 and 120 hours of M. 
tuberculosis infection, respectively. Thus, the maximum secretion of 
TNF-a in culture supernatants was observed after 24 hours of M. 
tuberculosis infection, followed by a substantial decrease at the 
remaining time intervals of culture. 
(b) Time-course effect of M. tuberculosis (H37RV) infection in 
healthy monocytes on M. tuberculosis housekeeping 16S rRNA 
as well as 85B gene: 
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In continuation to the above, an attempt was also made to 
investigate the time-dependent (0-120 hours) expression of M. 
tuberculosis 16S rRNA and 85B mRNA in M. fubercu/os/s-infected 
monocytes. As evident from Fig. 19, 16S rRNA expression was observed 
to linearly increase with time. Also, the expression of 85B mRNA 
continued to increase up to 120 hours (Fig. 20). The ratio of 85B:16S 
was found to increase with increasing time periods of infection. The 
858:168 ratio recorded at various time intervals were 0.0011, 0.0019 
(P<0.05), 0.0875 (P<0.001), 0.3488 (P<0.001) and 0.7947 (P<0.001), 
after 0, 4, 24, 72 and 120 hours of infection, respectively (Fig. 21). 
Furthermore, between 4 and 24 hours, M. tuberculosis 85B:16S 
increased significantly (P<0.001). This increase in 85B:16S ratio with 
time correlates with 85B mRNA levels at various time periods observed 
in Fig. 20. 
(c) Time-course effect of M. tuberculosis infection of monocytes 
on glutathione peroxidase (GPx) activity: 
GPx activity with respect to varying time intervals was determined 
in M. tuberculosis-intected monocytes. Uninfected monocytes served as 
controls. At zero time, GPx activity in uninfected control and M. 
tuberculosis-infected monocytes was observed to be nearly the same. 
No significant change in GPx activity was observed at any of the time 
intervals of culturing (0-120 hours) of uninfected control monocytes. 
However, in comparison to control monocytes, the M. tuberculosis-
infected monocytes exhibited a linear decrease in GPx activity with time. 
GPx activity in M. tuberculosis-infected monocytes was recorded as 66, 
54 (P<0.02), 41 (P<0.01), 32 (P<0.001) and 24 (P<0.001) U/mg protein, 
after 0, 4, 24, 72 and 120 hours of infection, respectively (Fig. 22). 
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(D) INVESTIGATIONS INVOLVING MODULATION OF TNF-
a AND 85B GENE EXPRESSIONS IN MONOCYTES 
INFECTED WITH M. tuberculosis 
(a) Dose-response effect of exogenous rhTNF-a on host TNF-a 
and M. tuberculosis 85B gene expression in M. tuberculosis-
infected monocytes: 
The above obtained data suggested a role for endogenous TNF-a 
in auto-induction and in the induction of M. tuberculosis 85B gene 
expression. This is in agreement to our earlier published results (154, 
156) Thus, to further assess the role of TNF-a, in other experiments, 
exogenous rhTNF-a was added to M. fubercu/os/s-infected monocytes, 
and then TNF-a and 85B mRNA was assessed. In these experiments, 
varying doses of rhTNF-a (0.1, 0.2, 2 and 10 ng/ml), or medium alone, 
were added to M. tuberculosis-infected monocytes. Negligible effects, to 
the extent of 100-200 copy numbers were observed at higher doses of 
rhTNF after 0 hrs i. e. immediately after adding and removing rhTNF 
from the infected culture (Fig. 23). After 4hrs, the level of TNF-a mRNA 
copy number was found to be 6.2 logs, 7.3 logs, 7.6 logs, 8.7 logs and 
9.3 logs at 0, 0.1, 0.2, 2 and 10 ng/ml of rhTNF-a respectively (Fig. 24). 
The 85B:16S ratio after 4 hours of M. tuberculosis infection changed 
linearly in a dose-dependent manner upon co-culturing with 0, 0.1, 0.2, 2 
and 10 ng/ml of rhTNF-a respectively (Fig. 25). Thereafter, evaluation of 
cultures harvested after 24 hours of infection revealed high magnitude 
expression of endogenous TNF-a mRNA as a result of M. tuberculosis 
infection in monocytes devoid of exogenous rhTNF-a. (Fig. 26). In 
comparison to control infected monocytes, an increase in endogenous 
TNF-a mRNA by around 1.0 logs (P<0.001), 1.6 logs (P<0.001), 2.3 logs 
(P<0.001) and 4.3 logs (P<0.001) was recorded with treatments of 0.1, 
0.2, 2 and 10 ng/ml of rhTNF-a, respectively (Fig. 26). Interestingly, a 
significant change was seen in 858:16S ratio after 24 hours of M. 
tuberculosis infection. As evident from Fig. 27, exogenous rhTNF-a was 
found to increase the ratio of 85B:16S in a dose-dependent way (Fig. 
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27). Further increase in time i. e. at 72 hrs and 120 iirs, showed down-
regulation in TNF-a mRNA copy numbers (Fig. 28 and 30), whereas on 
the contrary, a linear up-regulation in the 85B:16S ratio at both 72 hrs 
and 120 hrs after infection respectively (Fig. 29 and 31). The results 
indicate that cell activation by exogenous rhTNF-a induces expression of 
both TNF-a and M. tuberculosis 85B genes in M. tuberculosis-iniected 
monocytes. 
(b) Soluble TNF-a receptors Induced-effects on TNF-a and M. 
tuberculosis 85B gene expressions in M. tuberculosis-infected 
monocytes: 
Our above results indicates that the expression of M. tuberculosis 
85B is elevated after M. tuberculosis infection in monocytes, and 
correlates with TNF-a expression during the first 24 hours of infection. It 
exhibited that M. tuberculosis-induced TNF-a in monocyte cultures 
modulated M. tuberculosis 858 gene expression during the first 24 
hours. To probe the effect of intramonocyte TNF-a on M. tuberculosis 
858 expression, an attempt was made to inhibit the TNF-a signaling by 
employing its soluble receptors, namely TNFR-I and TNFR-II, which is 
known to bind and inactivate TNF-a. Thus, MT8-infected monocytes 
were cultured either with sTNFR-l (10 ng/ml) or sTNFR-ll (10 ng/ml), or 
medium alone, for 24 hours. We found that both soluble receptors 
inhibited TNF-a as well as M. tuberculosis 858 mRNA expression in 
monocytes significantly. In comparison to M. tuberculosis-infected 
monocytes, the infected cells co-cultured with sTNFR-l and sTNFR-ll 
exhibited a suppression in TNF-a mRNA levels by around 5.2 logs 
(P<0.001) and 3.1 logs (P<0.001), respectively (Fig. 32). Furthermore, 
inhibition of TNF-a by either sTNFR-l or sTNFR-ll also decreased M. 
tuberculosis 858 mRNA expression significantly in M. tuberculosis-
infected monocytes at 24 hours (P<0.001 for both) (Fig. 33). Therefore, 
inhibition of endogenous TNF-a was associated with down-modulation of 
both TNF-a and M. tuberculosis 858 gene expression. The results 
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indicate sTNFR-l to be a stronger inhibitor of TNF-a and M. tuberculosis 
85B gene expression in M. tuberculosis-\nfected monocytes than 
sTNFR-ll. 
(C)NF-KB playing an important role in M. tuberculosis-infected 
monocytes: 
Induction of TNF-a by cellular activation is known to be mediated 
via NF-KB (152-154). It has been well documented that TNF-a induced 
nuclear translocation of NF-KB was inhibited in SN50 peptide-treated 
human monocytic cell lines as demonstrated in EMSA (155). Thus, we 
employed SN50, an inhibitor of NF-KB, to assess the role of NF-KB in 
activation of gene expression in M. tuberculosis-mieded monocytes. 
SN50 (100 |jg/ml) was added to monocytes 3 minutes prior to M. 
tuberculosis infection. Control cultures did not receive SN50. At 24 hours, 
SN50 suppressed endogenous TNF-a mRNA expression in M. 
tuberculosis-mieded monocytes by around 6.2 logs (P<0.001) in 
comparison to control cultures devoid of SN50 pre-treatment (Fig. 34). To 
ensure that cellular inhibition was specific, we compared the effect of 
SN50 with its inactive analogue, SN50/M at the same concentration. As 
expected, SN50/M failed to show any effect on TNF-a mRNA expression 
(P>0.05) (Fig. 34). Similarly, SN50 was found to decrease the ratio of 
85B:16S in M. tuberculosis-'mfecied monocytes. This can be best viewed 
from the data depicted in Fig. 35, where M. tuberculosis 85B:16S ratio was 
found to be 0.09, 0.0003 (P<0.001) and 0.090 (P>0.05) for control infected 
monocytes, infected monocytes challenged with SN50, and infected 
monocytes challenged with SN50/M, respectively (Fig. 35). 
Therefore, it can be concluded that the increased expression of TNF-a 
and 85B mRNA in M. tuberculosis-'mfected monocytes is mediated 
mainly via NF-KB. 
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(d)Reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) having a role to play in M. tuberculosis-infected 
monocytes: 
Specific inhibitors of ROS and RNI pathways namely NAC and 
NMMA, as well as oATP, a known inhibitor of both ROI and RNS 
pathways, were used in the present study to probe their effects on TNF-a 
and 85B mRNA expression in M. tuberculosis-Infected monocytes. After 
infection of monocytes with M. tuberculosis, NAC (10 mM), NMMA (10 
mM), or oATP (10 mM) were added to cultures. Control cultures received 
medium alone. The antioxidant effects of NAC, NMMA and oATP on 
TNF-a and 85B gene expression were probed, and it was found that 
NAC, NMMA and oATP downregulated TNF-a mRNA expression by 
around 6.1 logs (P<0.001), 6.3 logs (P<0.001) and 7.2 logs (P<0.001), 
respectively, in cultures harvested after 24 hours of infection (Fig. 36), as 
compared to control cultures. Next, in light of the above data observed 
with negative modulators, an attempt was also made to probe the effects 
of positive modulators, namely, SNP, NADPH and NOC-9, on TNF-a and 
85B gene expression in M. tuberculosis-infected monocytes. As evident 
from Fig. 37, in comparison to control infected cultures devoid of any 
supplements and harvested after 24 hours of infection, M. tuberculosis-
infected monocytes that were co-cultured with SNP (0.5 pM), NADPH (5 
pM) and NOC-9 (300 pM) exhibited an augmentation in TNF-a by around 
0.9 log (P<0.01), 3.2 logs (P<0.001) and 2.1 logs (P<0.001), 
respectively. 
Furthennore, on determining the M. tuberculosis 858:16S ratio for the 
above cells, an appreciable increase in 858:16S ratio was observed with 
the above positive modulators. As illustrated in Fig. 38, the 858:16S ratio 
was 0.04 for control monocytes infected with M. tuberculosis that were 
devoid of any modulator, whereas the 858:16S ratio was 0.43 (P<0.001), 
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0.74 (P<0.001) and 1.1 (P<0.001) for infected monocytes co-cultured 
with SNP, NOC-9 and NADPH, respectively. 
(E) Modulation Studies of TNF-a and M. tuberculosis 85B 
Expression with the Natural Antioxidant 'EGCG' Found in 
Green Tea: 
(a) Effect of EGCG on the viability of cells: 
In the present study, the concentrations between 0-25 pg/ml of 
EGCG were employed. All the concentrations of EGCG employed in this 
study failed to show any adverse effect on monocytes as revealed by 
MTT (Fig. 39) or trypan blue exclusion assays. Cell viability is expressed 
as percent (mean ± SEM) viable cells compared to untreated cells (taken 
as 100% viable). 
(b) Dose-dependent effect of EGCG on TNF-a soluble protein 
expression: 
M. tuberculosis-Infected monocytes were co-cultured for 24 hours 
with varying doses of EGCG. Infected cultures devoid of EGCG served 
as control. In the present study, ELISA determined the dose-response 
effect of green tea polyphenol EGCG on TNF-a protein expression. As 
evident from Fig. 40, a significant EGCG-induced dose-dependent 
inhibition in the expression of soluble TNF- a protein in culture 
supernatants was observed. 
(c) Modulation of soluble TNF-a soluble protein expression: 
MTB-infected monocytes were co-cultured for 24 hours with varying 
doses of EGCG, where infected cultures devoid of EGCG served as 
control. As evident from Fig. 41, uninfected and untreated cultures of 
monocytes showed no or negligible soluble TNF-a, MTB-infected 
cultures devoid of any modulator showed the level of soluble TNF-a to 
the order of 174.25 pg/ml (P>0.001). Addition of exogenous rhTNF-a to 
infected cultures showed an augmentation in soluble TNF-a levels (209 
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pg/ml). However, addition of anti-TNF-a Abs or EGCG to infected cells 
that were co-cultured with rhTNF-a showed a suppressed expression of 
sTNF-a to the order of 154 and 104 pg/ml (P>0.001 for both) 
respectively. However, the results show that when infected cells that 
were devoid of exogenous rhTNF-a and were instead treated alone with 
either anti-TNF-a Abs or EGCG, then the sTNF-a levels decreased to the 
extent of 76 and 35 pg/ml (P>0.001) respectively (Fig. 41). 
(d) Dose-dependent effect of EGCG on TNF-a and MTB 85B gene 
expressions: 
Next, at the gene expression levels, in comparison to control, a linear 
downregulation of TNF-a mRNA copy numbers by ~3 logs (P<0.001), 4 
logs (P<0.001), 7 logs (P<0.001) and 8.3 logs (P<0.001) was recorded 
with 2, 5, 10 and 20 pg/ml of EGCG, respectively (Fig. 42). Thus, the 
amplification of TNF-a gene was dose-dependent, where EGCG was 
found to potently inhibit the gene expression of pro-inflammatory 
cytokine TNF-a. 
Thereafter, an attempt was made to probe the dose-response effect of 
EGCG on the M. tuberculosis 85B gene expression in MTB-infected 
monocytes that were cultured with or without various doses of EGCG for 
24 hours. The expression of 85B mRNA was normalized with 
mycobacterial 16S rRNA and expressed as 85B:16S. The 85B:16S ratio 
was computed to evaluate the effect of green tea polyphenol, namely 
EGCG. As evident from Fig. 43, the data clearly shows that the 85B:16S 
ratio decreased linearly with increase in EGCG concentration. The 
85B:16S ratio recorded were 0.09, 0.005, 0.0002, 0.0007 and 0.0002 
(P>0.001 for all) in M. fubercu/os/s-infected monocytes treated with 0, 2, 
5, 10 and 20 pg/ml of EGCG respectively (Fig. 43). 
(e) Dose-dependent effect of Antibiotics likes Streptomycin, 
Rifampicin and Isoniazid on TNF-a and IVITB 85B gene expressions 
in monocytes infected with MTB: 
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The effects of streptomycin, rifampicin and isoniazid (all 0-100 MQ/ml) on 
the expression of TNF-a and MTB 85B mRNA in 24 hr cultures were 
found to be dose-dependent. 
(i) Effect of Streptomycin. 
As evident from 'real time' RT-PCR data, non-treated control cultures 
showed TNF-G mRNA copy numbers to be expressed to the order of 
around 11.4 logs (Fig. 44). This was down regulated by streptomycin in a 
dose-dependent manner. As evident from fig. 44, TNF-a mRNA was 
found to decrease by around 2.2 logs, 4.1 logs, 5.9 logs, 8.3 logs and 9.2 
logs with 20, 40, 60, 80 and 100 |jg/ml of streptomycin respectively (Fig. 
44). Upon investigating the 85B:16S in the same samples, it was found 
that the ratio of 85:16S was around 0.094 in cultures devoid of any 
streptomycin (Fig. 45). No significant effect was observed upon 
treatment with 20|jgs/ml of streptomycin. Significant linear reduction in 
the ratio of 85B:16S was observed with 40, 60, 80 and 100 \iglm\ of 
streptomycin where the ratio observed was around 0.05, 0.01, 0.008 and 
0.0008 respectively (Fig. 45). The iC50 for 85B suppression was to be of 
the order of 80 pg/ml. 
(ii) Effect of Rifampicin. 
Next, an attempt was made to probe the effect of rifampicin. The TNF-a 
mRNA copy numbers was observed here to be suppressed in a dose-
dependent manner. As evident from Fig. 46, TNF-a mRNA was found to 
decrease by around 2.1 logs, 5.4 logs, 7.4 logs, 8.4 logs and 9.8 logs 
with 20, 40, 60, 80 and 100 |jg/ml of rifampicin respectively (Fig. 46). 
Furthermore, the 85B:16S ratio here was found to be around 0.09, 0.08, 
0.02, 0.003, 0.0009 and 0.0004 with 0, 20, 40, 60, 80 and 100 yg/ml of 
rifampicin respectively (Fig. 47). The IC50 for 85B suppression was to be 
of the order of 70|jg/ml. 
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(iii) Effect of Isoniazid. 
Thereafter, an attempt was also made to check the effect of isoniazid. 
Here, the TNF-a mRNA copy numbers was observed here to be inhibited 
in a dose-dependent manner like streptomycin and rifampicin. As 
illustrated in Fig. 48, in comparison to untreated infected control cells, the 
TNF-a mRNA was found to decrease by around 2.1 logs, 5.5 logs, 7.5 
logs, 8.6 logs and 10 logs with 20, 40, 60, 80 and 100 pg/ml of isoniazid 
respectively (Fig. 48). Moreover, the 85B:16S ratio was found to be 
around 0.09, 0.08, 0.008, 0.0009, 0.0005 and 0.0003 with 0, 20, 40, 60, 
80 and 100 |jg/ml of isoniazid respectively (Fig. 49). The IC50 for 85B 
suppression by isoniazid was found to be of the order of 60|jg/ml. 
(f) Modulation of Glutathione levels (GSH) by EGCG in monocytes 
cultures infected with MTB. 
Since glutathione (GSH) is essential for the control of the intracellular 
growth of M. tuberculosis, thus an attempt was made to probe the role of 
anti-oxidants EGCG and NAC in MTB-infected monocytes. Uninfected 
and untreated control monocytes in 24 hr cultures exhibited GSH levels 
to the order of 269 pg/ml (P>0.001) (Fig. 50). On the contrary, as 
expected, in 24 hrs cultures of MTB-infected monocytes that were devoid 
of any supplements, the GSH levels were found to decrease to 159 
pg/ml (P>0.001) (Fig. 50). However, upon addition of 5 pg/ml EGCG or 
10 mM NAC in MTB-infected monocytes that were cultured for 24 hrs 
exhibited an augmentation or reversal of GSH levels, which were to the 
order of 210 pg/ml and 204 pg/ml (P>0.001 for both) respectively (Fig. 
50). Thus, it appears that down-regulation of MTB 85B by EGCG is 
mediated by up-regulation of GSH. 
Next, an attempt was also made to determine the GPx activity in M. 
tuberculosis-infected monocytes co-cultured for 24 hours with varying 
doses of EGCG. MTB-infected monocytes cultures devoid of any EGCG 
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supplementation exhibited a suppressed GPx activity i. e. 19.94. An 
enhancement of ~1.87-folds in GPx activity was noticed upon treatment 
with 10jjg/ml of EGCG. A further increase in GPx activity by ~ 3-folds 
was recorded with the addition of 20 pg/ml of EGCG in MTB-infected 
monocyte cultures. Similar observations were noted upon further 
increasing the doses of EGCG (30pg/ml, 40|jg/ml and 50 ng/ml) (Fig. 
51). Thus, EGCG at concentrations in between 5-20 pg/ml proved to be 
enhancer / reversal agent of GPx activity. Next, the investigation of time 
course effect of EGCG (5|jg/ml) on GPx activity in uninfected control 
monocytes showed no or insignificant effect (Fig. 52). On the contrary, 
MTB-infected monocytes upon treatment with 5ijg/ml of EGCG for 
varying time intervals (0-120 hr) exhibited a linearly high magnitude 
inhibition in GPx activity (Fig. 53). 
(g) Modulation of soluble IFN-y levels by EGCG in monocytes 
cultures infected with IMTB. 
Probing the role of anti-oxidants EGCG and NAC on soluble IFN-y levels 
in MTB-infected monocytes carried out further in-sight studies. 
Uninfected and untreated control monocytes in 24 hr cultures exhibited 
IFN-Y levels to the order of 262 pg/ml (P>0.001) (Fig. 54). On the 
contrary, in 24 hrs cultures of MTB-infected monocytes that were devoid 
of any EGCG or NAC, the IFN-y levels were found to decrease to 81 
pg/ml (P>0.001) (Fig. 54). However, upon addition of 5 |jg/ml EGCG or 
10 mM NAC in MTB-infected monocytes that were cultured for 24 hrs 
exhibited an augmentation or reversal of IFN-y levels, which were to the 
order of 233 pg/ml and 217 pg/ml (P>0.001 for both) respectively (Fig. 
54). Thus, it appears that down-regulation of sIFN-y levels in culture 
supernatants of MTB-infected monocytes is reversed by EGCG. 
IMMUNOLOGICAL STUDIES FOR CULTURES OF MTB-INFECTED 
MONOCYTES THAT WERE TREATED WITH AND WITHOUT EGCG 
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Direct binding as well as inhibition ELISA were performed on microtiter 
plates that were coated with total protein lysates obtained from MTB-
infected monocytes that were separately untreated or treated with either 
5 pg/ml EGCG, 100pg/ml streptomycin, 100pg/ml rifampicin or 100|jg/ml 
isoniazid and cultured for 24 hrs. The antibodies used here was serially 
diluted sera from TB patients. 
As illustrated in Fig. 55, nearly all the TB sera selected in this study 
exhibited an antibody titer >1:12800 (P>0.001) on plates coated with 
total protein lysates (100 pl/well of 30 jjg/nil stock) obtained from MTB-
infected monocytes but devoid of any inhibitor/supplements. On the 
contrary, upon treatment of MTB-infected cells with 5 MQ/ml of EGCG 
revealed a sharp decrease in binding. In this case, the antibody titer was 
recorded as 1:200 only (Fig. 56). Thus, computation analysis of the data 
showed EGCG to suppress the immunoreactivity of MTB-infected cells 
against TB sera by around 3.6-folds (Fig. 57). 
Next, inhibition ELISA was performed in order to probe the specificity of 
the said immuno-interaction. As evident from Fig. 58, untreated MTB-
infected monocyte sonic extracts exhibited a maximum of 74.2 % 
inhibition in antibody (TB sera) activity at a maximum inhibitor 
concentration of lOpg/ml. The high degree of specificity was evident from 
fifty percent inhibition achieved at extremely low inhibitor concentration. 
Fifty percent inhibition in the activity of antibodies in TB sera was 
achieved at inhibitor concentrations of 0.06 ^lg/ml. Interestingly, co-
culturing of MTB-infected monocytes with 10 ng/ml of rhTNF-a was found 
to further increase the specificity of antibodies present in TB sera. Here, 
a maximum of 83.2% inhibition in antibody (TB sera) activity at a 
maximum inhibitor concentration of 1 ^Jg/ml was recorded (Fig. 59). Fifty 
percent inhibition was achieved at 0.01 pg/ml of inhibitor (Fig. 59). On 
the other hand, treatment with lOng/ml of anti-TNF-a antibody showed 
an appreciable suppression in binding, as only -32% inhibition could be 
achieved. Here, 50% inhibition in antibody activity could not be achieved 
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(Fig. 60). Similarly, treatment of MTB-infected cells with antibiotics like 
streptomycin, rifampicin or isonlazid (100|jg/ml for all) also failed to any 
significant binding, and that none of them showed 50% inhibition in 
antibody (TB sera) activity (Figs. 61-63). Similar observations were made 
for infected cells treated with 10 mM NAC (Fig. 64) or 5|jg/ ml of EGCG 
(Fig. 65). Indeed, EGCG-treated MTB-infected cells showed the least 
reactivity against antibodies in TB sera than the infected cells treated 
with antibiotics or NAC. Thus, the results indicate that 5 pg/ml of EGCG 
challenged with MTB-treated monocytes decreases the specificity of TB 
antibodies against Mycobacterium tuberculosis antigen(s). 
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Fig 6: Direct binding ELISA on microtiter plates coated with total MTB 
culture filtrate proteins (100 uL/well of 30 ug/ml stock) against 
antibodies in sera of patients with TB (n=10). Normal human sera 
(NHS) served as negative control. 
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Table 2. Direct binding ELISA of tuberculosis antibodies against 
Mycobacterium tuberculosis sonic extract (IVITSE) and culture filtrate 
(MTCF) protein antigens (100 uL / well of 30 pg/ml stock) coated onto 
micro titer ELISA plates. 
Number 
of TB 
patient' 
ssera 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
MTSE protein 
antigens 
Antibody titre* 
> 1:6400 
>1:12800 
> 1:6400 
> 1:12800 
> 1:12800 
>1:12800 
> 1:12800 
> 1:12800 
> 1:12800 
>1:12800 
> 1:6400 
> 1:12800 
> 1:12800 
> 1:12800 
> 1:12800 
IMTCF protein 
antigens 
Antibody 
titre* 
> 1:3200 
> 1:6400 
> 1:3200 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:3200 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
* Antibody titres of tuberculosis sera were calculated with respect to 
normal human sera. 
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Table 3: Inhibition ELISA for tuberculosis antibodies against 
Mycobacterium tuberculosis sonic extract (MTSE) and culture filtrate 
(MTCF) protein antigens (100 pL / well of 30 pg/ml stock) coated onto 
micro titer ELISA plates. 
Inhibitor 
Tuberculosis 
sera 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Mean ± SD 
MTSE protein antigens 
Concentration 
for 
50% inhibition 
(pg/ml) 
0.8 
1.0 
0.6 
0.1 
1.1 
0.6 
0.5 
0.6 
1.5 
1.3 
1.1 
0.3 
0.1 
0.5 
0.5 
0.8 ± 0.4 
Maximum 
inhibition 
(at 20 
ug/mi) (%) 
76.4 
74.3 
72.8 
78.2 
70.6 
75.5 
76.8 
78.9 
70.5 
72.7 
75.5 
80.3 
82.2 
76.5 
75.6 
74.4± 3.3 
MTCF protein 
antigens 
Concentration 
for 
50% inhibition 
(ug/mi) 
1.3 
0.5 
0.9 
0.2 
1.2 
1.7 
0.9 
0.7 
1.6 
1.3 
0.8 
1.2 
0.3 
0.3 
0.3 
0.9 ± 0.5 
Maximum 
inhibition 
(at 20 
pg/ml) (%) 
69.5 
72.6 
70.4 
71.5 
68.6 
64.4 
69.7 
71.8 
68.5 
68.7 
70.6 
67.9 
73.6 
72.5 
70.5 
69.5± 2.0 
Total numbers of patients were 15 
/
u' ,n«oa Ataa y -. 
V 
'; ' ^ ' ^ 
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Fig 7: Levels of soluble TNF- a (pg/ml) in sera of patients with 
tuberculosis and Normal Human sera. Data are means (2.26 SE) and 
(0.72 SE) respectively of fifteen experiments (p<0.001). 
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800-1 
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Fig 8: Levels of secreted antigen 85 complex (pg/mi) in sera of 
tuberculosis patients and Normal Human sera. Data are means with (-
17.40 SE) often experiments. 
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TBMNs NHMNs TB MNs+GSH 
Fig. 9. Modulation of secreted TNF-a expression in monocytes of 
tuberculosis patients. Monocytes from tuberculosis patients (TB 
MN's), healthy controls (NH MN's) and glutathione-co- cultured TB 
monocytes (TB MN's +GSH) were cultured for 24 hrs and harvested 
as described in methods. Data are means (+ SE) of ten experiments. 
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Fig. 10: Real-time RT-PCR for TNF-a mRNA expression in monocytes 
of tuberculosis patients and control healthy monocytes. Data are 
means (1.19E+05SE) and (7.83E-01SE) of six experiments. 
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Fig 11: Dose response effect of EGCG (0-25 pg/ml) on the expression 
of 16S rRNA in 14 days culture Mycobacterium tuberculosis H37RV 
The results are mean of 3 experiments (p>0.001) 
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Fig 12: Dose response effect of EGCG (0-25 |jg/ml) on the expression 
of 85B mRNA in 14 days culture Mycobacterium tuberculosis H37RV 
The results are mean of 3 experiments (p>0.001) 
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Fig 13: Dose response effect of EGCG (0-25 |jg/ml) on the ratio of 
85B:16S in 14 days culture Mycobacterium tuberculosis H37RV. 
The results are mean of 3 experiments (p>0.001) 
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Fig 14: Dose response effect of EGCG (0-25 pg/ml) on the 
secreted Ag 85B protein in 14 days culture supernatants of 
Mycobacterium tuberculosis H37RV. The results are mean of 
3 experiments (p>0.001) 
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Fig 15A: Gradient (10-20%) SDS-PAGE of Mycobacterium tuberculosis 
Culture filterarte proteins (MTCF). Here, the H37RV strain was cultured for 
14days without and with EGCG and thereafter harvested as described 
In methods. BSA (Lane#1); 0 |jg/ml EGCG (Lane#2); 5 \ig/m\ EGCG 
(Lane#3);10 (jg/ml EGCG (Lane#4); 25 pg/ml EGCG(Lane#5) Mariner 
(Lane#6) 
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Fig 15ft: Gradient (10-20%) SDS-PAGE of Mycobacterium tuberculosis 
sonic extract proteins (MTSE). Here, the H37RV strain was cultured for 
14days without and with EGCG and thereafter harvested and sonicated as 
described in methods. BSA (Lane#1); 0 pg/ml EGCG (Lane#2); 5 |jg/ml 
EGCG (Lane#3); 10 \ig/m\ EGCG (Lane#4); 25 pg/ml EGCG (Lane#5) 
Mari<er (Lane#6) 
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Fig 16: Time course kinetics of human housekeeping R18 rRNA 
expression in human monocytes that were infected in vitro with MTB 
in the ratio of 1:1 (1 bug :1 cell). Infected monocytes were harvested 
at varying time intervals and were subsequently subjected to analysis. 
The results are mean (+ SE) of 5 experiments (p>0.001) 
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Fig 17: Time course kinetics of TNF-a mRNA expression in human 
monocytes that were infected in vitro with MTB in the ratio of 1:1 (1 
bug :1 cell). Infected monocytes were harvested at varying time 
intervals and were subsequently subjected to analysis. The results are 
mean (+ SE) of 5 experiments (p>0.001) 
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Fig 18: Time course kinetics of soluble TNF-a expression in 
supernatants of human monocytes that were infected in vitro with MTB 
in the ratio of 1:1 (1 bug :1 cell). Infected monocytes were harvested 
at varying time intervals and the supernatants were subsequently 
subjected to analysis. The results are mean (+ SE) of 5 experiments 
(p>0.001). The levels of solubleTNF-a detected were in pg/ml. 
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Fig 19: Time course kinetics of MTB 16S rRNA expression in human 
monocytes that were infected in vitro with MTB in the ratio of 1:1 (1 
bug :1 cell). Infected monocytes were harvested at varying time 
intervals and were subsequently subjected to analysis. The results are 
mean (+ SE) of 5 experiments (p>0.001). 
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Fig 20: Time course kinetics of MTB 85B mRNA expression in 
human monocytes that were infected in vitro with IVITB in the ratio of 
1:1 (1 bug :1 cell). Infected monocytes were harvested at varying time 
intervals and were subsequently subjected to analysis. The results are 
mean (+ SE) of 5 experiments (p>0.001). 
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Fig 21: Time course kinetics expression of M. tuberculosis 85B:16S 
ratio in human monocytes that were infected in vitro with MTB in the 
ratio of 1:1 (1 bug :1 cell). Infected monocytes were harvested at 
varying time intervals and were subsequently subjected to analysis. 
The results are mean (+ SE) of five experiments (p>0.001). 
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Fig 22: Time course kinetic determination of glutathione peroxidase 
(GPx) activity in M. tuberculosis-'miecXed monocytes. Normal 
uninfected healthy control monocytes (light bars) and MTB-infected 
monocytes (dark bars) 
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Fig 23: Time course kinetic effect of exogenous rhTNF-a on the 
expression of TNF-a mRNA in M. tuberculosis-'mfected monocytes 
immediately after infection i. e. after 0 hrs of infection. Here, after 90 
min. of MTB infection as described in methods, varying doses of 
rhTNF-a (0, 0.1, 0.2, 2 and 10 ng/mj) were added and cells were 
harvested immediately and subsequently subjected to 'real time' RT-
PCR. The results are mean (+ SE) of 5 experiments (p>0.001). 
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Fig 24: Time course kinetic effect of exogenous rhTNF-a on the 
expression of TNF-a mRNA in M. tuberculosis-lniected monocytes 
after 4 hrs of infection. Here, after 90 min. of IVITB infection as 
described in methods, varying doses of rhTNF-a (0, 0.1, 0.2, 2 and 10 
ng/ml) were added and cells were harvested after 4 hrs and 
subsequently subjected to 'real time' RT-PCR. The results are mean 
(+ SE) of 5 experiments (p>0.001). 
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Fig 25: Time course kinetic effect of exogenous rhTNF-a on the 
expression of M. tuberculosis 85B:16S ratio in M. tuberculosis-'iniecied 
monocytes after 4 hrs of infection. Here, after 90 min. of MTB infection 
as described in methods, varying doses of rhTNF-a (0, 0.1, 0.2, 2 and 
10 ng/ml) were added and cells were harvested after 4 hrs and 
subsequently subjected to 'real time' RT-PCR. The results are mean 
(+ SE) of 5 experiments (p>0.001). 
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Fig 26: Time course kinetic effect of exogenous rhTNF-a on the 
expression of TNF-a mRNA in M. tuberculosis-'mfected monocytes 
after 24 hrs of infection. Here, after 90 min. of MTB infection as 
described in methods, varying doses of rhTNF-a (0, 0.1, 0.2, 2 and 10 
ng/ml) were added and cells were harvested after 24 hrs and 
subsequently subjected to 'real time' RT-PCR. The results are mean 
(+ SE) of 5 experiments (p>0.001). 
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Fig 27: Time course kinetic effect of exogenous rhTNF-a on the 
expression of M. tuberculosis 85B:16S ratio in M. tuberculosis-'miecXed 
monocytes after 24 hrs of infection. Here, after 90 min. of MTB 
infection as described in methods, varying doses of rhTNF-a (0, 0.1, 
0.2, 2 and 10 ng/ml) were added and cells were harvested after 24 hrs 
and subsequently subjected to 'real time' RT-PCR. The results are 
mean (+ SE) of 5 experiments (p>0.001). 
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Fig 28: Time course kinetic effect of exogenous rhTNF-a on the 
expression of TNF-a mRNA in M. fu/bercu/os/s-infected monocytes 
after 72 hrs of infection. Here, after 90 min. of MTB infection as 
described in methods, varying doses of rhTNF-a (0, 0.1, 0.2, 2 and 10 
ng/ml) were added and cells were harvested after 72 hrs and 
subsequently subjected to 'real time' RT-PCR. The results are mean 
(+ SE) of 5 experiments (p>0.001). 
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Fig 29: Time course kinetic effect of exogenous rhTNF-a on the 
expression of M. tuberculosis 85B:16S ratio in M. fubercu/os/s-infected 
monocytes after 72 hrs of infection. Here, after 90 min. of MTB 
infection as described in methods, varying doses of rhTNF-a (0, 0.1, 
0.2, 2 and 10 ng/ml) were added and cells were harvested after 72 hrs 
and subsequently subjected to 'real time' RT-PCR. The results are 
mean (+ SE) of 5 experiments (p>0.001). 
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Fig 30: Time course kinetic effect of exogenous rhTNF-a on the 
expression of TNF-a mRNA in M. tuberculosis-'m^ecied monocytes 
after 120 hrs of infection. Here, after 90 min. of MTB infection as 
described in methods, varying doses of rhTNF-a (0, 0.1, 0.2, 2 and 10 
ng/ml) were added and cells were harvested after 120 hrs and 
subsequently subjected to 'real time' RT-PCR. The results are mean 
(+ SE) of 5 experiments (p>0.001). 
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FJg 31: Time course kinetic effect of exogenous rhTNF-a on the 
expression of M. tuberculosis 85B:16S ratio in M. tuberculosis-Infected 
monocytes after 120 hrs of infection. Here, after 90 min. of IVITB 
infection as described in methods, varying doses of rhTNF-a (0, 0.1, 
0.2, 2 and 10 ng/ml) were added and cells were harvested after 120 
hrs and subsequently subjected to 'real time' RT-PCR. The results are 
mean (+ SE) of 5 experiments (p>0.001). 
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Fig 32: Effect of soluble TNFR-I and soluble TNFR-II receptors on the 
expression of intramonocyte TNF-a mRNA in M. tuberculosis-'miected 
monocytes after 24 hrs of infection. Here, after infecting the 
monocytes for 90 min. cells were co-cultured for 24 hrs either with 10 
ng/ml sTNFR-l or sTNFR-ll. Thereafter, cells were harvested and 
subsequently subjected to 'real time' RT-PCR. Uninfected healthy 
monocytes (MN only) as well as MTB-infected monocytes (-) that were 
devoid of sTNFR-l and sTNFR-ll served as controls. The results are 
mean (+ SE) of 5 experiments (p>0.001). 
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Fig 33: Effect of soluble TNFR-I and soluble TNFR-II receptors 
on the expression of intramonocyte MTB 85B:16S ratio in M. 
tuberculosis-infected monocytes after 24 hrs of infection. Here, after 
infecting the monocytes for 90 min. cells were co-cultured for 24 hrs 
either with 10 ng/ml sTNFR-l or sTNFR-ll. Thereafter, cells were 
harvested and subsequently subjected to 'real time' RT-PCR. 
Uninfected healthy monocytes (MN only) as well as MTB-infected 
monocytes (-) that were devoid of sTNFR-l and sTNFR-ll served as 
controls. The results are mean (+ SE) of 5 experiments (p>0.001). 
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Fig 34: Effect of SN50 and SN50/M on the expression of 
intramonocyte TNF-a mRNA in M. tuberculosis-'miecXed monocytes 
after 24 hrs of infection. Here, before infecting the monocytes for 90 
min., the cells were co-cultured for 3 min either with 100 ug/ml of 
SN50 or SN50/M. Thereafter, cells were cultulred for 24 hrs and 
harvested. Subsequently, the above cells were subjected to 'real time' 
RT-PCR. MTB-infected monocytes (-) that were devoid of SN50 
served as control. The results are mean (+ SE) of 5 experiments 
(p>0.001). 
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Fig 35: Effect of SN50 and SN50/M on the expression of 
intramonocyte MTB 85B:16S ratio in M. tuberculosis-'miecied 
monocytes after 24 hrs of infection. Here, before infecting the 
monocytes for 90 min., the cells were co-cultured for 3 min either with 
100 ug/ml of SN50 or SN50/M. Thereafter, cells were cultulred for 24 
hrs and harvested. Subsequently, the above cells were subjected to 
'real time' RT-PCR. MTB-infected monocytes (-) that were devoid of 
SN50 served as control. The results are mean (+ SE) of 5 
experiments (p>0.001). 
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Fig 36: Effect of NAC (10 mM), L-NMMA (10 mM) or oATP (10 mM) 
on the expression of intramonocyte TNF-a mRNA in M. tuberculosis-
infected monocytes after 24 hrs of infection. Here, after infecting the 
monocytes for 90 min. cells were co-cultured for 24 hrs either with 
NAC, L-NMMA or oATP. Thereafter, cells were harvested and 
subsequently subjected to 'real time' RT-PCR. MTB-infected 
monocytes (-) that were devoid of the above supplements served as 
control. The results are mean (+ SE) of 5 experiments (p>0.001). 
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Fig 37: Effect of SNP (10 mM), NADPH (10 mM) or NOC-9 (10 mM) 
on the expression of intramonocyte TNF-a mRNA in M. tuberculosis-
infected monocytes after 24 hrs of infection. Here, after infecting the 
monocytes for 90 min. cells were co-cultured for 24 hrs either with 
SNP, NADPH or NOC-9. Thereafter, cells were harvested and 
subsequently subjected to 'real time' RT-PCR. MTB-infected 
monocytes (-) that were devoid of the above supplements served as 
control. The results are mean (+ SE) of 5 experiments (p>0.001) 
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Fig 38: Effect of SNP (10 mM), NADPH (10 mM) or NOC-9 (10 mM) 
on the expression of intramonocyte MTB 85B:16S ratio in M. 
tuberculosis-infected monocytes after 24 hrs of infection. Here, after 
infecting the monocytes for 90 min. cells were co-cultured for 24 hrs 
either with SNP, NADPH or NOC-9. Thereafter, cells were harvested 
and subsequently subjected to 'real time' RT-PCR. MTB-infected 
monocytes (-) that were devoid of the above supplements served as 
control. The results are mean (+ SE) of 5 experiments (p>0.001) 
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Fig 39: MTT cell viability assay for dose-response (0 - 20 ug/ml) 
effect of ECGC on M. fu6ercu/os/s-infected monocytes. After 24 hrs of 
culture, the cells were harvested and processes as described in 
methods. Data represents the analysis of three independent 
experiments in duplicates, vi/hich are expressed as mean viable cells 
(+S. E.) percentage of controls. (p>0.001) 
110 
E 200 
I 
o 
o 
> 
<D 
175 
150 
125 
100 
75 
50 
25 
0 
MN MN+1:1mtb 
• 0 ug/ml D2ug/ml S5ug/ml @10ug/ml 
n i5ug /ml •20ug/ml @25ug/ml 
Fig. 40: ELISA for the determination of sTNF-a secreted in 24 hr 
culture supernatants of MTB-infected monocytes that were treated 
with varying concentrations of EGCG. The concentrations of EGCG 
employed here were 0, 2, 5, 10,15, 20 and 25 ugs/ml respectively. 
The concentrations of soluble TNF-a detected were in pg/ml. Data are 
means (+ SE) often experiments.(p>0.001) 
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Fig 4 1 : ELISA for the determination of sTNF-a secreted in 24 hr 
culture supernatants of MTB-infected monocytes that were 
treated with rhTNF- a (2 ng/ml), monoclonal anti-TNF- a Abs (10 
ng/ml), 5 ug/ml EGCG, mixture of rhTNF- a (2 ng/ml) + anti-TNF- a 
Abs (10 ng/ml) or mixture of rhTNF- a (2 ng/ml) + EGCG (5 ug/ml). 
The concentrations of soluble TNF-a detected were in pg/ml. 
Uninfected monocytes that were either untreated or treated with 5 
ug/ml of EGCG served as controls. These two controls are on the 
base line whose bars could not be seen due to the extremely low or 
negligible values. MN+1:1 mtb (black bars), MN+1:1 mtb+ TNF-a 
(white bars), MN+1:1 mtb+ anti-TNF-a Abs (horizontal line bars), 
MN+1:1 mtb+ TNF-a + anti-TNF-a Abs (grey bars), MN+1:1 mtb+ 
TNF-a + EGCG (small square bars) and MN+1:1 mtb + EGCG (brick 
bars) Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 42: Real time RT-PCR. Dose response effect of EGCG on the 
expression TNF-a mRNA in 24 hr cultures of MTB-infected 
monocytes. Varying doses of EGCG used here were 0, 2, 5, 10 and 
20 ug/ml. Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 43: Dose response effect of EGCG on 85B to 16S ratio in 24 hr 
culture of MN's infected with MTB assessed by 'real time' RT-PCR. 
Varying doses of EGCG used here were 0, 2, 5, 10 and 20 ug/ml. 
Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 44: Dose response effect of Streptomycin on the expression of 
TNF mRNA expression in 24hr cultures of MTB-infected monocytes. 
Varying doses of Streptomycin used here were 0, 20, 40, 60, 80 and 
100 ug/ml. Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 45: Dose response effect of Streptomycin on the expression of 
MTB 85B:16S ratio in 24hr cultures of MTB-infected monocytes. 
Varying closes of Streptomycin used here were 0, 20, 40, 60, 80 and 
100 ug/ml. Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 46: Dose response effect of Rifampicin on the expression of TNF 
mRNA expression in 24hr cultures of MTB-infected monocytes. 
Varying doses of Rifampicin used here were 0, 20,40, 60, 80 and 100 
ug/ml. Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 47: Dose response effect of Rifampicin on the expression of IVITB 
85B:16S ratio in 24hr cultures of MTB-infected monocytes. Varying 
closes of Rifampicin used here were 0, 20, 40, 60, 80 and 100 ug/ml. 
Data are means (± SE) of six experiments. (p>0.001) 
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Fig 48: Dose response effect of Isoniazid on the expression of 
TNF mRNA expression in 24hr cultures of MTB-infected nnonocytes. 
Varying doses of Isoniazid used here were 0, 20, 40, 60, 80 and 
100 ug/ml. Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 49: Dose response effect of Isoniazid on the expression of MTB 
85B:16S ratio in 24hr cultures of MTB-infected monocytes. Varying 
doses of Isoniazid used here were 0, 20,40, 60, 80 and 100 ug/ml. 
Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 50: Effect of NAC (10 mM) and EGCG (5 ug/ml) on glutathione 
(GSH) levels in 24 hr cultures of MTB-infected monocytes. Uninfected 
healthy normal monocytes as well as MTB-infected monocytes devoid 
of any supplements served as corresponding controls. Here, cells 
after infection as described in methods were co-cultulred for 24 hrs 
along with NAC (10 mM) or EGCG (5 ug/ml), and harvested. 
Subsequently, the above harvested cells were subjected to GSH 
determination. Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 51: Dose response effect of EGCG on the glutathione peroxidase 
(GPx) activity in 24hr cultures of MTB-infected monocytes. Varying 
doses of EGCG used here were 0, 10, 20, 30, 40 and 50 ug/ml. Data 
are means (+ SE) of six experiments. (p>0.001) 
122 
88 
87 
>, 86 
"> 
*i O 
< 
X 
Q. 
O 85 
84 
83 
24 
Time (hrs) 
72 120 
Fig 52: Time course kinetic effect of EGCG (5 pg/ml) on GPx activity 
in 24hr cultures of uninfected healthy normal monocytes. Varying time 
intervals at which GPx activity was monitored were 0 hr, 4 hr, 24 hr, 
72 hr and 120 hr. Data are means (+ SE) of six experiments. 
(p>0.001) 
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Fjg 53: Time course kinetic effect of EGCG (5 Mg/ml) on GPx activity 
in 24hr cultures of IVITB-infected monocytes. Varying time intervals at 
which GPx activity was monitored were 0 hr, 4 hr, 24 hr, 72 hr and 120 
hr after infection. Data are means (+ SE) of six experiments. (p>0.001) 
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Fig 54: Effect of EGCG (5 |jg/ml) and NAC (10 mM) on the production 
of soluble IFN-Y in supernatants of 24 hr cultures of uninfected and 
MTB-infected monocytes. Uninfected as well infected monocytes that 
were devoid of ant EGCG or NAC served as controls. Data are means 
(+ SE) of six experiments. (p>0.001) 
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Fig 55: Diect binding ELISA: Microtiter plates were separately coated 
with total protein lysates (100 ul / well from 30 ug/ml stock) from 
healthy uninfected monocytes as well as MTB-infected monocytes. 
The binding was checked against antibodies present in sera from 
patients with active tuberculosis (dark bars). Normal healthy human 
sera served as negative control (white bar). Data are means (+ SE) of 
ten experiments. (p>0.001) 
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Fig 56: Diect binding ELISA: l\/licrotiter plates were separately coated 
with total protein lysates (100 ul / well from 30 ug/ml stock) from 
EGCG-treated healthy uninfected monocytes as well as EGCG-
treated MTB-infected monocytes. The binding was checked against 
antibodies present in sera from patients with active tuberculosis (dark 
bars). EGCG-treated healthy uninfected monocytes served as 
negative control (white bar). The concentration of EGCG used in this 
experiment was 5 ug/ml. Data are means (+ SE) of ten experiments. 
(p>0.001) 
127 
•a 
a> 
• o * ' 
o u 
t s | 
.E -o 
o> re js a> 
re i 
4.00 
3.00 
o £ 
" o 
HI c 
1 - O 
o .2 « 
^ " I. 
•I i § 2.00 
I I I 
§ 2 
c ® 
C 10 
Em 
© c 
re « 
» o) 
b " 
» «! 
•o "5. 
£§ 
E 
1.00 
0.00 + 
MN 
Fig 57: Fold decrease in reactivity of EGCG (5 pg/ml) treated infected 
monocytes against anti-TB antibodies present in sera of patients 
with tuberculosis. This was computed from direct binding ELISA data 
depicted in Figs. 50 and 51. 
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Fig 58: Inhibition ELISA: Microtiter plates were coated with total 
protein lysates (100 ul / well from 30 ug/ml stock) from MTB-infected 
monocytes (24 hrs culture). The coating antigen as well as the 
inhibitor employed here were the same. The concentration of inhibitor 
used in this study was 0, 0.01, 0.1, 1, 10 and 20 ug/ml. The inhibition 
in the binding was checked against antibodies present in sera from 
patients with active tuberculosis. Data are means (+ SE) of ten 
experiments. (p>0.001) 
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Fig 59: Inhibition ELISA (modulation with rhTNF-a): Microtiter 
plates were coated with total protein lysates (100 ul / well from 30 
ug/ml stock) from rhTNF-a treated MTB-infected monocytes (24 hrs 
culture). The concentration of rhTNF-a used for co-culturing was 2 
ng/ml. The coating antigen as well as the inhibitor employed here 
were the same. The concentration of inhibitor used in this study was 0, 
0.01, 0.1, 1, 10 and 20 ug/ml. The inhibition in the binding was 
checked against antibodies present in sera from patients with active 
tuberculosis. Data are means (+ SE) often experiments. (p>0.001) 
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Fig 60: Inhibition ELISA (modulation with monoclonal anti-TNF-a 
Ab): Microtiter plates were coated with total protein lysates (100 ul / 
well from 30 ug/mi stock) from anti-TNF-a antibody treated MTB-
infected monocytes (24 hrs culture). The concentration of monoclonal 
anti-TNF-a Ab used for co-culturing was 10 ng/ml. The coating 
antigen as well as the inhibitor employed here were the same. The 
concentration of inhibitor used in this study was 0, 0.01, 0.1, 1, 10 and 
20 ug/ml. The inhibition in the binding was checked against antibodies 
present in sera from patients with active tuberculosis. Data are means 
(+ SE) often experiments. (p>0.001) 
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Fig 61: Inhibition ELISA (modulation with strptomycin): Microtiter 
plates were coated with total protein lysates (100 ul / well from 30 
ug/ml stock) from streptomycin treated MTB-infected monocytes (24 
hrs culture). The concentration of streptomycin used for co-culturing 
was 100ug/ml. The coating antigen as well as the inhibitor employed 
here were the same. The concentration of inhibitor used in this study 
was 0, 0.01, 0.1, 1, 10 and 20 ug/ml. The inhibition in the binding was 
checked against antibodies present in sera from patients with active 
tuberculosis. Data are means (+ SE) often experiments. (p>0.001) 
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Fig 62: Inhibition ELISA (modulation with rifampicin): Microtiter 
plates were coated with total protein lysates (100 ul / well from 30 
ug/mi stock) from rifampicin treated MTB-infected monocytes (24 hrs 
culture). The concentration of rifampicin used for co-culturing was 
100ug/ml. The coating antigen as well as the inhibitor employed here 
were the same. The concentration of inhibitor used in this study was 0, 
0.01, 0.1, 1, 10 and 20 ug/ml. The inhibition in the binding was 
checked against antibodies present in sera from patients with active 
tuberculosis. Data are means (+ SE) of ten experiments. (p>0.001) 
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Fig 63: Inhibition ELISA (modulation with isoniazid): Microtiter 
plates were coated with total protein lysates (100 ul / well from 30 
ug/ml stock) from Isoniazid treated MTB-infected monocytes (24 hrs 
culture). The concentration of isoniazid used for co-culturing was 
100ug/ml. The coating antigen as well as the inhibitor employed here 
were the same. The concentration of inhibitor used in this study was 0, 
0.01, 0.1, 1, 10 and 20 ug/ml. The inhibition in the binding was 
checked against antibodies present in sera from patients with active 
tuberculosis. Data are means (+ SE) often experiments. (p>0.001) 
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Fig 64: Inhibition ELISA (modulation with NAC): Microtiter plates 
were coated with total protein lysates (100 ul / well from 30 ug/ml 
stock) from NAC treated MTB-infected monocytes (24 hrs culture). 
The concentration of NAC used for co-culturing was 10 mM. The 
coating antigen as well as the inhibitor employed here were the same. 
The concentration of inhibitor used in this study was 0, 0.01, 0.1,1, 10 
and 20 ug/ml. The inhibition in the binding was checked against 
antibodies present in sera from patients with active tuberculosis. Data 
are means (+ SE) of ten experiments. (p>0.001) 
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Fig 65: Inhibition ELISA (modulation with EGCG). Microtiter plates 
were coated with total protein lysates (100 ul / well from 30 ug/nni 
stock) from EGCG treated MTB-infected monocytes (24 hrs culture). 
The concentration of EGCG used for co-culturing was 5ug/ml. The 
coating antigen as well as the inhibitor employed here were the same. 
The concentration of inhibitor used in this study was 0, 0.01, 0.1,1, 10 
and 20 ug/ml. The inhibition in the binding was checked against 
antibodies present in sera from patients with active tuberculosis. Data 
are means (+ SE) of ten experiments. (p>0.001) 
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DISCUSSION 
DISCUSSION: 
Tuberculosis is most common among the elderly, poor, 
malnourished, or immuno-compromised, especially persons infected 
with human immunodeficiency virus (HIV). Persistent infection may 
reactivate after decades ow/ing to deterioration of immune status; 
exogenous re-infection also occurs. Only around 5-10% of infected 
normal individuals develop active disease. Tuberculosis primarily 
affects the lower respiratory system. Chronic productive cough, low-
grade fever, night sweats, and weight loss are the main characteristics 
of this infectious disease. 
Tuberculosis remains an important world health problem. 
Around 2-3 million fatalities are reported annually due to infection by 
the exclusively human pathogen, Mycobacterium tuberculosis. 
Tuberculosis resurgence is assuming threatening proportions, and 
hence, it has been declared a global health emergency more than a 
decade ago (5). Among the important reasons for the causative killer 
parasite spiralling out of control at an alarming rate is attributed to the 
emergence of multidrug-resistant (MDR) strains and the AIDS 
epidemic (145, 154, 156). Despite current treatment regimens, which 
include streptomycin, rifampicin, isoniazid, etc., tuberculosis continues 
to evade control, thereby fuelling an urgent need for developing novel 
therapeutic strategies. 
The initial interaction (both, phagocytic and non-phagocytic) of 
M. tuberculosis with mononuclear phagocytes gives rise to a cytokine 
profile that is dominated by TNF-a, a pro-inflammatory cytokine (157, 
158). TNF-a is present at the site of active M. tuberculosis infection in 
humans, regardless of the stage of mycobacterial infection (159, 160). 
TNF-a is a pleiotropic cytokine, and its role in harmful or beneficial 
inflammatory processes is complex (161). Although this cytokine is 
involved in multiple cell regulatory and differentiation processes 
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leading to immunity in tuberculous infection, however, TNF-a also 
mediates effects deleterious to the host contributing to the 
pathophysiology of tuberculosis. High levels of the cytokine at the site 
of infection induce an excessive damaging inflammatory response that 
overwhelms its beneficial effects (110). 
Of the various M. tuberculosis genes shown to be upregulated 
after M. tuberculosis infection of human mononuclear cells, the 85B 
gene was expressed most frequently (162). M. tuberculosis 85B is a 
predominant protein produced during human M. tuberculosis infection 
(163); however its role in tuberculosis pathogenesis is not clear and 
wanrants further investigation. At least with regard to mycolyl 
transferase activity, which underlies cell-wall biosynthesis, it appears 
that both M. tuberculosis 85A and 85B are redundant (164). In sputum 
from patients with tuberculosis, levels of M. tuberculosis 85B protein 
and mRNA correlate with M. tuberculosis growth, and maintenance of 
85B levels correlates with a lack of response to therapy (165,103). The 
expression of antigen 85B in M. tuberculosis-'mfecled monocytes 
correlates positively with both the amount of secreted TNF-a and 
subsequent intracellular mycobacterial growth (103). Interestingly, 
although many mycobacterial components induce TNF-a in 
mononuclear phagocyte (145, 154, 166), only the members of 85 
complex interact with host fibronectin (100). Moreover, binding of 85B 
to fibronectin enhances the expression of TNF-a in monocytes (101). 
Therefore, the role of M. tuberculosis 85B in intracellular infection may 
be the maintenance of an inflammatory response. In addition, M. 
tuberculosis 85 complex may act as an intennediary to synthesis of 
trehalose dimycolate, which enhances the host inflammatory response 
(167). 
It has been previously shown that infection of human alveolar 
macrophages with M. tuberculosis induce M. tuberculosis 85B and, 
TNF-a, both at mRNA and protein levels, which may be important to 
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the immunopathogensis of disease (145). The rationale for the use of 
monocytes in this study is based on the fact that in vivo, the initial 
interaction of M. tuberculosis is with residential alveolar macrophages. 
If initial pulmonary defenses are overcome, successful control of the 
infection depends upon recruitment of blood monocytes, which are 
activated by cytokines, and form a granuloma restricting the growth 
and spread of this pathogen. Whereas the interaction of M. 
tuberculosis with more mature alveolar macrophages occurs at the 
very initiation and all through M. tuberculosis infection, the continuous 
recruitment of monocytes (69,168) to sites of M. tuberculosis infection 
ascertains that this less mature cell type interacts with M. tuberculosis 
intensely also. Thus, the cytokines and activation profile of both cell 
types need to be considered to develop a better understanding of 
host-M. tuberculosis interactions in situ. As mononuclear cells are 
recruited to sites of M. tuberculosis infection, their in vitro functional 
capacities may reflect in situ immune responsiveness (145,156). 
Although attenuation of the biological activity of TNF-a has 
lately become an important therapeutic intervention in the 
management of a wide variety of chronic inflammatory diseases (108), 
a growing body of clinical evidence indicates that neutralization of 
TNF-a is associated with an increased risk of opportunistic infections, 
including mycobacterial diseases (116). In view of this, modulation of 
TNF-a release is being proposed as the basis for novel therapeutic 
approaches (169). Focus has now shifted to development of 
compounds from natural sources that have anti-oxidant and anti-
mycobacterial activity. By boosting host immunologic responsiveness, 
these compounds may be particularly useful in the treatment of drug-
resistant tuberculosis. Our study involves the incorporation of such a 
compound, namely, EGCG in green tea, as the natural herbal 
component for tuberculosis management. 
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EGCG (epigallocatechin gallate) is the major biologically active 
component found in green tea. Resent studies on EGCG as a potent 
anti-oxidant found in plants have been proposed as hope for 
developments of various therapeutic strategies for treatment and 
prevention of many challenging life threatening diseases. The 
compound is present in green tea leafs, and in addition, it is also 
found in green grapes which is traditional source of OPCs. In tea leaf, 
the leaf bud and first leaves are richest in epigallocatechin gallate. All 
plants that have been studied for their OPC content have been found 
to contain a mixture of four forms of the substance. The most basic 
form, and least potent antioxidant, is epicatechin (EC). Then come 
epigallocatechin (EGC), epicatechin gallate (ECG), and 
epigallocatechin gallate (EGCG), which is the most potent antioxidant 
form. The content of EGCG in grape seed is about 15 percent of the 
total OPCs present. In green tea extracts, the amount of EGCG is 50 
percent of the total OPCs present. However, more of one form of OPC 
does not necessarily mean better. The other OPC forms "EC, EGC, 
and ECG" provide unique benefits. So, although some studies have 
found EGCG to be more effective than the three other OPC forms, in 
some situations it is less effective. For example, in tests of the effects 
of OPCs on reducing blood pressure, EGCG was found to be 15 times 
less effective than ECG. In tests investigating the ability of OPCs to 
destroy bacteria, EGCG was most effective at inhibiting some 
bacteria, but less effective at inhibiting others. 
EGCG possesses much stronger anti-oxidant activities and plays an 
important role in preventing from cancer and cardiovascular diseases. 
In addition, it is potently used as the reversal agent of MDR (Multidrug 
Resistance) (170), which may improve the sensitivity of the cancer cell 
to the chemotherapy drug and reduce the toxicity on the heart. It has 
been reported that EGCG inhibited cell growth, caused Gi arrest of the 
cell cycle, and also induced apoptosis in two cell lines (YCU-N861 and 
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YCU-H891) originally derived from human (head and neck squamous 
cell carcinoma) HNSCC. Treatment with EGCG increased the 
proportion of cells in the Gi phase of the cell cycle and induced 
apoptosis. In cells treated with EGCG, there was a decrease in the 
cyclin D1 protein, an increase in the cell cycle inhibitor p21Cip1 and 
p27Kipi proteins, and a reduction in the hyperphosphorylated form of 
pRB, changes that may account for the arrest in Gi. EGCG also 
caused a decrease in the anti-apoptotic Bcl-2 and Bcl-Xua proteins, an 
increase in the pro-apoptotic Bax protein, and activation of caspase 9, 
suggesting that EGCG induces apoptosis via a mitochondrial pathway. 
Treatment with EGCG inhibited phosphorylation of the EGFR, signal 
transducer and activator of transcriptions (Stat3), and extracellular 
regulated kinase (ERK) proteins and also inhibited basal and 
transforming growth factor-a-stimulated c-fos and cyclin D1 promoter 
activity. EGCG at 0.1 pg/nnl (a concentration found in serum after oral 
administration) markedly enhanced the growth-inhibitory effects of 5-
fluorouracil. Taken together, these findings provide insights into 
molecular mechanisms of growth inhibition by EGCG . The studies 
indicate that EGCG inhibited growth and induced apoptosis in human 
prostate, lung, colon, and gastric carcinoma and human leukemia 
cancer cell lines. Studies with EGCG in some cell types indicated that 
it can inhibit signaling pathways related to the activation of growth 
factor receptors. HNSCCs often display up-regulation of TGF-a/EGFR 
signal transduction pathways, (Stat3 lies downstream of the TGF-a 
/EGFR signaling pathway, and Stat3 is strongly implicated in the 
growth of these carcinomas and in protecting them from apoptosis. 
Population-based and clinical studies indicate that the antioxidant 
properties of green tea may help prevent atherosclerosis, particularly 
coronary artery disease. It was seen that 70% EGCG is a potent tool 
in nutritional arsenal not only as an antioxidant, but to address arterial 
inflammation. Highly sensitive C-reactive protein (hs-CRP) is a marker 
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of arterial inflammation. Inflammation is also believed to play a role in 
heart disease; EGCG is a potent anti-inflammatory. According to 
Japanese research, green tea reduces the levels of LDL or 'bad' blood 
cholesterol, thereby reducing the risk of coronary heart disease. 
Research also indicates that tea polyphenols may reduce the activity 
of platelets, which are the clotting agents of the blood. This is good, 
because 'sticky' blood is more likely to form artery-blocking clots. 
Green tea has demonstrated an ability to lower total cholesterol and 
raise HDL ("good") cholesterol in both animals and people. This 
suggest that polyphenols in green tea may block the intestinal 
absorption of cholesterol and promote its excretion from the body. 
EGCG has been reported to inhibit lipid peroxidation, an oxidative 
process implicated in several pathologic conditions, including 
atherosclerosis. It has been suggested that EGCG and other tea 
catechins suppress tumor promotion by inhibiting the release of tumor 
necrosis factor-alpha, which is believed to stimulate tumor promotion 
and progression of initiated cells as well as premalignant cells 
Furthermore, EGCG was shown to reduce specific binding of both the 
12-Otetradecanoylphorbol-13-acetate (TPA)-type and the okadaic 
acid-type tumor promoters (the two major classes of tumor-promoting 
agents) to their receptors. This "sealing" effect of EGCG is achieved 
by its interaction, with the phospholipid bilayer of the cell membrane. 
An EGCG act against urokinase, an enzyme often found in large 
amounts in human cancers, inhibits ornithine decarboxylase (a rate-
limiting enzyme closely associated with tumor promotion), and blocks 
type 1 5-alpha reductase (5AR). Inhibitors of 5AR may be effective in 
the treatment of 5 alpha dihydrotestosterone-dependent abnormalities, 
such as benign prostate hyperplasia, prostate cancer, and certain skin 
diseases. EGCG, inhibits tumor growth by inhibiting VEGF induction 
in human colon carcinoma cells. In the in vitro studies, (-)-
epigallocatechin gallate (EGCG) inhibited Erk-1 and Erk-2 activation in 
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a dose-dependent manner. However, other tea catechins such as (-)-
epigallocatechin (EGC), (-)-epicatechin gallate (ECG), and (-)-
epicatechin (EC) did not affect Erk-1 or 2 activation at a concentration 
of 30 M. EGCG also inhibited the increase of VEGF expression and 
promoter activity induced by serum starvation. In the in vivo studies, 
athymic BALB/c nude mice were inoculated subcutaneously with 
HT29 cells and treated with daily intraperitoneal injections of EC 
(negative control) or EGCG at 1.5 mg day^mouse^starting 2 days after 
tumour cell inoculation. Treatment with EGCG inhibited tumour growth 
(58%), microvessel density (30%), and tumour cell proliferation (27%) 
and increased tumour cell apoptosis (1.9-fold) and endothelial cell 
apoptosis (3-fold) relative to the control condition (P< 0.05 for all 
comparisons). EGCG may exert at least part of its anticancer effect by 
inhibiting angiogenesis through blocking the induction of VEGF. 
Tea polyphenol EGCG inhibits DNA methyltransferase and reactivates 
methylation-silenced genes in cancer cell lines(4).Hyper-methylation 
of CpG islands in the promoter regions is an important mechanism to 
silence the expression of many important genes in cancer. The 
hypermethylation status is passed to the daughter cells through the 
methylation of the newly synthesized DNA strand by 5-cytosine DNA 
methyltransferase (DNMT). It has been reported that (EGCG), can 
inhibit DNMT activity and reactivate methylation-silenced genes in 
cancer cells. With nuclear extracts as the enzyme source and 
polydeoxyinosine-deoxycytosine as the substrate, EGCG dose-
dependently inhibited DNMT activity, showing competitive inhibition 
with a K(0 of 6.89 uM. Studies with structural analogues of EGCG 
suggest the importance of D and B ring structures in the inhibitory 
activity. Molecular modeling studies also support this conclusion, and 
suggest that EGCG can form hydrogen bonds with Pro(1223), 
Glu(1265), Cys(1225), Ser(1229), and Arg(1309) in the catalytic 
pocket of DNMT. Treatment of human esophageal cancer KYSE 510 
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cells with 5-50 microM of EGCG for 12-144 h caused a concentration-
and time-dependent reversal of hypermethylation of p16(INK4a), 
retinoic acid receptor beta (RARbeta), 0(6)-methylguanine 
methyltransferase (MGMT), and human mutL homologue 1 (hMLHI) 
genes as determined by the appearance of the unmethylation-specific 
bands in PCR. This was accompanied by the expression of mRNA of 
these genes as determined by reverse transcription-PCR. The re-
expression of RARbeta and hMLHI proteins by EGCG was 
demonstrated by Western blot. Reactivation of some methylation-
silenced genes by EGCG was also demonstrated in human colon 
cancer HT-29 cells, esophageal cancer KYSE 150 cells, and prostate 
cancer PC3 cells. The results demonstrate for the first time the 
inhibition of DNA methylation by a commonly consumed dietary 
constituent and suggest the potential use of EGCG for the prevention 
or reversal of related gene silencing in the prevention of 
carcinogenesis. In addition to this EGCG activates endothelial nitric 
oxide synthase by a PI3K-, PKA-, and Akt-dependent pathway, and 
leads to endothelial-dependent vasorelaxation, the EGCG-induced 
endothelium-dependent vasodilation is primarily based on rapid 
activation of eNOS by a PI3K-, PKA-, and Akt-dependent increase in 
eNOS activity, independently of an altered eNOS protein content. 
This suggests that tea catechins may reduce the risk of 
cardiovascular. Interleukin-lbeta (IL-lbeta) induced inflammatory 
response in arthritic joints include the enhanced expression and 
activity of matrix metalloproteinases (MMPs) and their matrix 
degrading activity contribute to the irreversible loss of cartilage and 
may also be associated with sustained chronic inflammation. EGCG 
inhibited the IL-1 beta-induced mRNA and protein expression of MMP-
1, and MMP-13 in human chondrocytes, a differential dose-dependent 
effect of EGCG on the expression and activity of MMPs and on the 
activities of transcription factors NF-kappaB and AP-1 and provide 
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insights into the molecular basis of the reported anti- inflammatory 
effects of EGCG . 
Prior to any investigations, we first probed the reactivity of sera 
from tuberculosis patients against both, sonic extracts as well as 
MTCF protein antigens of cultured H37RV and found a remarkably high 
magnitude of immuno-binding of both, intracellular protein antigens as 
well as secretory MTCF protein antigens, with tuberculosis sera. 
Further characterization of tuberculosis sera used in our study 
revealed elevated basal levels of TNF-a and circulating M. 
tuberculosis antigen 85 complex, which was consistent with earlier 
studies. Monocytes from patients with active tuberculosis were also 
characterized similarly. Real-time RT-PCR was employed to evaluate 
TNF-a mRNA expression, and our results demonstrated that they 
were elevated appreciably. Furthemnore, supernatants of monocyte 
cultures from tuberculosis patients also exhibited appreciable levels of 
soluble TNF-a and secreted antigen 85 complex proteins. 
After establishing the virulence of the pathogenic M. 
tuberculosis strain used in our laboratory, we examined the 
effectiveness of EGCG as a natural antioxidant and antimycobacterial 
compound, focussing on its role as an antagonist of M. tuberculosis 
85B, in H37RV cultures. The selected EGCG concentrations in our 
study was non-toxic and failed to show any affect on M. tuberculosis 
growth, as revealed by an insignificant effect on the expression of M. 
tuberculosis housekeeping gene (16S rRNA). The dose-response 
studies clearly demonstrated down regulation of M. tuberculosis 85B 
mRNA expression in H37RV cultures. 
The electrophoresed gel results clearly indicate the decreased 
expression of antigen 85 complex (30/31 kDa) in M. tuberculosis 
cultures treated with varying doses of EGCG. ELISA results for 
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secreted antigen 85 complex in M. tuberculosis culture supernatants 
also indicate the decreased secretion of antigen 85 connplex when co-
cultured with varying doses of EGCG. To have further insight, we 
further designed immunoassays to study the effect of EGCG on the 
immuno-interaction of antibodies present in sera of patients with 
tuberculosis against protein antigens in M. tuberculosis sonic extract 
as well as in MTCF. A concentration of 5 pg/ml of EGCG proved to be 
a potent inhibitor of M. tuberculosis 85B mRNA as well as antigen 85B 
protein expression in M. tuberculosis cultures. 
Thereafter, an attempt was made to examine the interaction of 
M. tuberculosis with human monocytes, focussing on the relationship 
between expression of TNF-a and M. tuberculosis 85B mRNA, with or 
without modulators. It's well known that M. tuberculosis induces high 
amounts of TNF-a (157), and the success of intracellular growth of 
virulent M. tuberculosis has been in part attributed to the capacity to 
induce TNF-a. In agreement with previous findings, our data also 
revealed a time-dependent increase in TNF-a mRNA expression and 
protein production, reaching a maximum 24 hours post-infection. 
Interestingly, M. tuberculosis 858 mRNA expression and protein 
production were increased well beyond 24 hours of infection. Our 
results demonstrate that the induction of TNF-a and M. tuberculosis 
858 mRNA expression mutually corresponded at to and 24 hours. 
Thus, stronger cell activation, as has been reflected by induction of 
TNF-a, seems to be associated with increased expression of 858 
gene. In support of this finding, exogenous TNF-a was also found to 
significantly induce the expression of both TNF-a and M. tuberculosis 
858, in parallel. These results are suggestive of a modulatory role 
being exerted by M. tuberculosis-'mduced TNF-a, in monocyte 
cultures, over the expression of M. tuberculosis 858 during the initial 
24 hours of infection. 
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It is to be pointed out that TNF-a may not be involved in sustaining the 
continued expression of M. tuberculosis 85B with time. The 
maintenance of 85B expression at time points beyond 24 hours, when 
TNF-a activity is reduced, suggests the involvement of alternative 
mechanisms as has been previously observed in macrophages (145, 
154). The expression of the TNF-a gene and production of its protein 
are under strong intracellular control mechanisms. The TNF-a mRNA 
expression at 24 hours showed a positive linear correlation with the 
secretion of antigen 85B into parallel cultures. An effect of cytokines 
released by M. tuberculosisAn^ecied monocytes on intracellular 
expression of M. tuberculosis gene throughout infection of 
mononuclear phagocytes needs to be considered. The 858:16S ratio 
at 24 hours showed a positive linear correlation with the secretion of 
TNF-a into parallel cultures. 
It is well established that cellular signalling by TNF-a is mediated 
mainly through activation of NF-KB (145, 154). In turn, activation of 
NF-KB and other pathways sustain TNF-a activity (175). Thus, in order 
to probe the role of NF-KB in the expression of TNF-a in M. 
tuberculosis-Infected monocytes, SN50, an inhibitor of NF-KB was 
employed in our study. It was apparent from our results that the 
induction of TNF-a and M. tuberculosis 85B expression in M. 
tuberculosis-'miecied monocytes was mediated through activation of 
NF-KB, because both mRNAs were suppressed in cultures receiving 
SN50. On the contrary, the inactive analogue of SN50 failed to show 
any effect. Thus, our results show that cellular activation is associated 
with augmentation of expression of both TNF-a and M. tuberculosis 
85B in M. tuberculosis-Infected monocytes, and that, it is in agreement 
with the previously reported data on macrophages (145,154). 
It is worth mentioning out here that effective host defense 
mechanisms by innate immune cells to M. tuberculosis within the 
phagolysosomes of activated macrophages is known to include the 
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production of reactive oxygen (ROI) and reactive nitrogen 
intermediates (RNI). Phagocytosis of microbes as well as cellular 
activation activates ROIs (171), and H2O2, a product of the ROI 
pathway activates the expression of iNOS and production of NO 
(172). Reactive oxygen intermediates (ROI) and reactive nitrogen 
intermediates (RNI) are both downstream mediators of macrophage-
actlvating cytokines and are considered to be microbicidal. Activation 
of iNOS and production of NO may be important in the final 
containment of M. tuberculosis by macrophages (173). However, M. 
tuberculosis has evolved resistance mechanisms against both, ROI 
(174) and RNI (175). 
Regarding antioxidant studies, here, when the activation of RNI and 
ROI was inhibited by NMMA, NAC, or oATP, the expression of both 
TNF-a and M. tuberculosis 85B was significantly downregulated in 
monocytes infected with M. tuberculosis. Our results have 
substantiated these observations by using agents that release oxygen 
radicals (NADPH) or NO (SNP or NOC-9). In M. fu5ercu/os/s-infected 
monocytes, these reagents increased expression of both TNF-a and 
M. tuberculosis 85B. Thus, both RNI and ROI, induced early after M. 
tuberculosis infection of monocytes, activate expression of M. 
tuberculosis gene. 
Thus, our study demonstrates that M. tuberculosis-mlecWon of 
monocytes leads to a concomitant induction of TNF-a, and expression 
of the M. tuberculosis 85B gene. Based on these findings, we probed 
here the regulation of TNF-a and 85B activation in M. tuberculosis-
Infected human monocytes, by EGCG. 
The effect of varying doses of EGCG have previously been 
investigated in chondrocytes and cells isolated from patients with 
other diseases by various investigators in (144). In our system here, 
cell viability and potential cytotoxicity of EGCG were determined for 
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varying concentrations employed in this study using trypan blue and 
MTT assays, where viability of ~98-99% was observed. Interestingly, 
no effect of EGCG was observed on human housekeeping genes like 
R18, thereby demonstrating that the effect of EGCG was not mediated 
by cellular death, but rather by specific inhibition of expression as well 
as secretion of TNF-a and M. tuberculosis 85B. Furthermore, it is to 
be mentioned out here that EGCG failed to show any effect on the 
intracellular growth of M. tuberculosis as inferred by the data obtained 
exhibiting insignificant effect of EGCG on 16S rRNA expression. 
EGCG has earlier been reported to inhibit spontaneous and 
TNF-a induced secretion of pro-inflammatory cytokines in human 
chondrocytes (144). To the best of our understanding, we show for the 
first time that EGCG exerts potent anti-inflammatory effects on host 
mononuclear cells infected with M. tuberculosis as evidenced by a 
strong inhibition of the pro-inflammatory cytokine TNF-a and in turn, of 
M. tuberculosis 85B. The results indicate an appreciably high 
magnitude suppression in soluble TNF-a secretion as well as 
endogenous TNF-a mRNA expressions with 5 |jg/ml of EGCG in M. 
tuberculosis-infected monocytes. A parallel dose-response effect of 
EGCG was found on M. tuberculosis 85B protein secretion as well as 
on 858 mRNA expression in M. tuberculosis-infecied monocytes. 
The production of autocrine cytokine TNF-a in monocytes is 
regulated at multiple intracellular levels, beginning with transcription 
(145). Elevated expression of TNF-a mRNA and activation of a 
relevant transcription factor, NF-KB (145, 152) have been reported in 
monocytic cells infected with M. tuberculosis. Induction of TNF-a 
expression was mediated through activation of NF-KB, as evidenced 
by the suppression of TNF-a mRNA in the presence of SN50, an 
inhibitor of NF-KB. On the contrary, SN50/M, an inactive analogue of 
SN50, failed to show any such effect. It has been well established that 
TNF-a induced nuclear translocation of NF-KB is inhibited by SN50 
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peptide as demonstrated in EMSA (155). In light of the above view, it 
seems from our results obtained that this effect involved inhibition of 
the NF-KB pathway induced by EGCG, probably by inhibiting the 
degradation of IKBQ. The NF-KB heterodimer is retained in the 
cytoplasm in an inactive form through association with one of the IKBS 
inhibitory proteins. IKBQ is phosphorylated by a specific kinase 
complex (IKK) leading to its ubiquitination and subsequent proteolysis 
by the 28S proteosome due to stimulation by TNF-a (176). The 
degradation of IKB releases active NF-KB, which translocates to the 
nucleus and regulates gene expression by binding to KB binding sites 
or by interacting with other transcriptional factors (177). Since a 
number of genes involved in inflammatory responses are regulated by 
NF-KB pathway, thus a high magnitude downregulation of the NF-KB 
pathway by green tea polyphenol, namely EGCG, would predictably 
reduce the elaboration of NF-KB-mediated TNF-a mRNA expression 
and thereby, 85B mRNA expression. In addition, EGCG exerted a 
higher degree of neutralizing effects than NAC on TNF-a-induced 
actions in M. tuberculosis-m1ecte6 human monocytes. 
The exact mechanism underlying the antioxidant activity of EGCG in 
MTB-infected monocytes still remains poorly understood. Anti-oxidant-
induced enhancement of glutathione peroxidase activity has been 
reported (178, 179). Furthermore, a role for the antioxidant enzyme 
glutathione peroxidase (GPx) in infected mononuclear cells was 
investigated with respect to various modulators employed in this 
study. Glutathione directly reacts with ROS, and GPx catalyzes the 
removal of hydrogen peroxide (180). Decrease in GPx activity 
indicates impairment of hydrogen peroxide-neutralizing mechanisms 
(181, 182). Here, we observed a decline in GPx activity in M. 
tuberculosis-Infected monocytes that were untreated or treated either 
with H2O2, SN50/M or H2O2+SN50/M, thereby concurring with earlier 
reports that substantial amounts of ROS are being generated in cells 
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infected with M. tuberculosis due to cellular activation (145). 
Enhancement of GPx activity in M. fubercu/os/s-infected monocyte 
cultures after addition of NAC, a precursor of the in vivo antioxidant 
glutathione, indicates reversal of impaired neutralizing mechanisms. 
Interestingly, the GPx activity was found to be further enhanced / 
augmented when 5 \ig/m\ of EGCG was co-cultured instead of NAC, 
thereby inferring EGCG to be an effective natural antioxidant 
combating ROS which was generated due to stimulation by TNF-a of 
cellular activation in M. tuberculosis-'mlected mononuclear 
phagocytes. In continuation to the above, the EGCG-induced up-
regulation of soluble IFN-y in culture supernatants coupled with 
simultaneous down-regulation of TNF-a at both the gene and protein 
levels is indicative for the anti-inflammatory and elicitation of protective 
immune response properties of EGCG. 
Furthermore, it is to be pointed out here that, our 'real time' data 
revealed EGCG to be even better antagonist of MTB 85B than 
antibiotics like Isoniazid, rifampicin and streptomycin. The suppression 
of 85B by antibiotics showed IC-50 values of the order of 60pg/ml, 
ZOpg/ml and 80pg/ml for isoniazid, rifampicin and streptomycin, 
respectively. 
Thus, in summary, the present study shows that in human 
monocytes early after infection with /W. tuberculosis, a vicious circle 
may exist in which expression of host inflammation and 
mycobacterial products amplify one another. Our study also shows 
enhancement of GPx activity by EGCG, which correlated inversely 
with the downregulation of TNF-a and M. tuberculosis 858 mRNA 
expression as well as TNF-a and M. tuberculosis 858 protein 
expression in monocytes infected with M. tuberculosis. The up-
regulation of soluble IFN-y in culture supernatants coupled with 
simultaneous down-regulation of TNF-a at both the gene and protein 
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levels by EGCG is indicative for the anti-inflammatory and elicitation of 
protective immune responses properties of EGCG. 
Moreover, based on the IC50 of values, EGCG proved to be 
even a better inhibitor of MTB 85B and TNF-a gene expressions than 
antibiotics like isoniazid, rifampicin and streptomycin. Thus the 
antimicrobial effects of EGCG investigated earlier in other systems 
(183, 184) as well as the data generated in the present study involving 
infected human monocytes, appears to strongly indicate EGCG to be 
potential adjunct in the treatment of tuberculosis 
In conclusion, It can be Inferred from the present study that: 
1. EGCG suppresses the expression of M. tuberculosis 85B mRNA and 
the secretion of M. tuberculosis 85B protein in M. tuberculosis (H37RV) 
cultures. 
2. Activation of monocytes by M. tuberculosis induces the expression of 
both TNF-a and M. tuberculosis 85B mRNA. 
3. Both RNI and ROI, induced early after M. tuberculosis infection of 
monocytes, increase expression of both TNF-a and M. tuberculosis 
85B mRNA. 
4. Activation of monocytes by M. tuberculosis initiates a cascade of 
events whereby a vicious circle may exist in which expression of host 
inflammation and mycobacterial products amplify one another. 
5. 5|jg/ml EGCG exhibited no toxic effect on the viability of human 
monocytes. Moreover, this concentration of failed to show any 
inhibitory effect on the growth of M. tuberculosis. 
6. EGCG inhibits the expression of TNF-a mRNA and its protein 
production in a dose-dependent manner in M. tuberculosis infected 
monocyte cultures after 24 hours of infection. 
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7. Post 24 hours of M. tuberculosis infection, EGCG was found to down 
regulate the expression of M. tuberculosis 85B mRNA as well as its 
protein secretion in monocyte cultures. 
8. Suppression of TNF-o and M. tuberculosis 85B by EGCG in M. 
tuberculosis-\nfec\ed monocytes is mediated mainly via NF-KB. 
9. EGCG enhances the glutathione peroxidase activity in M. 
fi/bercu/os/s-infected monocytes. 
10. The up-regulation of soluble IFN-g in culture supematants coupled 
with simultaneous down-regulation of TNF-a at both the gene and 
protein levels by EGCG is indicative for the anti-inflammatory and 
elicitation of protective immune response s properties of EGCG. 
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